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Circulatory shock is a life-threatening disease that accounts for around one-third of
all admissions to intensive care units (ICU). It requires immediate treatment and can
result in irreversible damage to organs or even death. That is why it is important
to provide fast and interpretable tools that can detect a clear therapeutic target for
dealing with shock. This work uses machine learning techniques combined with
clinical data to identify such targets.
This Master’s thesis attempts to identify biomarkers that can be used as indica-
tors for mortality prediction in patients with shock. This work uses the ShockOmics
project dataset (75 observations and 333 features) to extract biomarkes that show
good performance as features in the outcome prediction task. Multiple imputation
techniques and machine learning models were used in the preliminary experiments
in order to analyze the data set. Then, several feature selection techniques were
applied to different subsets of the complete dataset. However, only the univariate
feature selection based on ANOVA F-values and the Random Forest-based selection
were able to achieve six promising feature sets. They were later used to build causal
Bayesian Network structures that revealed some of the causal relationships between
individual features and the outcome.
The main result of this work is a list of candidate features for mortality predic-
tion. Some of the indicators in the list (e.g. SOFA, APACHE II) are well-known,
and some of them (e.g. Inferior vena cava distensibility index, X Norepinephrine) re-
quire more thorough consideration. Moreover, the findings show that biomarkers
have the most predictive value at certain time-steps. This means that, as shock pro-
gresses, different biomarkes should be prioritized. The main limitation of this study
is the low amount of observations available for analysis. In future work, the findings
of this thesis should be tested on a larger dataset.
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1Chapter 1
Introduction
Shock (or circulatory shock) is a life-threatening medical condition that requires im-
mediate treatment. It occurs when the organs and tissues of the body are not receiv-
ing enough blood. As a result, the cells do not receive oxygen and nutrients from the
blood, and the organs become damaged. Low blood pressure, fast pulse rate, rapid
breathing and fever are among the common symptoms [1]. The outcome of an indi-
vidual case depends on the stage of shock, the underlying condition and the general
medical state of the patient [1]. It is crucial to detect this condition early since it can
result in irreversible damage to organs or even death.
The mortality rate of shock remains very high and depends on its type. For
example, it is around 30% for septic shock (according to the new definition of such
condition [2]) and between 35.9% and 64.7% for in-hospital mortality in patients
with cardiogenic shock (depending on the stage, [3]). Usually, shock is treated in the
Intensive Care Unit (ICU), where it is carefully monitored. As a result, large amounts
of data are produced for each patient. And hence, multiple omes (e.g. genome,
proteome, transcriptome) sequencing can be used for identification of shock. Using
such data is the essence of the multi-omics approach.
Machine learning (ML) techniques can help find the required biomarkers and
predict the outcome of the patients with shock, using multi-omics data. Mult-omics
approach requires a vast spectrum of features for each patient and, as a result, multi-
omics data has very high dimensionality. Combining statistics and ML, one can
retrieve new knowledge and causal relationships between different features from
such high-dimensional data [4]–[6]. Having a model that may improve the general
understanding of shock and help reduce the mortality rates can be a great asset in
the ICU environment, where time is of the essence.
This work analyzes the dataset that was gathered within the ShocOmics research
project. Usually, there are four types of shock that are commonly defined: hypo-
volaemic shock (e.g. hemorrhagic shock), cardiogenic shock, distributive shock (e.g.
septic shock) and obstructive shock. However, in the collected dataset there are only
two types of shock: septic and cardiogenic. Septic shock is the most common, and
it is caused by infection. The second most frequent form of shock is the cardiogenic
shock and it is a result of a heart failure. The multiscale nature of the ShockOmics
dataset allows to search for biomarkers that are related to mortality induced by these
two types of shock. This work attempts to analyze one part of the ShockOmics data,
namely clinical data.
1.1 Motivation of the Thesis
When it comes to the detection of circulatory shock, physicians and therapists largely
depend on a combination of clinical, hemodynamic and biochemical signs. For a
treatment to be chosen, prompt identification of shock is necessary. Appropriate
2 Chapter 1. Introduction
treatment is based on a good understanding of the physiological mechanisms be-
hind the condition. And shock is difficult to treat. Usually, there are other conditions
that go along with shock (e.g. hypotension and hemodynamic instability, inflamma-
tion and multiple organ failure (MOF)). Since they have similar symptoms, it makes
addressing causes of shock very difficult and hence, the therapist can not act prop-
erly at the beginning of the condition. For this reason, it is important to provide fast
and interpretable tools that can detect a clear therapeutic target in order to prevent
mortality or any irreversible consequences caused by shock.
Current research is focused on assessing the potential of different marker tar-
gets for resuscitation related to different stages of shock. Extensive description of
the most common practices in shock diagnosis and treatment can be found in [7].
However, there are still many issues that can be addressed. For example, the poten-
tial of microcirculatory markers of tissue perfusion in microcirculation-oriented or
microcirculation-guided management and/or therapy of early shock resuscitation
[7] and the duration of hemodynamic effects of colloids and crystalloids after initial
resuscitation [8]. Additionally, there are no simple and unambiguous clinical criteria
or biological, imaging, or laboratory features that uniquely identify a septic patient
[9], which makes the treatment of septic shock very difficult. Moreover, the research
related to shock is compounded by several factors: the origin of shock, the degree
of vasodilation, the supposed degree of capillary leak, and the shock severity. Cur-
rent research will benefit from standardized clinical examination and the definition
of appropriate statistical indexes. Clinical data combined with ML techniques may
statistically estimate the therapeutic target for circulatory shock, providing the re-
quired analytical tools for studying and prognosis of shock. And can be later used
as a part of the larger multi-omics study.
1.2 Thesis Objectives
The main objectives of this Master’s thesis are set around identifying the biomarkers
that can predict mortality of a patient with shock. This can help defining new targets
for therapy in order to overcome the shortcomings of current therapies for circula-
tory shock. Along the way, several goals should be achieved, listed as follows:
1. Studying evolution of shock in the context of these biomarkers. It is important to
analyze the biomarkers at different time steps. Because as shock progresses,
it shows different symptoms, and these symptoms should be addressed with
different priorities. The biomarkers that can predict mortality of a patient at
different time steps can reveal the priorities for therapeutic targets and reduce
any potential harm caused by shock.
2. Identifying relationships between these biomarkers. Addressing the importance
of a single biomarker might not be enough. Depending on the whole set of
biomarkers, individual biomarkers have different diagnostic values. For ex-
ample, having all important aspects covered by a set of biomarkers is prefer-
able than having a set of important biomarkers that covers only a few aspects.
This is why it is important to study the influence of biomarkers in groups.
3. Assessing effectiveness of already existing scoring systems for mortality prediction.
The current scoring systems (e.g. SOFA, APACHE II) are calculated at admis-
sion of a patient to the ICU. But there might be other variables that play an
important role as indicators for mortality prognosis. Better understanding of
1.3. Considerations on the Analyzed Dataset 3
the mortality prediction value of existing scoring systems may help to identify
what such systems are missing. This information can be later used for im-
proving the mortality prediction models that are based on the extensive use of
scoring systems.
4. Building a model for ICU mortality predictions based on the ShockOmics dataset. Fi-
nally, three previous points rely on an ML model that can predict mortality in
the ShockOmics dataset. Trying out different sets of biomarkers (feature sets)
and evaluating the model can provide us with an estimation of the impor-
tance of biomarkers. Naturally, we expect that the models that use important
features should have a higher score. A model that can predict mortality is a
valuable analytical tool for studying biomarkers and the evolution of shock in
the ICU.
1.3 Considerations on the Analyzed Dataset
This Master’s thesis analyses the dataset that was collected for the ShockOmics re-
search project. According to [10]:
The ShockOmics study is a multicenter prospective observational trial
aimed at identifying new biomarkers of acute heart failure in circulatory
shock, by means of a multiscale analysis of blood samples and hemody-
namic data from subjects with circulatory shock.
The patients for the study were recruited in three ICUs: Hopital Erasme, Uni-
versite Libre de Bruxelles, Belgium; Hospital Universitari Mutua Terrassa, Spain;
Hopitaux Universitaires de Geneve, Switzerland. This dataset allows to apply the
multi-omics approach for analysis of clinical data. It has multiscale biomarkers from
gene expression to protein synthesis, and from metabolite expression to organ spe-
cific injury. In this thesis only clinical data of the ShockOmics dataset is used.
The clinical data and blood samples were collected at three fixed time-steps: less
than 16 hours, 48 hours and 7 days after the shock diagnosis. The dataset has 75
patients and more than 300 features that include different scores (more about scoring
systems can be found in Chapter 2), analyses results and vital signs that are used for
monitoring purposes. There are patients with septic shock, cardiogenic shock and a
control group of patients that do not have shock. This dataset is described in detail
in Chapter 3.
1.4 Expected Contributions
The main contribution of this Master’s thesis can be viewed from two different view-
points: clinical and ML-related. From a clinical point of view, it is expected to define
the candidate biomarkers that can be successfully used as prognostic factors for the
prediction of mortality due to shock. These biomarkers should be identified as novel
targets for therapy to prevent shock progression. This can improve the overall accu-
racy of already existing prognostic tools and reduce any irreversible harmful impact
on patients treated for circulatory shock.
From the ML point of view, it is expected to build a probabilistic graphical model
that can predict mortality due to shock. The model should achieve high performance
with the ShockOmics dataset and have a fixed feature set. This feature set needs to
be a result of the thorough analysis of the initial dataset. For this reason, we expect
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to perform multiple feature selection techniques and select the most promising fea-
tures from that. The graphical model should incorporate the relations between the
variables and predict the mortality, given full or partial values for those features. So
analysis of the architecture of the this model is another contribution of the thesis.
1.5 Thesis Structure
The thesis is organized as follows:
• Chapter 2 describes the condition of shock in more details. The chapter’s main
focus is to provide an overview of the pathology of shock: its symptoms, epi-
demiology and treatment. The emphasis is on septic and cardiogenic shock,
since they are the most common types and since other types of shock are not
present in the dataset. This chapter provides the medical background that is
relevant to the problem of the thesis.
• Chapter 3 focuses on the descriptions of the techniques that are currently used
for mortality prediction and diagnosis of shock. This chapter introduces the
multi-omics approach for analysis of diseases, scoring systems that are com-
monly used when shock is treated and the ML framework that is often used
for the mortality prediction. The last section includes relevant work that shows
different approaches to mortality prediction and analysis of biomarkers.
• Chapter 4 describes preliminary experiments with the ShockOmics dataset.
The experiments were done in the context of the analysis of the data. The chap-
ter presents the description of the dataset along with the first results of mor-
tality prediction. It describes multiple imputation techniques and ML models
that were used to obtain the preliminary results. The best imputation tech-
nique and ML model are later used in the thesis.
• Chapter 5 is dedicated to the feature selection procedure. It presents the re-
sults of the experiments with four subsets of the ShocOmics dataset and de-
scribes the feature selection techniques that were used. The purpose of these
experiments is analyzing shock biomarkers. In the end of this chapter, several
promising feature sets (biomarkers) are presented. They are later used in the
remaining experiments.
• Chapter 6 presents the set of the experiments, where different Bayesian Net-
work structures are compared and analyzed. These structures provide the
causal relationship information between biomarkers that allows identifying
which features have the most influence on the outcome.
• Chapter 7 presents the conclusions and suggestions for future work based on
the results of the thesis.
5Chapter 2
Medical Background: the Shock
Pathology
As was mentioned in the previous chapter, circulatory shock is a life-threatening
syndrome resulting in a multiorgan failure and a high mortality rate. It is best de-
fined as a generalized form of acute circulatory failure associated with inadequate
oxygen utilization by the cells. It is a state in which the circulation is unable to
deliver sufficient oxygen to meet the demands of the tissues, resulting in cellular
dysfunction [7]. In the 2014 Consensus on circulatory shock [7], the authors listed
the quantitative and qualitative descriptions of indicators typically associated with
shock. Patients with shock require a full clinical examination. It includes assessment
of skin color and temperature, jugular venous distention, and peripheral edema.
According to [1], the diagnosis can be refined with point-of-care echocardiographic
evaluation, which includes assessment for pericardial effusion, measurement of left
and right ventricular size and function, assessment for respiratory variations in vena
cava dimensions, and calculation of the aortic velocity–time integral, a measure of
stroke volume.
Circulatory shock can result from four mechanisms, described in [1]. The first
of these mechanisms is a decrease in venous return due to a loss of circulating vol-
ume (i.e. due to internal or external loss of fluids). The second is a failure of the
pump function of the heart that results from a loss of contractility (resulting from
ischemia, infarction, myopathy, myocarditis), or a major arrhythmia (such as ven-
tricular tachycardia, or a high degree A-V block). The third is an obstruction due to
pulmonary embolism, tension pneumothorax or cardiac tamponade. The fourth is
loss of vascular tone that results in maldistribution of blood flow (due to sepsis, ana-
phylaxis or spinal injury). Each of these mechanisms respectively correspond to four
categories of shock: hypovolaemic, cardiogenic, obstructive and distributive. Some
studies prove that a patient admitted with shock may later develop other types of
shock [11], [12].
The rest of the chapter is built around the four categories of shock and their
different aspects. The emphasis is made on septic and cardiogenic shock. They are
particularly important for this thesis, since these are types of shock that are present
in the ShockOmics dataset.
2.1 Diagnosis and Causes of Shock
A diagnosis of shock is based on clinical, hemodynamic, and biochemical signs.
Circulatory shock is usually diagnosed by three main indicators that are typically
present in the patients with shock [1]. The first one is systemic arterial hypotension.
Usually in such patients, the systolic arterial pressure is less than 90 mm Hg or the
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FIGURE 2.1: Initial assessment of shock states (source: [1]).
mean arterial pressure is less than 70 mm Hg. The second symptom is tissue hy-
poperfusion. It can be detected by cold and clammy skin, small urinal output and
altered mental state. Lastly, hyperlactatemia is typically present in patients with cir-
culatory shock, indicating abnormal cellular oxygen metabolism. These indicators
are often revisited and they are a big part of the active research and discussion in the
scientific community.
Having these symptoms present means that a patient has circulatory shock. How-
ever, this generic diagnosis is not enough and the specific type of shock should be
identified as well. Figure 2.1 summarizes the pipeline for shock diagnosis that is
presented in the rest of this section. It shows the initial assessment of a patient
with shock (Panel A), relative frequencies of the main types of shock (Panel B), and
schematic representations of the four main types of shock (Panel C) [1].
2.1.1 Distributive (Septic) Shock
The first step in the diagnosis pipeline is to eliminate the possibility of Distributive
shock. For this reason, it is crucial to monitor the estimate cardiac output and SvO2
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(venous oxygen saturation). If one of these indicators is normal or high, it usually
means that cardiac chambers are normal and heart contractility is preserved. And
hence, distributive shock is diagnosed. Distributive shock occurs as a result of poor
distribution of blood to the tissues, leading to inadequate tissue perfusion. Multiple
types of shock fall under this category such as spinal, septic, and anaphylactic shock.
The distributive shock is also known as relative hypovolaemia. It happens when an
allergic reaction, or damage to the nervous system cause blood vessels to vasodilate
or become leaky.
There are three subtypes of distributive shock: anaphylactic, neurogenic and sep-
tic shock. Anaphylactic shock refers to an allergic reaction that causes low blood
pressure. Neurogenic shock is caused by a damaged central nervous system and
also leads to low blood pressure. Septic shock is the most common type of distribu-
tive shock.
In the context of distributive shock, septic shock is of particular interest for this
thesis. According to [13] and based on a consensus process using results from a
systematic review, surveys, and cohort studies, septic shock is defined as a subset
of the more general sepsis pathology in which underlying circulatory, cellular, and
metabolic abnormalities are associated with a greater risk of mortality than sepsis
alone. Adult patients with septic shock can be identified using the clinical criteria
of hypotension requiring vasopressor therapy to maintain mean blood pressure of
65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L after
adequate fluid resuscitation.
2.1.2 Hypovolaemic (or Hemorrhagic) Shock
If the estimate cardiac output or SvO2 is low, then the next step in the diagnos-
tic pipeline is to check whether the shock is hypovolaemic. For this purpose, it is
important to check the central venous pressure (CVP). If it is low the shock is hy-
povolaemic. This means that the contractility of a heart is high and that the cardiac
chambers are small. This is a result from blood, plasma loss or excessive fluid loss
(e.g., major burns). Usually, it requires more than 20 percent (one-fifth) of the body’s
blood or fluid supply to be lost. Hypovolaemic shock is very common with young
children and older adults. It often results from a bleeding due to trauma (e.g. se-
rious cuts, blunt injuries, internal bleeding, etc.). Among other causes of this type
of shock, we find severe burns, excessive diarrhea, vomiting and sweating. The ex-
tensive loss fluid related to hypovolaemic shock causes a wide range of symptoms:
from mild symptoms like headaches and nausea, to severe symptoms like pale skin,
rapid breathing, rapid heart rate, lightheadedness and weak pulse. However, these
symptoms are very common among other types of shock, so it is important to check
for any types of wounds, internal bleeding and other indications of blood loss to de-
tect hypovolaemic shock. Hypovolaemic shock occurs when dehydration or hemor-
rhage reduces blood volume.
2.1.3 Cardiogenic Shock
Once the hypovolaemic and cardiogenic shock diagnoses are discarded, there are
still two candidate types of shock: cardiogenic or obstructive. Cardiogenic shock
occurs when the heart is unable to circulate enough blood volume to maintain ad-
equate tissue perfusion. It results in large ventricles and poor contractility due to
a damage to the heart. Cardiogenic shock is a result of an acute episode of heart
failure or a heart attack. In [14], the authors pointed out that cardiogenic shock has
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clinical signs of hypoperfusion and/or serum lactate > 2 mmol/L despite fluid re-
suscitation (n = 219, mean age 67, 74% men). Usually, risks for cardiogenic shock
include previous history of myocardial infarction (heart attack), plaque buildup in
the coronary arteries (arteries supplying blood to the heart) and long-term valvular
disease (disease affecting the valves of the heart).
Since most symptoms of cardiogenic shock are very similar to those of other
types of shock, it is important to look for potential causes of a heart failure. They
include inflammation of the heart muscle (myocarditis), infection of the heart valves
(endocarditis), inability of the heart muscle to work properly (e.g. sudden blockage
of an artery in the lung, damage to the valves allowing the backflow of blood, fluid
buildup around the heart reducing its filling capacity, etc.), drug overdoses or poi-
soning with substances that can affect heart’s pumping ability, etc. All these factors
may damage the main pumping chamber of the heart and cause cardiogenic shock.
Cardiogenic shock happens when injury prevents heart from pumping efficiently.
2.1.4 Obstructive Shock
If the estimate cardiac output or SvO2 is low and CVP is high, then there is a pos-
sibility of obstructive shock. It can occur due to some kind of obstruction in the
cardiovascular system like pulmonary embolism (blood clot in the lung), cardiac
tamponade (compression of the heart due to fluid build up), tension pneumothorax
(collapsed lung), heart lesions (obstruct the flow of blood from the heart), or vena
cava syndrome (a major vein in the body becomes blocked and cannot carry blood
from the body to the heart) [1]. This means that despite normal intravascular vol-
ume and myocardial function (heart pumping well), there are physical changes that
lead to obstruction during diastolic filling of the ventricles, in contrast to biological
or chemical changes. Hence, the flow of the blood to the heart is decreased due to
obstruction. Signs, symptoms, management and treatment of obstructive shock are
dependent upon the cause.
Signs and symptoms of obstructive shock are very similar to those of cardiogenic
shock. The main difference is that obstructive shock is caused by an obstruction of
blood flow outside of the heart. While in cardiogenic shock the cause of the shock is
in the heart itself. Obstructive shock occurs due to a reduction in venous return, but
may also be caused by blockage of the aorta.
2.2 Epidemiology of Shock
According to [15], up to one-third of patients admitted to the ICU are in circulatory
shock. In the 1,679 ICU patients in the European Sepsis Occurrence in Acutely Ill
Patients II trial, septic shock was the most frequent cause of shock, accounting for
62% of cases, followed by cardiogenic shock (16%), hypovolemic shock (in 16%),
other types of distributive shock (in 4%), and obstructive shock (in 2%) [16]. Figure
2.1(B) shows relative frequencies of the main types of shock. Since the septic shock
and cardiogenic shock are the most frequent and of particular interest for this thesis,
they require more attention.
Septic shock is the most severe manifestation of sepsis. Based on the 1,656 pa-
tient study[16], the reported case-fatality rates due to septic shock are in the range
of 40–50%, reaching as high as 80%. More recent studies report that the septic
shock–associated crude mortality is 46.5% [13] and 58.8% [17] (see Figure 2.2). This
systematic review identified 44 studies reporting septic shock outcomes (total of 166
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FIGURE 2.2: Hospital incidence and mortality rates for septic shock
in Germany, 2007-2013 (source: [17]).
479 patients) from a total of 92 sepsis epidemiology studies. The epidemiology of
septic shock in low-income countries is very limited, although some literature sug-
gest that its incidence is increasing [7]. Among the patients admitted to IC,U the
reported incidence of septic shock is between 6.3% and 14.7% [18], [19]. The epi-
demiology of shock is complicated by differences in shock identification. Multiple
studies report different cutoffs and combinations for blood pressure (BP), fluid resus-
citation, vasopressors, serum lactate level, and base deficit to identify septic shock
[7]. Septic shock is the most common form of shock and it remains the leading cause
of mortality in the ICU.
Cardiogenic shock is less frequent compared to septic shock. It remains the sec-
ond most frequent form of shock, though. It has most commonly been studied in the
setting of acute myocardial infarction. Among these patients, 6-9% develop cardio-
genic shock [12]. In a multinational observational study of 65,119 patients hospital-
ized for an acute coronary syndrome between 1999 and 2007, 4.6% developed cardio-
genic shock, and the in-hospital case-fatality rate was 59.4% [7]. Cardiogenic shock is
the leading cause of mortality in patients hospitalized with acute coronary syndrome
(ACS). In a study conducted between 2001 and 2014 [20], among the 28,217 patients
with ACS, 1,209 (4.3%) had cardiogenic shock: 526 (44%) at the time of admission
and 683 (56%) later on during hospitalization. Among all age groups, a marked in-
crease in the use of coronary angiography and revascularization, with a substantial
reduction in the adjusted in-hospital mortality rate, was observed [20]. Overall in-
hospital cardiogenic shock mortality decreased from 60.3% in 1995 to 47.9% in 2004
(P<.001) [12].
2.3 Treatment of Shock
Treatment of shock depends on a cause. It requires a good understanding of the
underlying pathophysiological mechanisms and it is critical to identify the type of
shock correctly. Even though the treatment varies depending on the shock type,
there are general guidelines that are universal for all types. Treatment should be
based on the correction of the cause of shock and hemodynamic stabilization through
fluid infusion and administration of vasoactive agents. Blood lactate measurements
and clinical evaluation are used for the patient’s response monitoring [1].
According to [1], there are four phases in the treatment of shock (see Figure
2.3). During the first (salvage) phase, the goal is to stabilize the blood pressure
and cardiac output that are required for survival. This phase requires performing
lifesaving procedures to treat the underlying cause of shock. In the second (opti-
mization) phase, the treatment is focused on increasing cellular oxygen availability
and targeting hemodynamic status [21]. During this phase, cardiac output, mixed
venous oxygen saturation (SvO2), and lactate levels are carefully monitored. When
the hemodynamic stability is achieved, it is time for the third (stabilization) phase,
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FIGURE 2.3: Four Phases in the Treatment of Shock (source: [1]).
where the goal is to prevent organ dysfunction, even after hemodynamic stability
has been achieved. Finally, the fourth (de-escalation) phase attempts to wean the
patient from vasoactive agents and promote spontaneous polyuria or provoke fluid
elimination through the use of diuretics or ultrafiltration to achieve a negative fluid
balance [1].
Resuscitation of the patient should be started in parallel with the investigation
of the cause. The important components of resuscitation are summarized in the VIP
rule: ventilate (oxygen administration), infuse (fluid resuscitation), and pump (admin-
istration of vasoactive agents)[1]. Once identified, the cause must be corrected.
Hemodynamic support restores blood pressure, provides adequate cellular metabolism
and decreases the blood lactate level. Early, adequate hemodynamic support of pa-
tients in shock is crucial to prevent worsening organ dysfunction and failure [1]. In
patients with shock and a blood lactate level of more than 3 mmol/L, Jansen et al. [22]
found that targeting a decrease of at least 20% in the blood lactate level over a 2-hour
period seemed to be associated with reduced in-hospital mortality. Hemodynamic
support is crucial when it comes to prevention of worsening organ dysfunction and
failure.
The four phases described in this section are essential for the circulatory shock
treatment. The treatment should be immediate, while the cause of shock is being
identified. The most important steps of the treatment are the stabilization of blood
pressure so that heart and brain are perfused with blood, treatment of the cause of
shock, increasing heart contractility, and providing oxygen and airway protection.
Once the treatment has gone through all four phases, the patient’s life is not in dan-
ger and the possible damage caused by shock is reduced.
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Chapter 3
State of the Art: Mortality
Prediction in the ICU
This chapter describes important aspects of the work related to this thesis. Even
though the thesis uses only clinical data, it is a part of the ShockOmics research
project the manages multi-omics data. To our knowledge, there is no multi-omics
study of mortality prediction in patients with circulatory shock. But since the mor-
tality prediction model for one medical condition can be extended to other diseases,
the state of the art techniques for mortality prediction not related to circulatory shock
are relevant for this thesis. Additionally, the chapter includes the description of the
multi-omics approach, the benefits and challenges of using it, and the description of
some common scoring systems that are often used as features in the machine learn-
ing (ML) framework. This chapter is built around the ML framework, the multi-
omics data it can use, and scoring systems that incorporate relevant information for
mortality prediction knowledge, reducing the amount of features in the model.
3.1 The Multi-omics Approach for Disease Analysis
In recent years, advances in omics technologies have allowed to gather a big amount
of diverse data at different levels, including genomics, proteomics, peptidomics,
transcriptomics and metabolomics. This has created an opportunity to improve
the understanding of multiple medical conditions and the biological processes un-
derneath them. Encompassing multiple omics levels in the data and using these
data for analysis is often called a multi-omics approach. The analysis of such data has
been used to build comprehensive and dynamic models for such difficult conditions
as cancer, where it had a higher performance in clinical outcome prediction and
higher stability [23], and chronic kidney disease, where it allowed to track molecu-
lar changes for the purpose of drug discovery [24]. Multi-omics models have been
shown to substantially increase the confidence in the identified biomarkers, thera-
peutic targets and outcome prediction in multiple recent studies [23]–[27].
A pilot study for mortality prediction in patients with severe septic shock by Fer-
rario et al. [28] attempted to verify a metabolomic approach to determine changes
in circulating metabolites able to characterize the progress of septic shock condition
and to reveal the involved pathways for the ShockOmics project. In this study, they
concluded that the use of omics tools able of examining physiological responses at
system level is a particularly promising approach for complex and heterogeneous
conditions such as septic shock. They also noted that it should be proved in a larger
cohort by including different phenotypes (not only the severe patients) and multi-
markers information such as multi-omics data [28].
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This thesis addresses some of the proposals for future work of the Ferrario et al.
study [28] by using multi-level biomarkers.
3.2 Scoring Systems
Scoring systems are widely used for mortality prediction in the ICU. Various scores
are designed to determine the current health status of the patient, to increase un-
derstanding of the effectiveness of treatment and to optimize the use of hospital
resources. Different scores are developed for certain conditions such as, for instance,
cancer, liver failure, or sepsis. Scores are calculated from the data collected on the
first day of stay in the ICU, throughout ICU stay, or for the first several days in the
ICU. These calculations are based on physiological variables and medical history
information. Many studies have shown the effectiveness of scoring systems in pre-
dicting hospital mortality and most of the available scores are comparable in terms
of outcome prediction [29].
There are two types of scores: subjective and objective. Subjective scores are
established by a panel of experts who choose the variables and assign a weight to
each variable based on their personal expert opinion. The more abnormal the result,
the higher the weight that is assigned [30]. Objective score variables are collected
using logistic regression modeling techniques and clinical judgment to determine
ranges and to assign weights [31]. A scoring system usually comprises two parts –
a score (a number assigned to disease severity) and a probability model (equation
giving the probability of hospital death of the patients) [31]. A model refines the
ability of scores or scales to be used in comparing various groups of patients for
the purpose of treatment, triage or comparative analysis, and thus helps in decision
making [32].
Scoring systems are also used for the mortality prediction for patients with shock.
Some of the scores are developed specifically for certain types of shock. For example,
the CardShock risk Score [14] is used for patients with cardiogenic shock; mortality
prediction performance for this score is 0.85 (area under the receiver operating char-
acteristic curve).
In this section, three scoring systems are considered in more detail, since they are
relevant to the ShockOmics data and important for this thesis: the sequential organ
failure assessment score (SOFA); the acute physiology and chronic health evaluation
II (APACHE II); and the Glasgow Coma Scale.
3.2.1 SOFA
The SOFA score (or sepsis-related organ failure assessment) was designed to track a
status of the patient during the stay in an ICU over time. It is a subjective score with
the data collected throughout the ICU stay or for the first three days [31]. Its main
goal is to determine the extent of patient’s organ failure. It is based on the degree of
organ dysfunction data on six organ failures and is scored on a scale of 0-4 [31]. The
guideline for calculating the SOFA score is shown in Figure 3.1. Although the score’s
main purpose is to assess organ dysfunction, it is reported to be a good indicator of
prognosis during the first few days of ICU admission (both the mean and highest
SOFA scores are particularly useful) [35].
The performance of the models that use SOFA for outcome prediction is usu-
ally assessed based on area under the receiver operating characteristic curve (AUC).
In research that studied critically ill patients [29], the SOFA score showed an AUC
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FIGURE 3.1: Sequential organ failure assessment score [33]–[35]
(source: [31]).
of 0.776 for day-1 scores. A more recent study [36] involving 184,875 patients sup-
ports this performance showing an AUC of 0.753. Moreover, Rivera-Fernández et al.
[37] showed that 28-day mortality was related to mean and maximum daily SOFA
scores in a cohort of patients who were critically ill with an AUC of 0.95. The SOFA
score shows a significant prognostic value for in-hospital mortality prediction, out-
performing SIRS criteria and the qSOFA score in an ICU setting [36].
3.2.2 APACHE II
APACHE II is a subjective score that was designed to measure the severity of disease
for patients admitted to ICU. The score is calculated based on the data collected on
the first ICU day [31]. It uses such variables as age, preexisting diseases, and 12
acute physiological variables to calculate a score from 0 to 71 [38]. The guideline for
calculating the APACHE II score is presented in Figure 3.2. The focus on the disease
severity measurement makes the APACHE II score a good mortality prediction tool.
APACHE II is often used for outcome prediction. According to [39], APACHE II
scores were able to predict the mortality and correlated positively with actual mor-
tality (r = 0.84, p < 0.01). These findings were supported by the work of Agarwal et
al. [40], where the mean APACHE II scores correlated well with the surgical outcome
in patients of perforation peritonitis and with the hospital and ICU stay. The mean
Apache II score in survivors was 4.05 and in non-survivors was 12.75 and p value <
0.0001 which is highly significant [40].
Additionally, APACHE II scores of discharge and admission were very useful for
predicting post-ICU mortality and ICU readmission during the same hospitalisation
in a surgical ICU [41]. Based on their results, the discharge APACHE II score is con-
firmed to be useful in predicting post-ICU mortality and is superior to the admission
APACHE II score in predicting early ICU readmission in surgical ICU patients [41].
The discharge and admission scores in predicting in-hospital mortality was 0.631
and 0.669, respectively; and 0.606 and 0.574 for predicting all forms of readmission
[41]. The APACHE II score showed very promising results for outcome prediction,
and combining it with other scores (e.g. IMPACT [42]) seems to improve the predic-
tive accuracy.
3.2.3 Glasgow Coma Scale
The Glasgow Coma Scale (GCS) is rarely used for mortality prediction but it is often
a part of other scoring systems. It is a part of both SOFA and APACHE II scores,
as can be seen in Figure 3.1 and 3.2. The reason behind this is that the GCS was
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FIGURE 3.2: Acute physiologic and chronic health evaluation
(APACHE II) [38] (source: [31]).
designed for assessing the depth and duration of impaired consciousness and coma
[43]. And as a result it provides the status of the central nervous system. Several
studies have shown that there is a good correlation between GCS and neurological
outcome [31], [44]. Currently, GCS is often used in studies related to traumatic brain
injury mortality [45], [46]. Despite the focus of GCS on central nervous system and
recommendations to apply it in the context of other physiologic information and
the patient’s specific diagnosis [47], it is still useful for mortality prediction. The
guideline for calculating GCS is presented in Figure 3.3.
GCS was successfully used for mortality prediction in a big study involving 1,695
critically ill patients [48], it yielded an AUROC of 0.715. Higher results were shown
in an earlier study [49], where the outcome was predicted among comatose patients.
In this study, GCS yielded an AUROC of 0.87. This considerable difference in the
performance between the two studies can be explained by the fact that GCS was
primarily designed for patients in coma. Other studies also report the significance
of GCS for mortality prediction (e.g. for organophosphate poisoning [50]), however,
using GCS alone for this task is less common than using SOFA or APACHE II.
3.3 Machine Learning Framework
In the ICU, it is often difficult to accurately predict when patients develop shock or
other critical conditions occur. As was mentioned, shock can be detected only after-
wards, as most of the critical conditions that require immediate treatment. And at
that time the damage (e.g organ injury) is already present. Multiple studies proved
that critical physiological changes are seen in 51–86% of patients who suffered a sub-
sequent cardiopulmonary arrest on general wards, often several hours before the
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FIGURE 3.3: Glasgow coma score [43] (source: [31]).
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arrest event [51]. And if some critical conditions can be predicted by tracking physi-
ologic changes, then there is a need to identify which variables should be monitored.
This is not a trivial task.
Predicting the occurrence of some critical condition (e.g. circulatory shock) re-
quires a minimal monitoring dataset to identify patients with a targeted condition
across all possible processes, and then specifically monitor their responses to tar-
geted therapies known to improve outcome [52]. For this problem, an ML frame-
work can be used. Since prediction of outcome is a classification problem, then it
requires multivariable datasets and data-driven classification techniques. Usually,
this approach involves libraries of responses across large and comprehensive collec-
tions of records of diverse subjects whose diagnosis, therapies, and course is already
known to predict not only disease severity, but also the subsequent behavior of the
subject if left untreated or treated with one of the many therapeutic options [52].
This approach is beyond human intellectual scope and requires more advanced and
data-driven techniques, such as ML methods.
Various ML algorithms can be used for pattern detection in multi-variable data
for outcome prediction or qualitative analysis of medical conditions. Over the last
decade, they have gained a lot of attention, since they have shown better perfor-
mance than traditional statistical approaches, work well with large amounts of data
and can be used in various tasks that occur in the ICU: from outcome prediction
to therapeutic targets detection. And an improved detection of the physiological
changes, together with the identification of new biomarkers (that a human observer
can easily miss), is crucial in impacting the potential to rescue unstable patients.
3.3.1 Comparison with Statistical Approaches
In statistical approaches, logistic regression is commonly used for outcome predic-
tion. However, even though this approach is very common, it is less accurate com-
pared to ML techniques. There are multiple studies that support this statement and,
as a result, more studies use an ML framework even in cases where single scores can
be used.
ML techniques can outperform scoring systems and logistic regression for mor-
tality prediction. In a recent study, Motwani et al. [53] compared LogitBoost, a
boosted ensemble algorithm, with existing clinical metrics (FRS, SSS, SIS, DI) and lo-
gistic regression. They used coronary computed tomographic angiography (CCTA)
data to evaluate prognostic risk in individual patients with suspected coronary artery
disease. Their findings suggest that ML algorithms predicted 5-year ACM signifi-
cantly better than existing clinical or CCTA metrics alone (AUC): 0.79 vs. FRS: 0.61,
SSS: 0.64, SIS: 0.64, DI: 0.62; P< 0.001 [53]. Another study by Allyn et al. [54] provided
similar results, comparing a greedy ensemble algorithm (a weighted sum of Gradi-
ent Boosting Machine, Random Forest, Support Vector Machine and Naive Bayes)
with traditional methods for predicting mortality after elective cardiac surgery. AU-
ROC for the ML model was 0.795 against 0.737 for the scoring system and 0.742
for logistic regression. Finally, the ML model (Random Forest) outperformed the
Modified Early Warning score and logistic regression models in predicting clinical
deterioration on the wards (AUC): 0.8 vs. 0.7 and 0.77 [55].
The ML framework effectively individualizes risk assessment and overcomes
many of the limitations of a standard statistical approach. ML models are more
accurate in predicting mortality and it justifies their usage in the field of medical
prediction [55]–[57]. In the work of Taylor et al. [56], relevant for this thesis, they
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compared ML and logistic regression models for mortality prediction of 4,676 pa-
tients with sepsis. Once again, based on AUC, logistic regression was outperformed
(0.86 vs. 0.76) [56]. However, in predicting 30-day Heart Failure readmission, the ML
algorithms (a tree-augmented naive Bayesian network, a random forest algorithm,
and a gradient-boosted model) did not improve the results compared to traditional
statistical methods using two independently derived logistic regression models and
a least absolute shrinkage and selection operator method [58].
3.3.2 Multi-Omics Data Usage
The ML methodology scales up correlational analyses to potentially very highly
multivariate, high-frequency, and perhaps multisource data that could help empiri-
cally discover leading indicators of instability [52]. Integrating multi-omics data into
an ML framework has been a focus of much attention in the past years. Before that,
little has been done to use multiple levels of omics biomarkers for improving the
prediction accuracy. While prediction modeling using a single type of omics mark-
ers is a well-studied topic, it is not clear how different types of biomarkers should be
handled simultaneously when deriving a prediction model [25]. But encompassing
biomarkers on multiple levels might be a difficult task, since it requires consider-
ation of hundreds or even thousands variables. And it is much more difficult to
implement in clinical practice than a model including only a handful of variables
[25].
Models including several hundreds/thousands of variables raise a problem of
choosing an ’optimal’ subset of variables for prediction, which is a critical task in
personalized medicine. Using a large number of variables in ICU is not practical,
since it requires a lot of monitoring efforts and cost. Unfortunately, although using
omic markers for prediction has been a well-studied topic, it is not clear how the
different modalities should be handled [59]. In general, there are two common ap-
proaches on how to handle different levels and modalities. The first one is to simply
merge all the data and ignore the source of the variables. The second one is more
sophisticated, and it requires analyzing each modality on its own and then merging
the results [60]. Some authors even suggest that merging can be performed at dif-
ferent stages of the analysis [61]. Even though the literature is often vague on when
to use different strategies [59], one should always consider using a small number of
variables, as opposed to a large number of variables.
Numerous studies involve an ML framework for predicting outcome with multi-
omics data. Some of them use traditional ML methods like Random Forests [62] to
provide new insights, for example, into the multifactorial nature of Crohn’s disease
and help highlight cohort-specific to disease pathophysiology [26]. The model that
Douglas et al. [26] presented in their study could be extended in the future to other
diseases and to other data types such as transcriptomics and metabolomics to better
understand the relative importance of each of these features.
Other studies tried to provide a novel systematic approaches to identify inter-
action models between pathways based on multi-omics data. For example, dif-
ferent modifications of the lasso method [63], such as priority-Lasso [25] and IPF-
LASSO [59], were successfully applied recently. Different evolutionary algorithms
are also used for mortality prediction with multi-omics data. The Grammatical Evo-
lution Neural Networks method is proposed by Kim and colleagues [27] in their
metadimensional knowledge-driven genomic interactions study. They claim that
their novel framework identifies interaction models between pathways based on
multi-omics data and incorporates biological knowledge into such models [27]. In a
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different study by Kim et al. [64] an expression balance analysis algorithm was used
to predict expression in a gene knockout condition, and the predictive performance
of their model ranges from 0.54 to 0.87 for the various omics layers, which far ex-
ceeds various baselines [64]. They drew a conclusion that determining variability
in molecular signatures based on these interactions between pathways may lead to
better diagnostic/treatment strategies for better precision medicine [27].
3.3.3 Other Related Work
Various ML algorithms have successfully been used for outcome prediction. The
alternating decision tree model showed an accurate continuous probabilistic score
for the prediction of day 100 overall transplantation-related mortality [65]. Multiple
methods like Neural Networks, Naive Bayes, Decision Trees, and logistic regression
were compared in traumatic brain injury outcome prediction: Neural Networks was
the best for 6-month functional outcome prediction (AUROC of 0.961), and Naive
Bayes was the best predictive model for mortality (AUROC of 0.911) [66]. Prob-
abilistic co-occurrence analysis and principal component analysis were applied in
a leading indicators of adverse health events study, the AUROC of the proposed
framework was 0.857 [67]. Probabilistic co-occurrence analysis was used for to seg-
ment each high-frequency measurement channel into sequences of non-overlapping
time intervals, and to independently characterize waveform frequency spectrum in
each segment, while principal component analysis applied to the spectra observed
during a specific physiologic state (e.g., periods of stability) to envelope the range of
variability of waveform patterns that can be expected in the particular state [67].
Some studies tried to achieve interpretable results, for example, a temporal rule
learning methodology was used to extract human-interpretable logical statements
for automatic identification of artifacts in monitoring critically ill patients [68]. Fit-
erau et al. showed that the identification of artifacts in real time high frequency
vital sign data can be handled automatically and in a human understandable fash-
ion [68]. The performance of the Gaussian Process Regression was investigated for
the functional characterisation of vital-sign trajectories [69]. It was shown that the
proposed approach was able to discriminate between abnormal patient trajectories
corresponding to those who deteriorated physiologically and were admitted to a
higher level of care, from those belonging to patients who had no clinically relevant
events. Most of the mentioned work can be extended for mortality prediction. And
once again, they confirm that big data–driven, ML approach outperforms traditional
analytic techniques for predicting in-hospital mortality.
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Chapter 4
Preliminary Results: the Analysis
of the Data
The focus of this chapter is on the ShockOmics dataset (clinical data) analysis and
corresponding preliminary results for outcome prediction. Since the dataset had a
lot of missing values, it was important to try out different data imputation tech-
niques and see the results they provide. Here, we compare different multiple im-
putation techniques, which are divided into two categories: those that work for
multiple-types of data (Predictive mean matching, K-Nearest Neighbor, Random
Forest, Classification/regression trees) and those that work only with numeric data
(Bayesian Linear Regression, Linear Regression ignoring model error, Linear Regres-
sion using bootstrap, Linear regression with predicted values). To measure their
performance, several machine learning (ML) algorithms were used, with the accu-
racy and the Matthews correlation coefficient (MCC) as performance measures (their
mean ± st.d.).
The goal of the ML models is to predict the outcome of patients and the feature
set for these experiments includes common markers for mortality risk assessment.
These features were chosen based on the literature and modern-day practices for
shock outcome prediction. After the imputation techniques and ML models were
evaluated, the reconstruction errors were calculated to choose the imputation tech-
nique to be used in the later experiments. Here, we assume that the imputation
techniques that works the best for the chosen subset will be the best for the whole
dataset. So, for later experiments only one imputation technique is used.
After reconstruction errors were calculated a few Bayesian Networks with cus-
tom structures were tested. The structures were chosen based on casual relation-
ship assumptions, motivated by the pseudo time-series nature of the ShockOmics
dataset. The results obtained in these experiments were used as a baseline for the
later experiments.
4.1 Dataset Description
As previously mentioned, the ShockOmics dataset was collected within the Shock-
Omics European research project (“Multiscale approach to the identification of molec-
ular biomarkers in acute heart failure induced by shock”, Nr. 602706, http://shockomics.
org) in three ICUs: Hopital Erasme, Universite Libre de Bruxelles, Belgium; Hos-
pital Universitari Mutua Terrassa, Spain; and Hopitaux Universitaires de Geneve,
Switzerland. A systematic analysis of expression levels of transcripts, genes and
their protein products and of peptides generated by proteolysis were carried out on
blood samples obtained from ICU patients [10]. The data covered 7 days of hemo-
dynamic signals since the diagnosis of shock (T0). Clinical data and blood samples
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FIGURE 4.1: Observations, features and their missing values in the
ShockOmics data. The full list of features and their missing values
can be found in Appendix A, Figures A.1, A.2, A.3, A.4
were collected for analysis at: 1) T1 < 16 h from T0; 2) T2 = 48 h after T0; 3) T3 =
day 7 or before discharge or before discontinuation of therapy in case of fatal out-
come [10]. Since a lot of patients either died or were discharged during the study,
the dataset has a lot of missing values at later time-steps (especially at T3).
The ShockOmics data contains scoring systems (e.g. SOFA, APACHE II, Glasgow
Coma Scale) and biomarkers on multiple levels. The major focus of the data is on
molecular triggers of acute heart failure associated with shock and inflammatory
mediators and markers which are activated after an initial insult. According to [70]:
Several data sources integrate the ShockOmics database: a) plasma sam-
ples from existing bio-banks (Albios and Proteosepsis); b) blood samples
and hemodynamic recordings from septic shock (SS) and cardiogenic
shock (CS) patients, and from sepsis patients; c) bio-samples and hemo-
dynamic data obtained from animal models of shock; d) data from in
vitro models of cardiac injury in shock (Neuro-Zone SRL, Milano, Italy).
The clinical data of the ShockOmics dataset, that is used in this thesis (later re-
ferred to as the ShockOmics dataset), has 333 features and 75 observations. 32.1% of
all values are missing, and the highest percentage of missing values in one feature
is 97%. Figure 4.1 shows a graphical depiction map of missing values for each ob-
servation (for the full list of features and their corresponding missing values please
refer to Appendix A, Figures A.1, A.2, A.3, A.4). The dataset has both numerical and
categorical values, but the majority of data is numerical (see Appendix A, Figures
A.5).
4.2 Preliminary Experiments Methodology
For a better understanding of the ShockOmics dataset, a series of experiments were
conducted. Since the initial dataset had a lot of features and missing values, it was
required to choose a subset of features (see Sections 4.2.3 and 4.2.4) and then use
imputation techniques (see Section 4.2.1) to get rid off the missing values. Multiple
imputation techniques were applied to the data and then evaluated. The evalua-
tion was based on two factors: the first was the performance of the ML models, the
second, the reconstruction error.
For the evaluation of the performance of the ML models (see Section 4.2.2) the
Accuracy and the MCC were used as performance measures. The training was per-
formed 100 times using 75% of the data. Each time, the split of the data was random.
Then the mean and the standard deviation of the 100 executions (using the test set)
were calculated for both performance measures.
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For the reconstruction error, a different subset of features was used (Section
4.2.4). The chosen subset did not have any missing values. It was artificially re-
duced to have 10%, 20% and 35% of missing values. Then it was imputed by each of
the techniques. Based on the lowest reconstruction error, the imputation techniques
were chosen. Additionally, the performance of ML models was similarly measured
as in the imputation experiments, for the data with 35% of missing values. Then,
these results were compared with the performance of the models using the original
dataset with no missing values.
After the data was completed by the imputation technique that showed the best
performance, the Bayesian Network structure experiments were conducted. Their
purpose was to identify the number of variables discretization and to choose be-
tween the Maximum Likelihood Estimator and the Bayesian Estimator. The results
of all experiments were designed to evaluate the data and the performance that can
be achieved for the outcome prediction task.
4.2.1 Imputation Techniques
Two types of the imputation techniques were used in the experiments. The first one
handles multi-type data that can handle missing values of different types (numeri-
cal, categorical, etc.). And the second one is only for numerical missing values. In
this section, a list of these techniques is presented, including their short description
and further notation. The imputations were done in R [71] using different packages
with imputation techniques. The default parameters of the methods were used.
The experiments include the following imputation techniques for multi-type data
and their further notation:
• pmm. Imputation by predictive mean matching [72]. A general purpose semi-
parametric imputation method. Calculates imputations for univariate missing
data by predictive mean matching (mice package [73]);
• knn. K-Nearest Neighbour imputation based on a variation of the Gower Dis-
tance for numerical, categorical, ordered and semi-continous variables (VIM
package [74]);
• missForest. Non-parametric missing value imputation using Random Forest
[75]. It can be used to impute continuous and/or categorical data including
complex interactions and nonlinear relations (missForest package [76]);
• cart. Imputation by classification and regression trees [72]. Imputes univariate
missing data using classification and regression trees (mice package [73]).
The experiments include the following imputation techniques for numeric data
and their further notation:
• norm. Imputation by Bayesian linear regression [77]. Calculates imputations
for univariate missing data by Bayesian linear regression, also known as the
normal model (mice package [73]);
• norm.nob. Imputation by linear regression without parameter uncertainty
[73]. Similar to norm, except it does not account for the uncertainty of the
model parameters (mice package [73]);
• norm.boot. Imputation by linear regression using bootstrap [73]. Imputes uni-
variate missing data using linear regression with bootstrap (mice package [73]);
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• norm.predict. Imputation by linear regression through prediction [78]. Im-
putes the "best value" according to the linear regression model, also known as
regression imputation (mice package [73]);
4.2.2 Machine Learning Models
The mortality prediction task at hand is a classification problem with two classes:
Dead (18 observations) and Alive (57 observations). Several ML algorithms were
chosen for the experiments. The scikit-learn [79] library was used for their imple-
mentation. The following algorithms were used in the experiments:
• SVC-R. Support vector machines classification [80] with the radial-basis func-
tion kernel, enabled probability estimates and automatically adjusted weights,
that are inversely proportional to class frequencies in the input data. The
rest of the parameter were used by default. The full name of the method
in the scikit-learn library is sklearn.svm.SVC (see http://scikit-learn.org/
stable/modules/generated/sklearn.svm.SVC.html#sklearn.svm.SVC);
• LDA. Linear Discriminant Analysis [81]. A classifier with a linear decision
boundary, generated by fitting class conditional densities to the data and using
Bayes’ rule. The model fits a Gaussian density to each class, assuming that all
classes share the same covariance matrix. The default parameters were used.
The full name of the method in the scikit-learn library is klearn.discriminant_-
ana-lysis.LinearDiscriminantAnalysis (see http://scikit-learn.org/stable/
modules/generated/sklearn.discriminant_analysis.LinearDiscriminantAnalysis.
html);
• KNN. Classifier implementing k-nearest neighbors [82]. The number of neigh-
bors was set to three, the rest parameters were set to default. The full name of
the method in the scikit-learn library is sklearn.neighbors.KNeighborsClassifier
(see http://scikit-learn.org/stable/modules/generated/sklearn.neighbors.
KNeighborsClassifier.html);
• G-NB. Gaussian Naive Bayes classifier [83]. The default parameters were used.
The full name of the method in the scikit-learn library is sklearn.naive_bayes.Gaus-
sianNB (see http://scikit-learn.org/stable/modules/generated/sklearn.
naive_bayes.GaussianNB.html);
• M-NB. Naive Bayes classifier for multinomial models [84]. The default param-
eters were used. The name of the method in the scikit-learn library is sklearn.na-
ive_bayes.MultinomialNB (see http://scikit-learn.org/stable/modules/generated/
sklearn.naive_bayes.MultinomialNB.html);
4.2.3 Imputation Experiments Feature Subset
In the imputation experiments, the subset of features from the ShockOmics dataset
was used. As can be seen in Table 4.1, there are 14 features with one target value,
namely Result in ICU. In order to perform the mortality risk assessment, a few most
common biomarkers were chosen. Some of the imputation methods failed to com-
plete APACHE II at T3 and SOFA at T3 columns, so they were left out. Table 4.1
shows the types of the features and the amount of available observations for each
column (where 75 means that there is no missing values for the feature). Addition-
ally, it should be noted that the only categorical feature was not included in the
experiment with numerical imputation techniques.
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Name of the column Num. of observations Type
Which type of shock 75 categorical (4 val)
Lactate levels (mmol/L)T1 72 numerical (cont)
Lactate levels (mmol/L)T2 64 numerical (cont)
Lactate levels (mmol/L)T3 38 numerical (cont)
Mean arterial pressure (mmHg)T1 75 numerical (cont)
Mean arterial pressure (mmHg)T2 71 numerical (cont)
Mean arterial pressure (mmHg)T3 44 numerical (cont)
SOFAT1 75 numerical (cont)
SOFAT2 71 numerical (cont)
APACHE I IT1 75 numerical (cont)
APACHE I IT2 71 numerical (cont)
Result in ICU 75 categorical (2 val)
TABLE 4.1: Imputation Experiments Feature Subset: 14 feature
columns and 1 target column, namely Result in ICU. Columns with
missing data are highlighted in bold.
Name of the column Num. of observations Type
Mean arterial pressure (mmHg)T1 49 numerical (cont)
SOFAT1 52 numerical (cont)
APACHE I IT1 54 numerical (cont)
Result in ICU 75 categorical (2 val)
TABLE 4.2: Reconstruction Error Experiments Feature Subset: 3 fea-
ture columns and 1 target column (Result in ICU). Each of these fea-
tures had 75 examples originally.
4.2.4 Reconstruction Experiments Feature Subset
The feature subset for the reconstruction experiments is a reduced version of the
subset from the imputation experiments. Only numerical features with no missing
values were left (see Table 4.2). Then, from this subset of data and for each column,
random observations were replaced by missing values. The percentage of missing
values for each feature was different. For the Mean arterial pressure column, 65% of
values left, while for the SOFA and the APACHE scores the numbers were 69% and
72%, respectively. This incomplete data was used with different imputation tech-
niques and ML models. The idea was to gauge the performance of the ML models
with this artificially reduced dataset.
The reconstruction error was calculated using the same subset of features. Three
datasets with different ratios of missing values were obtained by random removal
of values from the complete dataset: 35%, 20% and 10% of missing values. For each
column, the ratio of missing values was a little bit different but close to the target
ratio. After three datasets with missing values were imputed, they were compared
with the complete dataset, and the reconstruction error was calculated as the mean
squared error.
4.3 Preliminary Experiments
In these experiments, eight imputation techniques were tested (all techniques and
their notations are listed in Section 4.2.3). Experiments are organized in two groups.
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Models pmm knn missForest cart
SVC-R 0.7368 ± 0.0 0.7368 ± 0.0 0.7368 ± 0.0 0.7368 ± 0.0
LDA 0.7426 ± 0.0815 0.8226 ± 0.0664 0.7805 ± 0.0752 0.7984 ± 0.0791
KNN 0.7647 ± 0.0634 0.8468 ± 0.0666 0.8121 ± 0.0719 0.7679 ± 0.0649
G-NB 0.8095 ± 0.0758 0.8258 ± 0.0685 0.8484 ± 0.0663 0.8289 ± 0.0742
M-NB 0.7868 ± 0.0833 0.8126 ± 0.0654 0.8095 ± 0.079 0.7868 ± 0.083
(A) Here, G-NB shows the best result with the missForest imputation. However, most of the
models show their best performance with the knn imputation.
Models norm norm.nob norm.boot norm.predict
SVC-R 0.7368 ± 0.0 0.7368 ± 0.0 0.7368 ± 0.0 0.7368 ± 0.0
LDA 0.7921 ± 0.0793 0.7889 ± 0.0789 0.8026 ± 0.0775 0.8021 ± 0.0774
KNN 0.7847 ± 0.0666 0.7568 ± 0.0701 0.7642 ± 0.068 0.8432 ± 0.0627
G-NB 0.8489 ± 0.0668 0.8463 ± 0.0769 0.8489 ± 0.0673 0.8442 ± 0.0751
M-NB 0.8205 ± 0.0809 0.7932 ± 0.0915 0.7942 ± 0.0774 0.8095 ± 0.0705
(B) G-NB shows the best result with the norm.boot and the norm imputations. The
norm.predict imputation shows overall improvement in accuracy for all models, but only
the KNN model reaches the maximum performance with it.
TABLE 4.3: Imputation experiments: the accuracies (mean ± stan-
dard deviation) of the machine learning models for each dataset, im-
puted with a different technique. For each model the best results are
highlighted in bold. Meaning that a certain imputation techniques
works the best for the model. The best results in the experiment
groups are underlined: (a) for a multi-type imputation group; (b) for
a numeric imputation group.
The goal of the first group is to measure the performance of ML models (their de-
scription can be found in Section 4.2.2) on the data imputed with different tech-
niques. Here, these experiments are referred to as imputation experiments. The second
group is called reconstruction experiments. It is structured in two parts: the first one is
similar to the imputation experiments but with the smaller dataset, while the second
calculates the reconstruction error of the same dataset imputed with different impu-
tation techniques and for percentages of missing data. The accuracy and the MCC
are used to measure the performance of the ML models, while the mean squared
error (MSE) is used for the reconstruction error.
4.3.1 Imputation Experiments Results
Once the models had been trained 100 times, using multiple datasets imputed by
different methods, the accuracy and the MCC were calculated. The dataset was
split, 75% for the training set and 25% for the test set. Each time, the observations
were split randomly.
The accuracy measures for the experiments are shown in Table 4.3. The G-NB
model showed the best accuracy with the norm and the norm.boot imputation tech-
niques. The second best accuracy was obtained by the G-NB combined with the
missForest imputation. The knn imputation is worth mentioning since it showed very
good performance for all ML models and achieved the third best accuracy with the
KNN model.
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Models pmm knn missForest cart
SVC-R 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
LDA 0.2994 ± 0.2242 0.5618 ± 0.2022 0.4335 ± 0.184 0.386 ± 0.2201
KNN 0.2952 ± 0.2165 0.6059 ± 0.1854 0.5274 ± 0.2258 0.3011 ± 0.2343
G-NB 0.5741 ± 0.1801 0.5934 ± 0.1983 0.6471 ± 0.1635 0.5345 ± 0.2098
M-NB 0.5209 ± 0.1765 0.597 ± 0.1611 0.5971 ± 0.159 0.5046 ± 0.1921
(A) The best performance once again was shown by the G-NB model with the missForest im-
putation. The same combination showed the best accuracy. Here, the missForrest imputation
was the best for G-NB and M-NB, while the knn imputation was the best for the KNN and
the LDA models.
Models norm norm.nob norm.boot norm.predict
SVC-R 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
LDA 0.4467 ± 0.2311 0.4447 ± 0.2056 0.4818 ± 0.1692 0.486 ± 0.1814
KNN 0.4293 ± 0.2262 0.2654 ± 0.2455 0.3255 ± 0.1912 0.5842 ± 0.1875
G-NB 0.6249 ± 0.1918 0.6267 ± 0.1811 0.6454 ± 0.1405 0.6415 ± 0.1645
M-NB 0.6025 ± 0.1723 0.5747 ± 0.1505 0.5711 ± 0.1645 0.6042 ± 0.1601
(B) Again the G-NB model showed the best results with the norm.boot imputation. The same
combination that showed the best accuracy. The rest of the models achieved their highest
performance with the norm.predict.
TABLE 4.4: Imputation experiments: the MCC (mean ± standard de-
viation) of the machine learning models for each dataset, imputed
with a different technique. For each model the best results are high-
lighted in bold. Meaning that a certain imputation techniques works
the best for the model. The best results in the experiment groups are
underlined: (a) for a multi-type imputation group; (b) for a numeric
imputation group.
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Models Accuracy MCC
SVC-R 0.6968 ± 0.0428 -0.0933 ± 0.0811
LDA 0.7721 ± 0.0737 0.3434 ± 0.2227
KNN 0.7111 ± 0.0746 0.1924 ± 0.204
G-NB 0.7216 ± 0.1002 0.4401 ± 0.175
M-NB 0.7542 ± 0.0968 0.4695 ± 0.1625
TABLE 4.5: Reconstruction experiments: the accuracies and the
MCCs (mean ± standard deviation) of the machine learning mod-
els using the original dataset without any missing values. The best
accuracy and MCC are underlined.
The MCC measures are shown in Table 4.4. The G-NB model outperformed other
models, but now the best result was achieved using the missForest imputation, fol-
lowed by the norm.boot technique and then the norm.predict imputation (with the
same G-NB model). The MCC shows that the G-NB is much better than other mod-
els and that the missForest and the norm.predict imputations performed the best. The
missForest showed the highest result and with the norm.predict all other models aside
G-NB achieved their best performance.
The imputation experiments results show that the G-NB is a clear winner from all
other models in terms of the MCC, and it also outperformed other models in terms
of the accuracy (with a smaller gap). As for imputation techniques, the missForest
and the norm.predict imputations showed the most promising results.
4.3.2 Reconstruction Experiments: Models Performance
Before calculating the reconstruction error for several artificially made datasets with
different percentages of missing data, it was important to see the performance of the
ML models on one of such datasets. The dataset with 35% of missing values was
chosen for evaluating ML models, and the experiments were done using the same
methodology as in the imputation experiments. In the complete dataset a random
sample of data (around 35% for each feature) was replaced with missing values.
Then this data was imputed by different techniques and evaluated with the same
models.
The accuracy and the MCC of the ML models for the original dataset (without
missing values) are shown in Table 4.1. The LDA performed the best in terms of ac-
curacy and the M-NB model showed the highest MCC. Once the performance on the
data without missing values had been achieved, the random values were removed
for the data, so approximately 35% of missing values was in each column (see Table
4.2).
After removal of some values in the data, the data was imputed by different im-
putation techniques and the performance was measured again. The accuracy of the
models for different imputation techniques can be found in Table 4.6. As can be
seen from the table, the LDA model and the norm.predict imputations worked the
best. Additionally, the best performances for most of the ML models were achieved
with the norm.predict (except the G-NB model). The second and the third best accu-
racies were shown by the KNN model and the cart and the missForest imputations,
respectively.
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Models pmm knn missForest cart
SVC-R 0.7316 ± 0.0629 0.7126 ± 0.0775 0.7984 ± 0.0552 0.7932 ± 0.0563
LDA 0.8237 ± 0.0692 0.8295 ± 0.0679 0.7995 ± 0.0681 0.8074 ± 0.0658
KNN 0.8074 ± 0.0756 0.8037 ± 0.0818 0.8589 ± 0.0669 0.8621 ± 0.0677
G-NB 0.7305 ± 0.1045 0.7384 ± 0.0916 0.7758 ± 0.0847 0.7726 ± 0.1104
M-NB 0.7937 ± 0.0854 0.8089 ± 0.0807 0.8568 ± 0.0691 0.7879 ± 0.0895
(A) The best accuracy was shown by the cart imputation with the KNN model. Most of the
models performed better with the missForest technique.
Models norm norm.nob norm.boot norm.predict
SVC-R 0.7258 ± 0.0512 0.7258 ± 0.0543 0.7221 ± 0.0269 0.8195 ± 0.0472
LDA 0.8279 ± 0.0694 0.8121 ± 0.0679 0.7779 ± 0.0634 0.8716 ± 0.0629
KNN 0.8021 ± 0.0748 0.7537 ± 0.0702 0.7332 ± 0.0683 0.8526 ± 0.0572
G-NB 0.8105 ± 0.0809 0.7426 ± 0.0794 0.7468 ± 0.0873 0.7805 ± 0.0832
M-NB 0.7821 ± 0.0849 0.7637 ± 0.0916 0.7726 ± 0.0905 0.8447 ± 0.0671
(B) The majority of models were improved with norm.predict imputation. The best result was
shown by this technique and the LDA model.
TABLE 4.6: Reconstruction experiments: the accuracies (mean± stan-
dard deviation) of the ML models for each dataset, imputed with a
different technique. For each model the best results are highlighted in
bold. Meaning that a certain imputation techniques works the best for
the model. The best results in the experiment groups are underlined:
(a) for a multi-type imputation group; (b) for a numeric imputation
group.
The MCC measures for these experiments can be found in Table 4.7. Once again
the norm.predict imputation showed very promising results, having the first, the sec-
ond and the third best MCCs with the LDA, the M-NB and the KNN models, respec-
tively. Most of the models performed the best with the norm.predict imputation.
From the ML models performance comparison it is clearly seen that the LDA
model and the norm.predict imputation stand out. However, the performance of the
models with the imputed dataset is higher than with the original dataset. This prob-
lem should be addressed by calculating the reconstruction error.
4.3.3 Reconstruction Experiments: Reconstruction Error
The reconstruction error was calculated as the Mean Squared Error (MSE). The el-
ements of the imputed datasets were subtracted from the corresponding elements
in the original dataset. Three datasets with the different percentages of missing val-
ues were used in the experiments: 35%, 20% and 10%. The reconstruction errors for
these datasets are shown in Table 4.8. It is seen that for each of the datasets the best
imputation technique is different. For the 35% of missing values the cart imputa-
tion showed the lowest error, for 20% – the norm.predict technique, for 10% – the knn
imputation.
Since there was no best imputation method in the experiment and since the orig-
inal ShockOmics data had very different ratios of missing values for different fea-
tures, it was decided to calculated the sum of the MSEs for all three datasets. The
lowest error in all three dataset was achieved by the norm.predict imputation, fol-
lowed by the missForest technique. The gap between these two methods is small,
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Models pmm knn missForest cart
SVC-R 0.1218 ± 0.2098 0.113 ± 0.2316 0.3894 ± 0.226 0.3724 ± 0.2314
LDA 0.4908 ± 0.2233 0.4501 ± 0.1928 0.4583 ± 0.2164 0.4772 ± 0.1771
KNN 0.4704 ± 0.2015 0.4058 ± 0.1786 0.6123 ± 0.2069 0.6238 ± 0.1713
G-NB 0.3841 ± 0.1955 0.4102 ± 0.214 0.4836 ± 0.1923 0.4736 ± 0.2342
M-NB 0.5209 ± 0.1765 0.597 ± 0.1611 0.5971 ± 0.159 0.5046 ± 0.1921
(A) The pair of the KNN model and the cart imputation showed the best MCC in the multi-
type group. However, the missForest imputation improved the same amount of models.
Models norm norm.nob norm.boot norm.predict
SVC-R 0.1165 ± 0.214 0.097 ± 0.2237 -0.0464 ± 0.0681 0.4854 ± 0.1961
LDA 0.5427 ± 0.197 0.4309 ± 0.2195 0.3584 ± 0.2213 0.7115 ± 0.1735
KNN 0.5115 ± 0.2006 0.3023 ± 0.2036 0.2092 ± 0.2072 0.6467 ± 0.1671
G-NB 0.5426 ± 0.1752 0.381 ± 0.1959 0.3398 ± 0.1846 0.5075 ± 0.1587
M-NB 0.5 ± 0.191 0.4284 ± 0.1836 0.3916 ± 0.1899 0.652 ± 0.1684
(B) Here, the results are almost the same as with the accuracy. The absolute winner is the
norm.predict imputation with the highest MCC for the LDA model.
TABLE 4.7: Reconstruction experiments: the MCC (mean ± standard
deviation) of the ML models for each dataset, imputed with a dif-
ferent technique. For each model the best results are highlighted in
bold. Meaning that a certain imputation techniques works the best for
the model. The best results in the experiment groups are underlined:
(a) for a multi-type imputation group; (b) for a numeric imputation
group.
and since the missForest has an advantage over the norm.predict imputation in deal-
ing with multi-type data, a decision was made to use the missForest imputation for
the later experiments of this thesis.
4.4 Bayesian Network Experiments
After the data was imputed with the norm.predict imputation (all features with
missing values were numerical), different Bayesian Networks Structures were tested
for the outcome prediction. The structures of the chosen Bayesian Networks can be
seen in Figure 4.2. Each of the configurations were given a number for a later use in
the table with the results. The Bayesian Networks had different features and the in-
dependence assumptions, that were based on time-series nature of the ShockOmics
dataset. Additionally, it was important to see the number of variable discretization
(the maximum amount of different values that can be assigned to one variable). For
this role the range from 2 to 5 was tested. Additionally, two different estimators
were used: the Maximum Likelihood Estimator and the Bayesian Estimator. The
accuracy, the MCC, the sensitivity, the specificity and the AUC were used as perfor-
mance measures. All the models were trained ten times on randomly split dataset,
similarly as was done in the previous experiments.
4.4.1 Results
Table 4.9 presents the results of applying the Maximum Likelihood and the Bayesian
estimators. The experiments show that the structure 1 was the best among all other
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35% missing 20% missing 10% missing sum
Num.of examples 49, 52, 54 61, 59, 57 68, 65, 67
pmm 8671 5083 3226 16980
knn 6556 2784 838 10178
missForest 4753.7 3842.9 1073.5 9670.1
cart 4524 6527 866 11917
norm 7831.4 5097.9 3184.8 16114.1
norm.nob 6482.8 4371.5 1866.9 12721.2
norm.boot 12124.3 5706.7 1795.9 19626.9
norm.predict 5917.42 2437.7 1005.9 9361.02
TABLE 4.8: Reconstruction experiments: the MSE for datasets with
missing values and the imputation techniques. Num. of examples
shows the number of examples for each of the features in the follow-
ing order: Mean arterial pressure at T1, SOFA at T1, APACHE II at T1.
The sum column represents the sum of all three MSEs for each impu-
tation technique. The best results for each column are highlighted in
bold.
configurations. It showed the best accuracy, the MCC and the AUC, as well as the
best specificity (see Tables A.2 and A.4 from Appendix A). Three and four discretiza-
tion variables scored the best performance for each of the six structures. Based on the
overall performance, the structure 1 had the biggest success with three discretization
variables and the Bayesian Estimator. It showed the best sensitivity/specificity ratio
in the experiments.
The table shows that, in general, the Bayesian Estimator performed better than
the Maximum Likelihood Estimator. And from these results one can conclude that
adding APACHE IIT3 and SOFAT3 features (in structures 4, 5 and 6) made the perfor-
mance of the Bayesian Networks worse. Moreover, one may notice that all models in
the experiments have high standard deviations. This inconsistency can be explained
by the fact that the ShockOmics dataset has a low number of observations. There
were much more positive examples compared to the negative ones in the experi-
ments, so the models tended to have a high sensitivity and low specificity.
As already mentioned, the best results were yielded by the Bayesian Network
with three discretization variables and the Bayesian Estimator. These results are
comparable with other ML methods that were tested previously in the imputation
experiments. The accuracy of the best ML model in those experiments (G-NB) is
comparable of the results achieved by the best Bayesian Network performance. It
is 0.8632 ± 0.0573 here, against 0.8489 ± 0.0673 in the G-NB model. However, the
Bayesian Network shows the lower MCC: 0.6181 ± 0.0854 against 0.6471 ± 0.1635.
These experiments show that the Bayesian Networks are not only capable of shed-
ding some light on casual relationship between the features, but can also perform in
pair to other ML models even with very general independence assumptions.
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(A) Structure 1
(B) Structure 2
(C) Structure 3 (D) Structure 4
(E) Structure 5 (F) Structure 6
FIGURE 4.2: Bayesian Network structured from the Bayesian Net-
work experiments. Each horizontally connected row represents the
same feature at different time steps. All features at the last time step
are connected to the outcome.
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Struct. Discr. Accuracy MCC AUC
1 3 0.8526 ± 0.0614 0.6023 ± 0.1441 0.8526 ± 0.0614
1 4 0.8526 ± 0.1219 0.6381 ± 0.2973 0.8526 ± 0.1219
2 3 0.8421 ± 0.0471 0.5723 ± 0.1157 0.8421 ± 0.0471
2 4 0.8 ± 0.0614 0.1063 ± 0.1399 0.8 ± 0.0614
3 3 0.7895 ± 0.0333 0.364 ± 0.1988 0.7895 ± 0.0333
3 4 0.8421 ± 0.0881 0.2749 ± 0.3367 0.8421 ± 0.0881
4 3 0.7053 ± 0.0537 0.0585 ± 0.1893 0.7053 ± 0.0537
4 4 0.7368 ± 0.0881 0.1405 ± 0.2938 0.7368 ± 0.0881
5 3 0.6316 ± 0.0577 0.0337 ± 0.1509 0.6316 ± 0.0577
5 4 0.7053 ± 0.0976 0.0009 ± 0.1749 0.7053 ± 0.0976
6 3 0.7263 ± 0.0394 0.0094 ± 0.1194 0.7263 ± 0.0394
6 4 0.7474 ± 0.0394 -0.0092 ± 0.1216 0.7474 ± 0.0394
(A) Most of the structures work the best with three discretization variables. The first three
structures performed better than the last three. Full Maximum Likelihood Estimator results
can be found in Tables A.1 and A.2.
Struct. Discr. Accuracy MCC AUC
1 3 0.8632 ± 0.0537 0.6181 ± 0.0854 0.8632 ± 0.0537
1 4 0.8421 ± 0.0577 0.5863 ± 0.1127 0.8421 ± 0.0577
2 3 0.8 ± 0.0774 0.4197 ± 0.1773 0.8 ± 0.0774
2 4 0.8421 ± 0.0744 0.368 ± 0.2782 0.8421 ± 0.0744
3 3 0.8526 ± 0.0211 0.1882 ± 0.2306 0.8526 ± 0.0211
3 4 0.7158 ± 0.0855 0.153 ± 0.1931 0.7158 ± 0.0855
4 3 0.7053 ± 0.0632 0.0924 ± 0.168 0.7053 ± 0.0632
4 4 0.7368 ± 0.0577 0.0502 ± 0.2463 0.7368 ± 0.0577
5 3 0.7158 ± 0.0421 0.0056 ± 0.1152 0.7158 ± 0.0421
5 4 0.7579 ± 0.0537 0.1688 ± 0.2054 0.7579 ± 0.0537
6 3 0.7263 ± 0.0774 0.11 ± 0.1692 0.7263 ± 0.0774
6 4 0.7474 ± 0.0842 0.2249 ± 0.1893 0.7474 ± 0.0842
(B) The results are very similar to those shown by the Maximum Likelihood Estimator. The
gap in the performance between the second and the third structures is more clearly here (the
structure 2 performed better). Full Bayesian Estimator results can be found in Tables A.3 and
A.4.
TABLE 4.9: Different Bayesian Networks structures with different
numbers of discretization variables: a) for the Maximum Likelihood
Estimator; b) for the Bayesian Estimator. The best results in each col-
umn are highlighted in bold. Full results for the experiments (with
additional specificity and sensitivity measures) are in Appendix A.
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Chapter 5
Feature selection: Identifying
Promising Biomarkers
This chapter is dedicated to the data feature selection procedure from an ML point of
view. Therefore, it deals with the problem of finding the most promising biomarkers
from the medical point of view. In order to do this, four subsets of the ShockOmics
data were analyzed, giving them different names: Full+, Full, T1+T2 and T1 (de-
scription in the following sections). The goal of the experiments was to analyze
different feature sets resulting from the feature selection procedure, and to mea-
sure their performance with the Gaussian Naive Bayes (G-NB) model. There is an
assumption behind the experiments, namely that the feature sets with the best per-
formances are the same those that can potentially help with the mortality prediction.
The evaluated feature sets were obtained by applying five different feature selec-
tion techniques to the four mentioned datasets: Univariate feature selection based on
ANOVA F-value (UFS); recursive feature elimination with Support Vector Classifi-
cation (RFE); recursive feature elimination with cross-validation and Support Vector
Classification (RFECV), two stage feature selection (UFS+RFE) and Random Forest
(RF) feature selection. The dataset was imputed with the missForest imputation, and
all the ShockOmics features were used if not specified otherwise. The identification
of the promising feature sets was based on the performance and stability scores.
The chapter is organized as follows. The first section contains all the details
about the experimental methodology. It starts with a description of all the datasets
and then describes the feature selection methods used, as well as how the resulting
feature sets were evaluated and how the stability scores were calculated. The next
section discusses the results of applying the feature selection procedure for each
of the datasets in particular and presents their stability scores. After this, the final
section presents the final sets of promising features for further experiments.
5.1 Feature Selection Methodology
In order to identify promising feature sets, five feature selection techniques (see
Section 5.1.2) were applied to four subsets of the ShockOmics datasest (see Section
5.1.1). The resulted feature sets were used to train the G-NB model from the previ-
ous chapter. Then, the models were evaluated as in the previous chapter (see Section
5.1.3). The accuracy, the MCC, the specificity, the sensitivity and the AUC were used
as performance measures. The training was performed 100 times using 75% of the
data, that was randomly split. Then the mean and the standard deviation of the 100
executions (using the test set) were calculated for all five performance measures.
Once all feature sets, obtained with the feature selection techniques, were evalu-
ated, they were used to calculate the stability scores (see Section 5.1.4). The stability
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scores were based on the occurrences of features throughout the feature selection
results. The stability scores for the first four features and for the RF feature selec-
tion were calculated separately, since the RF is the only stochastic technique in the
experiments and was treated differently.
5.1.1 Datasets Description
The decision of using four different subsets of the ShockOmics dataset was made
because it was important to achieve stable features that behave consistently at dif-
ferent time-steps and that are clinically relevant. For this reason, each of the datasets
targeted different features: some of them because of their low amount of missing
values, some of them because they were important at different time. The datasets
were obtained by imputing missing values from the ShockOmics dataset with the
missForest imputation from the previous chapter. All the datasets contain both nu-
merical and categorical features, and they are subsets of the ShockOmics dataset.
The first dataset was named Full+. It was achieved by filtering features from the
ShockOmics dataset (that had 333 features). It was obtained by the manual removal
of certain features that did not make sense from the classification point of view. They
either looked like very general comments in natural language or revealed some in-
formation about the outcome of the patient. Both of the categories were not reliable
as features in the machine learning model. The following features were manually re-
moved from the ShockOmics dataset: Reason for admission; ICU admission; RV area/LV
area (T1, T2, T3); Microorganisms (three columns with the same name); ID; Death due
to withdrawal of care; Mortality 28 days, 100 days (two columns); Hospital results; Total
days in ICU, in Hospital (two columns). The resulting dataset had 317 features with
one target feature.
The second dataset is the Full dataset. Its purpose was to address certain draw-
backs of the Full+ dataset by removing the features with a lot of missing values.
From all the list of the Full+ features, only those that had more than 50% values
originally were taken. The imputation techniques are not accurate when there are
more missing than present values, especially when it comes to datasets where the
amount of observation is very low. So, the removal of the features with too many
missing values was used to increase the stability of the promising features in the end
of the experiments. After filtering, the dataset contained 242 features with one target
feature.
Additionally, there was an assumption that the closer in time the feature to the
final outcome, the better the prediction of the mortality. This assumption was ad-
dressed by making two last datasets: the T1+T2 dataset and the T1 dataset. both of
them were obtained from the Full+ dataset by filtering features at certain time-steps.
From the T1+T2 dataset all T3 features were removed, resulting in 180 features with
a target feature. From the T1 dataset both T2 and T3 time-step features were left out,
and the resulted dataset contained 104 features and a target feature.
5.1.2 Feature Selection Methods
The scikit-learn [79] library was used for the implementation of the feature selection
methods. The default parameters of the methods were used in the experiments, if
not otherwise specified. Five feature selection techniques were used in the identifi-
cation of promising biomarkers:
• Univariate feature selection based on ANOVA F-values (UFS). Univariate
feature selection [85] works by selecting the best features based on univariate
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statistical tests. In this case, the ANOVA F-tests are used. The UFS was imple-
mented using the sklearn.feature_selection.SelectKBest method that removes
all but the k highest scoring features (see http://scikit-learn.org/stable/
modules/generated/sklearn.feature_selection.SelectKBest.html#sklearn.
feature_selection.SelectKBest) and sklearn.feature_selection.f_classif for the
ANOVA F-tests (see http://scikit-learn.org/stable/modules/generated/
sklearn.feature_selection.f_classif.html#sklearn.feature_selection.
f_classif) ;
• Recursive feature elimination with SVC (RFE). Given an external estimator
that assigns weights to features (e.g., the coefficients of a linear model), the goal
of the RFE is to select features by recursively considering smaller and smaller
sets of features [86]. The RFE was implemented through the sklearn.feature_-
selection.RFE method (http://scikit-learn.org/stable/modules/generated/
sklearn.feature_selection.RFE.html). For the external estimator, the SVC
model [80] was used with the help of the sklearn.svm.SVC method (see http:
//scikit-learn.org/stable/modules/generated/sklearn.svm.SVC.html);
• Recursive feature elimination with cross-validation and SVC (RFECV). Fea-
ture ranking with the RFE and cross-validated selection of the best number
of features. Different scores were used of the cross-validation: AUC, recall,
accuracy, precision, average precision, neg log loss, f1, f1 micro, f1 macro (the de-
scription of these scores can be found in http://scikit-learn.org/stable/
modules/model_evaluation.html#scoring-parameter. The sklearn.-feature_-
selection.RFECV method allowed to use this feature selection technique (see
http://scikit-learn.org/stable/modules/generated/sklearn.feature_selection.
RFECV.html). Once again, the SVC model was used as the external estimator
(see previous entry);
• Two stage feature selection: UFS + RFE. This is a combination of two feature
selection techniques from this list. During the first stage, UFS preselects the
80 best features based on the ANOVA F-value and then RFE (SVC) choses the
best features in the second stage. For the implementation details, please, refer
to the individual techniques from above this list;
• Random Forest (RF) feature selection. Feature selection [86] based on the
trained RF model [62] and its feature rankings. In the experiments, this fea-
ture selection was based on 500 runs of the RF model with 10 trees. This
was carried out because the RF feature selection was the only stochastic tech-
nique, and multiple experiments were required to achieve a high level of cer-
tainty in the results. The final feature selection was based on the stability
scores from all the executions. The most frequent features got in the final fea-
ture subset and all the performance evaluation was done using this feature
set. The sklearn.feature_selection.SelectFromModel method was used to re-
trieve the feature rankings (see http://scikit-learn.org/stable/modules/
generated/sklearn.feature_selection.SelectFromModel.html) and the sk-
learn.ensemble.RandomForest-Classifier (see http://scikit-learn.org/stable/
modules/generated/sklearn.ensemble.RandomForestClassifier.html) method
to train the RF model.
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5.1.3 Feature Sets Evaluation
As an output, the applied feature selection techniques present either an unranked
(e.g. RFECV), or a ranked (the rest of the methods) set of features. In the first case,
there is a set of features that is fixed in size. Based only on the output, there is
no way of identifying which features are more important. And from the feature
selection point of view, these features play equally important roles in the set. For the
second case, it is different and all features get their own rank. So, naturally, and in
order to limit the size of the selected features, only the first ones should be selected
and evaluated. But the number of features that should be used for the training is
unclear. That is why for the feature selection techniques that provide the rank of
features, multiple feature set sizes in the range from 2 to 30 were tested. The upper
boundary 30 was chosen because the final set of features should be relatively small
to be usable and effective enough in the ML model.
Each feature set was used for the training of the G-NB model and carefully evalu-
ated. The G-NB classifier was chosen because it showed promising results in the pre-
liminary experiments and because technically it can be considered as a special case
of Bayesian Networks. Unfortunately, conducting all the experiments with Bayesian
Networks was unfeasible because there was no clear understanding of the inde-
pendence assumptions. Therefore, the G-NB model was used as the substitution.
In order to evaluate the feature sets, the G-NB was trained and tested 100 times for
each one of them. The mean and the standard deviation from all the executions were
subsequently calculated. The results are presented separately for each dataset and
each feature selection method. The accuracy, the MCC, the specificity, the sensitivity
and the AUC were used as performance measures.
5.1.4 Stability Scores
Once all the feature sets were tested and their performances were measured, the
stability scores were calculated. For each of the dataset there were two groups of
stability scores. The first group contained only features obtained with the RF feature
selection. The second group had the rest of the methods. The reason behind the
difference between these two groups is that the RF feature selection is stochastic.
Therefore, it was executed 500 times and each time it gave a slightly different feature
set. The methods in other group were applied only once, since the result is always
the same. By separating two groups, and by giving their stability scores the equal
weight in the decision making, the difference of the methods was compensated.
In each group, the stability scores were calculated as frequencies. The number
of individual feature occurrences was divided by the number of feature selection
procedure executions in the group. So, in the RF group it was divided by 500, and
in the second group it was divided by three plus the number of the RFECV feature
sets. The number of the RFECV feature sets varied depending on the dataset. This
is because different scores may lead to different feature sets. And only the number
of unique feature sets was used for calculating the stability scores. In the end each
dataset had two groups of stability scores. And each group was represented using
30 features with the highest stability scores.
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5.2 Feature Selection Results
The feature selection experiments are divided into four groups. Each group corre-
sponds to its own dataset: Full+, Full, T1+T2 and T1. All five feature selection tech-
niques were applied to the datasets. The results were used to train the G-NB model,
and the performance of each feature set with the model was evaluated. In this sec-
tion, the best models from all feature selection experiments and their accuracy, MCC
and AUC are presented. For the complete experiments, results and additional mea-
sures as the sensitivity and the specificity, please refer to the individual subsections
and corresponding appendix sections. They include full results for each dataset.
Table 5.1 shows the comparison of different feature sets: their size, the dataset
and the feature selection method that was used. The feature sets from the same
dataset are grouped together. The additional IFS dataset in the table corresponds
to the feature set from the preliminary experiments, it contains 13 features and it is
used as a baseline for other models performance. It was interesting to compare the
usual common features for mortality prediction and the new feature sets. The table
presents the best results for each feature selection method.
As can be seen from Table 5.1, the UFS and the RF models show consistently
good results. Their performance is better than the models with the IFS feature set,
and this is especially noticeable when it comes to the MCC. The best results in the
experiments were found for the RF feature selection in the T1+T2 dataset. This is
interesting, and it may be interpreted as the T3 time-step being less significant for the
outcome prediction. An alternative interpretation is that there is too much noise in
the T3 features, since the patient with shock becomes very unstable at that point, or
maybe because there are too few observations at that time-step. The T1+T2 feature
sets performed very well despite the absence of the T3 time-step.
The RFECV features showed the worst results. This is partially because the SCV
model was used for cross-validation, but the performance was measured with the
G-NB. It was impossible to use the G-NB model, since it can not evaluate the im-
portance of features. When the SVC model was used for testing the performance, it
showed slightly better results. As for the USF+RFE selection, it performed slightly
worse than the UFS in general. The RFE feature showed reasonably good perfor-
mance but worse than the UFS+RFE.
5.2.1 Full+ Dataset Results
This subsection describes the experimental results for the Full+ dataset. The com-
plete set of tables from this subsection can be found in Appendix B. Table B.1 shows
the performance of the models that used the UFS technique for feature selection.
The models with 9 and 10 features performed the best. The first one has the best
MCC and the sensitivity and the second one outperformed all other models in the
accuracy and the AUC. The features in these models can be found in Table B.6, the
first 9 and 10 features respectively.
The performance of models that used the RFE feature selection can be seen in
Table B.2. Here, two models performed well compared to others. The first model
has 16 features and it showed the best accuracy and the AUC. The second model
has 20 features and it has the best MCC. The features of these models can be found
in Table B.6. As for the RFECV features, their performance is in Table B.3. There
are only two models since this method uses cross-validation to choose the best set
of features. The first model used the average precision metric, the second used the
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F Data Method Accuracy MCC AUC
13 IFS - 0.802 ± 0.081 0.403 ± 0.327 0.802 ± 0.081
9 Full+ UFS 0.862 ± 0.069 0.667 ± 0.168 0.862 ± 0.069
10 Full+ UFS 0.863 ± 0.078 0.663 ± 0.194 0.863 ± 0.078
16 Full+ RFE 0.765 ± 0.083 0.359 ± 0.237 0.765 ± 0.083
20 Full+ RFE 0.763 ± 0.076 0.354 ± 0.21 0.763 ± 0.076
17 Full+ RFECV 0.748 ± 0.081 0.31 ± 0.233 0.748 ± 0.081
19 Full+ RFECV 0.719 ± 0.084 0.228 ± 0.235 0.719 ± 0.084
4 Full+ UFS+RFE 0.842 ± 0.104 0.6 ± 0.235 0.842 ± 0.104
30 Full+ UFS+RFE 0.841 ± 0.079 0.605 ± 0.189 0.841 ± 0.079
28 Full+ RF 0.861 ± 0.062 0.655 ± 0.161 0.861 ± 0.062
24 Full UFS 0.872 ± 0.073 0.687 ± 0.173 0.872 ± 0.073
11 Full RFE 0.822 ± 0.088 0.559 ± 0.222 0.822 ± 0.088
13 Full RFE 0.828 ± 0.083 0.546 ± 0.229 0.828 ± 0.083
12 Full RFECV 0.788 ± 0.088 0.468 ± 0.223 0.788 ± 0.088
23 Full RFECV 0.756 ± 0.071 0.292 ± 0.247 0.756 ± 0.071
25 Full UFS+RFE 0.803 ± 0.071 0.395 ± 0.27 0.803 ± 0.071
30 Full UFS+RFE 0.799 ± 0.06 0.421 ± 0.221 0.799 ± 0.06
7 Full RF 0.866 ± 0.075 0.68 ± 0.179 0.866 ± 0.075
15 Full RF 0.866 ± 0.075 0.673 ± 0.18 0.866 ± 0.075
16 Full RF 0.866 ± 0.07 0.663 ± 0.169 0.866 ± 0.07
28 T1+T2 UFS 0.855 ± 0.06 0.64 ± 0.155 0.855 ± 0.06
27 T1+T2 RFE 0.819 ± 0.085 0.561 ± 0.212 0.819 ± 0.085
41 T1+T2 RFECV 0.812 ± 0.078 0.534 ± 0.201 0.812 ± 0.078
28 T1+T2 UFS+RFE 0.791 ± 0.052 0.371 ± 0.216 0.791 ± 0.052
5 T1+T2 RF 0.874 ± 0.073 0.693 ± 0.181 0.874 ± 0.073
30 T1 UFS 0.867 ± 0.063 0.668 ± 0.158 0.867 ± 0.063
20 T1 RFE 0.764 ± 0.067 0.197 ± 0.296 0.764 ± 0.067
29 T1 RFE 0.755 ± 0.058 0.207 ± 0.253 0.755 ± 0.058
31 T1 RFECV 0.75 ± 0.069 0.203 ± 0.252 0.75 ± 0.069
21 T1 UFS+RFE 0.791 ± 0.043 0.357 ± 0.206 0.791 ± 0.043
29 T1 UFS+RFE 0.776 ± 0.072 0.393 ± 0.198 0.776 ± 0.072
4 T1 RF 0.848 ± 0.078 0.621 ± 0.206 0.848 ± 0.078
TABLE 5.1: The best feature sets of the feature selection techniques,
and their comparison to the initial feature set (IFS): the size of the
feature set, the dataset, the feature selection technique and different
performance measures. For full experiment results, please, see Ap-
pendices B, C, D, E.
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accuracy. It was important to test both models, since they showed very different set
of features. These sets can be found in Listing B.2.
Finally, Table B.4 shows the two-stage feature selection results. Two feature sets
with different sizes of 4 and 30 stand out. Table B.5 presents the performance of the
features chosen using the RF. The 28 feature sets showed the best performance foR
this feature selection technique. The list of features for both techniques can be found
in Table B.7.
Table F.1 from Appendix F shows the stability scores for the Full+ dataset.
5.2.2 Full Dataset Results
Appendix C contains all the tables that are discussed here. Table C.1 shows the
performance of the models that used the UFS technique. The model with 24 features
performed the best. The features that belong to this model can be seen in Table C.6,
the first 24 features. The performance of models that used the RFE feature selection
can be seen in Table C.2. Two models are considered to be the best ones here. The
first model has 11 features and it showed the best MCC. The second model has 13
features and it has the best accuracy and the AUC. The features of these models can
be found in Table C.6, the first 11 features for the first model, 13 – for the second.
The results of the experiments using the RFECV are to be found in Table C.3.
There are only two models, since this method uses cross-validation to choose the
best set of features. The first model used the precision metric, the second used the
AUC. Both feature sets can be found in ListingC.2. Table C.4 shows the two-stage
feature selection results. Table C.5 presents the performance of the features chosen
using the RF. The list of features for both models can be found in Table C.7.
Table F.2 from Appendix F shows the stability scores for the Full dataset.
5.2.3 T1+T2 Dataset Results
The T1+T2 dataset result tables and listing are to be found in Appendix D. Table D.1
shows the results for the UFS feature selection. It seems that the best results were
produced by feature sets with relatively high sizes. For example, the feature set with
28 showed the best accuracy and AUC. And the size 26 feature set achieved the best
MCC which is also a very important performance measure. The rankings of features
selected by the UFS are shown in Table D.6.
The RFE performance is shown in Table D.2. As can be seen, the situation is sim-
ilar here: the feature sets with high sizes score better. The best results were achieved
with the size 27. This feature set showed the best accuracy, MCC and AUC. The sizes
26 and higher showed very similar results. The ranking of the features selected by
the RFE can be found in Table D.6.
The RFECV extracted 5 different feature sets using multiple metrics. Table D.3
shows the performance of these sets. The best candidate here for a feature set is
the set with the size 41. It shows the best accuracy, MCC, sensitivity and AUC.
However, these results are much lower than those shown by the UFS and the RFE.
These feature sets are in Listing D.2.
The USF+RFE showed worse results than the UFS, but the same amount of fea-
tures showed the best performance. The feature set with the size 28 achieved the
best accuracy, MCC, sensitivity and AUC. The ranking of features achieved with this
method are shown in Table D.7 along with the RF features. The RF features results
can be found in Table D.5. A feature set with only five features achieved significant
performance for such small set.
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Table F.3 from Appendix F shows the stability scores for the T1+T2 dataset.
5.2.4 T1 Dataset Results
The T1 dataset results can be found in tables and listing from Appendix E. This time
the UFS performed the best among other methods. However, it took 30 features to
outperform other candidates. Table E.1 shows the results of applying this method to
the T1 dataset. As can be seen, the feature set with the size 30 performed the best.
It has the highest accuracy, the MCC and the AUC. The ranking of features obtained
by this method are in Table E.6.
The RFE with T1 performed quite poorly in comparison to other datasets. Table
E.2 shows the performance of the chosen feature sets. From the reported results, it
seems that there is no clear best performance. The MCC and sensitivity is very low
among all feature sets. The feature set with the size 20 showed the highest accuracy,
the AUC and the second best MCC, so it may be considered as the best feature set
shown in the table. The ranking of features for this method can be found in Table
E.6.
This time, the RFECV showed 6 different feature sets that were achieved with
multiple metrics. The performance of these feature sets can be found in Table E.3.
The average precision metric was used for the best feature set that scored the best
accuracy, MCC and AUC. The feature sets for all metrics can be found in Listing E.2.
The USF+RFE feature sets performed slightly better than feature sets from the
last two methods. From Table E.4 one may notice that all feature sets performed
very similarly. It is difficult to point the best feature sets but feature sets with sizes 21
and 29 could be the candidates. Since the first one showed the highest accuracy and
AUC while the second one performed the best in the MCC measure. The ranking
of features achieved with this methods can be found in Table E.7. The performance
of the RF features is in Table E.5 with the features ranking in Table E.7. This time
the performance was lower than in the previous subsection, however, the size was
smaller too.
Table F.4 from Appendix F shows the stability scores for the T1 dataset.
5.3 Promising Features Sets
In order to obtain the most promising feature sets, the best results from the feature
selection experiments were filtered based on their size and performance. During this
procedure, a requirement was to prioritize small feature sets (with less than 20 fea-
tures). This is because using big feature sets is not practical for outcome prediction:
it is more difficult to train a model with a high number of features and it is harder to
deal with independence assumptions for the Bayesian Network. Furthermore, the
resulting models might be more difficult to interpret. As for the performance, the
combined filtering was used. Only the feature sets with minimum accuracy ≥ 0.85,
MCC ≥ 0.6, sensitivity and specificity ≥ 0.75 and AUC ≥ 0.85 were considered as
promising ones. Because, for example, if the accuracy is high and the specificity is
very low, then this is probably a bad model, since there are too few negative exam-
ples in the ShockOmics dataset.
The performance of the filtered feature sets can be found in Table5.2 along with
the best feature sets performance from the preliminary experiments (IFS). The fea-
ture sets themselves can be found in Listing 5.3. As can be seen, new feature sets
outperform the IFS features. The lists of new feature sets are interesting. The usual
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indicators as SOFA or APACHE II are present in the feature sets. And the new fea-
tures (e.g. X Norepinephrine) have fairly high stability scores. Interestingly, the RF
stability scores turned out to be much better at predicting valuable features. The
features in the filtered sets have not only high performance, but they also go along
with the traditional practices for outcome prediction and stability scores (especially,
for the RF feature selection).
The promising feature sets identified in this chapter are used for exploring their
causal relationships in the Bayesian Network in the next chapter.
Full+ (9 and 10, UFS): APACHE II_T1, APACHE II_T2, APACHE II_T3,
Inferior vena cava distensibility index _T3, LA dilatation by
eyeballing_T1=No, LA dilatation by eyeballing_T1=Yes, SOFA_T1,
SOFA_T2, SOFA_T3, X Norepinephrine mg kg min _T2;
Full (24, UFS):APACHE II_T1, APACHE II_T2, APACHE II_T3, FiO2_T2,
FiO2_T3, Glasgow Coma Scale_T2, Glasgow Coma Scale_T3, Heart rate
bpm _T3 1, LA dilatation by eyeballing_T1=No, LA dilatation by
eyeballing_T1=Yes, Lactate levels mmol L _T2, Number of affected
organs, Respiratory rate_T1, SOFA_T1, SOFA_T2, SOFA_T3, Sat O2
FiO2_T2, Sat O2 FiO2_T3, Sedation Scale SAS _T2, Tidal volume VT
_T1, Tracheal Intubation_T2=No, Tracheal Intubation_T2=Yes, X
Norepinephrine mg kg min _T1, pH_T2;
Full (7, 15, RF): SOFA_T2, APACHE II_T1, APACHE II_T3, Lactate levels
mmol L _T2, Urine Output mL day _T1, Heart rate bpm _T3,
Respiratory rate rpm _T1, APACHE II_T2, Urine Output mL day _T2, X
Norepinephrine mg kg min _T1, E wave cm s _T1, FiO2_T3, Sat O2
FiO2_T3, SOFA_T1, SOFA_T3;
T1+T2 (5, RF): Lactate levels mmol L _T2, SOFA_T2, Respiratory rate rpm
_T1, APACHE II_T1, E wave cm s _T1.
List of promising feature sets. They are presented as the dataset, the size of the
feature set (if more than one size is in the parenthesis then there are two different
feature sets with two different sizes) and the feature selection technique that was
used.
.
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F Data Method Accuracy MCC AUC
13 IFS - 0.802 ± 0.081 0.403 ± 0.327 0.802 ± 0.081
9 Full+ UFS 0.862 ± 0.069 0.667 ± 0.168 0.862 ± 0.069
10 Full+ UFS 0.863 ± 0.078 0.663 ± 0.194 0.863 ± 0.078
24 Full UFS 0.872 ± 0.073 0.687 ± 0.173 0.872 ± 0.073
7 Full RF 0.866 ± 0.075 0.68 ± 0.179 0.866 ± 0.075
15 Full RF 0.866 ± 0.075 0.673 ± 0.18 0.866 ± 0.075
5 T1+T2 RF 0.874 ± 0.073 0.693 ± 0.181 0.874 ± 0.073
TABLE 5.2: Feature sets from Table 5.1, filtered according to the per-
formance measures: the accuracy≥ 0.85, the MCC≥ 0.6, the sensitiv-
ity and the specificity ≥ 0.75 and the AUC ≥ 0.85.
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Chapter 6
Causal Discovery: The Bayesian
Network Approach
This chapter presents the results of the analysis of potential causal relationships be-
tween the data features that were obtained in the previous chapter. Having a set of
potential biomarkers is not enough for mortality prediction. It is important to know
the causal relationships between them. Different structure learning algorithms for
Bayesian Networks can potentially reveal this information. Not only Bayesian Net-
works allow to see how the biomarkers influence each other and the outcome, but
they also work with the partial information. And in the medical environment it is
often very difficult to obtain the full picture of the situation and have all feature
values.
The feasibility and interest of the use of Bayesian Network models in the medical
field has been tested in numerous studies. Some examples amongst the most recent
studies include: causal relationships in patients with primary OCD and co-morbid
depression symptoms [4]; biophysical interactions of radiation pneumonitis in non-
small-cell lung cancer [5]; and identifying causative genome alterations within indi-
vidual tumors [6]. Given the high effectiveness of the Bayesian Network approach,
it was decided to use it for identifying the interactions between the biomarkers that
were selected in the experiments reported in the previous chapter.
This chapter includes a single section containing all the details of the casual dis-
covery experiments. A description of the methodology is provided first. This is fol-
lowed by a short overview of the Fast Greedy Search (FGES) algorithm for structure
learning. The second and last subsection presents the structures that were achieved
with this algorithm.
6.1 Causal Discovery Experiments
In order to achieve the causal Bayesian Network (CBN) structures that would re-
veal the interactions between the features, multiple algorithms were applied. Some
of them, like the Max-Min Parent-and-Children [87], the Hill Climbing method [87]
or the Max-Min Hill-Climbing heuristic [87], produced structures that were very
similar to the Gaussian Naive Bayes configuration, but in reverse (all arrows went
from the outcome to other features). Such structures did not fit outcome predic-
tion and they did not allow to retrieve any additional information from feature sets.
The Structural Expectation-Maximization algorithm [88], [89] also failed to achieve
meaningful structures. Although they were different from the structures obtained
with three previous methods, there were some clear problems. For example, Figure
6.1 shows one such structure obtained using the T1+T2 (5, RF) feature set. According
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(A) (B)
FIGURE 6.1: The Bayesian Network structure of the T1+T2 (5, RF) fea-
ture set achieved with the Structural Expectation-Maximization algo-
rithm
to this structure, the Lactate levels at time-step 2 influence the Respiratory rate at time-
step 1, which is clearly wrong. And since all the directions are clear, it is very hard to
explain such connectivity between the features. Additionally, from the same figure
it can be seen that after adding the target feature, the CBN substantially changes.
This happens with all other CBNs that are built with this method, meaning that that
the CBNs are unstable.
The problems with the aforementioned algorithms can be caused by the small
size of the dataset. In order to address this issue, it was decided to use the Fast
Greedy Search (FGES) algorithm. It also returns the most probable CNB, but should
it not be able to determine the direct causation, it would return an undirected edge
between two features. So, technically, the algorithm returns a "pattern" containing
arcs, which represent direct causation, and undirected edges, where such an edge
indicates there is a causal arc, but its direction cannot be determined. Additionally,
it works with real-valued variables, and most of the features in this chapter are of
that type.
The algorithm was applied twice for each of the feature sets obtained in the pre-
vious chapter. First, the algorithm was applied only to the features, excluding the
outcome, and the second time it was applied to both features and the outcome. The
expectation was to have few or no differences between features that did not involve
the outcome. That would mean that the CBNs are stable enough to draw some clear
conclusions.
6.1.1 FGES Algorithm
The Fast Greedy Search (FGES) algorithm is an optimized and parallelized version of
the Greedy Equivalence Search algorithm [90]. It heuristically searches the space of
CBNs and returns the model with the highest Bayesian Information Criterion (BIC)
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(A)
(B)
FIGURE 6.2: The CBN for the Full+ (9, UFS) feature set achieved with:
a) without the target feature; 2) with the target feature.
[91] it finds. It starts with the empty graph and then adds new edges to increase
the Bayesian score. The process stops when there is no edges that increase the score.
After that, it starts removing the edges until no single edge removal can increase the
score.
The algorithm works on the assumption that the causal process generating the
data is accurately modeled by a CBN. Each node in this CBN is a a linear function
of its parents, plus a finite additive Gaussian noise term. Each observation in the
data is independent, and was obtained by randomly sampling all the variables from
the joint distribution. Given all these assumptions, the FGES procedure outputs the
CBN structure that contains:
1. an arc X→ Y, if and only if X causes Y;
2. an edge (—), if and only if either X causes Y or Y causes X;
3. no edge between X and Y, if and only if X and Y have no direct causal relation-
ship between them.
The FGES algorithm was used with the help of the Tetrad software (see http:
//www.phil.cmu.edu/tetrad/).
6.1.2 Results
The full lists of features for feature sets in this section can be found at the end of
the previous chapter (see Listing 5.3). Here, for each of the feature sets there are two
corresponding CBNs. The first one (the CBN "a") was built without the target feature
(Result in ICU), the second one (the CBN "b") included all features and the target.
Figure 6.2 shows the CBNs for the Full+ (9, UFS) feature set. After adding the tar-
get feature, the direction of the edge between SOFA at T1 and T2 changed. According
to the second CBN, the Result in ICU depends only on Inferior vena cava distensibility
index at T3. Both CBNs are fully connected and have complex interconnectivity.
Figure 6.3 shows the CBNs for the Full+ (9, UFS) feature set. The difference
between the previous feature set and this one is the addition of X Norepinephrine at
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(A)
(B)
FIGURE 6.3: The CBN for the Full+ (10, UFS) feature set achieved
with: a) without the target feature; 2) with the target feature.
T2. According to the CBNs, it only influences APACHE II at T2 and after adding
the target feature the direction of the causality becomes clear. There are no other
differences for this feature set, as compared to the previous one, meaning that the
CBNs for both of the feature sets are stable.
Figure 6.4 shows the CBNs for the Full (24, UFS) feature set. The edges in two
CBNs are exactly the same (except the ones that are connected to the target value).
The target feature in the second CBN is connected to FiO2 at T2, SOFA at T2 and X
Norepinephrine at T1. This is the biggest feature set in the experiments and it is very
interesting to compare the connections here to those of the rest of the feature sets. A
lot of the directions in the edges are missing, the node Heart rate at T3 is disconnected
from the network. Finally, SOFA at T2 is the only direct influence on the target.
Figure 6.5 shows the CBNs for the Full (7, RF) feature set. Both CBNs do not have
any edges with the established directions of causality. Once again, Heart rate at T3 is
disconnected from the rest of the network. This time there is a second node that do
not have any edges which is Respiratory rate at T1. After adding the outcome, only
one new undirected edge between SOFA at T2 and Result in ICU appeared. This is
the second feature set, where SOFA at T2 is connected to the outcome.
Figure 6.5 shows the CBNs for the Full (15, RF) feature set. In these CBNs there
are two disconnected nodes for Heart rate at T3 and E wave at T1 features. Af-
ter adding the target feature, the CBN changes slightly. The directed edge from
APACHE II at T1 to X Norepinephrine at T1 disappeared, and a new undirected con-
nection between X Norepinephrine at T1 and SOFA at T2 was added. The edge from
X norepinephrine at T1 to Respiratory rate at T1 became undirected. Once again, SOFA
at T2 is the only direct connection to the outcome.
Figure 6.7 shows the CBNs for the T1+T2 (5, RF) feature set. This is the smallest
feature set in the experiments. And two nodes in both CBNs are disconnected: E
wave at T1 and Respiratory rate at T1. Here, SOFA at T2 is the only direct connection
for the target feature. The connections between the feature are very similar to those
observed in the previous feature sets.
In all pairs of CBNs, the presence of the target value did not generate much
change. In some cases, new edges appeared, but, in the majority of cases, only few
edges changed their directions. It should be noted that the majority of edges were
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(A)
(B)
FIGURE 6.4: The CBN for the Full (24, UFS) feature set achieved with:
a) without the target feature; 2) with the target feature.
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(A)
(B)
FIGURE 6.5: The CBN for the Full (7, RF) feature set achieved with: a)
without the target feature; 2) with the target feature.
undirected. This might be because of the small amount of data available for model
generation. Nevertheless, some clear patterns are noticeable throughout the exper-
iments. The next chapter summarizes the results and draws the conclusions of the
thesis work.
6.1. Causal Discovery Experiments 49
(A)
(B)
FIGURE 6.6: The CBN for the Full (15, RF) feature set achieved with:
a) without the target feature; 2) with the target feature.
(A)
(B)
FIGURE 6.7: The CBN for the T1+T2 (5, RF) feature set achieved with:
a) without the target feature; 2) with the target feature.
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Chapter 7
Discussion and Conclusions
The previous chapters introduced the problem of mortality prediction in patients
with shock. They described shock pathology, the biomarkers that are currently used
to detect it and different approaches that allow to predict outcome of diseases. They
also introduced three major experiment sets with their methodologies and results.
Here, in this chapter the results of the experiments are discussed to draw a number
of conclusions. Apart from conclusions this chapter addresses the limitations of the
thesis and proposes possible future lines of work.
7.1 Conclusions
The work described in this thesis has led to a list of the biomarkers that can be poten-
tially helpful for the outcome prediction in patients with shock. The work identified
that, at different time steps, some features might be more or less important than
others in those terms. The result is a list of promising features that can be found
in Listing 7.1, with the corresponding time steps when these features are relevant
(T1 < 16 hours from the diagnosis of shock, T2 = 48 h after the diagnosis; T3 = day
7 since the diagnosis). The subsection discusses conclusions of the experiments in
more details.
Features from the Causal Discovery experiments: SOFA T1, SOFA T2, SOFA
T3, APACHE II T1, APACHE II T2, Inferior vena cava distensibility
index T3, Lactate Levels T2, Tracheal Intubation T2, X
Norepinephrine T1, FiO2 at T2;
Additional features from the Feature Selection experiments: Respiratory
rate T1, Urine Output T1, Urine Output T2, Heart rate T3.
List of biomarkers that were considered promising for the outcome prediction in
patients with shock (see Sections 7.1.2 and 7.1.3 for more details).
7.1.1 Preliminary Experiments
The first in the series of experiments were the preliminary experiments from Chapter
4. Their main goal was to establish the missing data imputation technique and the
ML model that performed best for mortality prediction task. The Gaussian Naive
Bayes turned out to be such best model. As for the imputation technique, impu-
tation by linear regression through prediction showed the best results (the lowest
reconstruction error). However, since it only worked with the numerical features,
the Random Forest imputation was used for all later experiments instead. It was the
imputation method with the lowest reconstruction error.
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In addition to justifying the choice of the imputation technique for the later us-
age, the preliminary experiments showed the feasibility of using Bayesian Networks
for mortality prediction. Bayesian Networks showed a comparable performance to
other tested ML models in the analyzed datasets. This is an important result, since
these models provide a certain level of interpretability to the outcome prediction
through probabilities and the structure of the network. And interpretable models
allow knowledge extraction and improve understanding of causal relationships be-
tween the features. Finally, the tested structures for the Bayesian Networks raise
a doubt that SOFA and APACHE II at the time-step 3 are helpful for the mortality
prediction, at least in the analyzed datasets. The models generated without them
showed much better performance.
7.1.2 Feature Selection Experiments
The second group of experiments was dedicated to the feature selection procedure
in four subsets of data: Full+, Full, T1+T2, T1. It was described in Chapter 5. The
goal of these experiments was to identify promising feature sets. The criteria for
their selection was the performance of the Gaussian Naive Bayes model with these
feature sets. After all feature sets were filtered based on the performance, only six of
them left (see Listing 5.3). Apart from this, stability scores were calculated and they
were used as measures of usefulness for individual features in the resulted feature
sets.
By looking at stability scores, one may notice that the RF stability scores have a lot
of reoccurring features, while the scores for other feature selection methods are very
diverse. The later causal discover experiments show that the RF scores were more
accurate. The features like SOFA, APACHE II, Lactate levels, Heart rate, Respiratory rate,
Urine Output and X Norepinephrine usually scored high. In most of the cases, SOFA
and APACHE II features were also highly rated by other feature selection methods.
Although such patterns of features are noticeable, the differences between fea-
ture sets in different datasets are also important. For example, if we compare the
stability scores of the Full+ and the Full datasets, we observe that after removing
the features with more than 50% of missing values, there are a lot of similarities
between the first few best features for the RF and other selection methods. Both
stability scores rank SOFA, APACHE II and Heart rate high. Interestingly, there is
a gain to the performance after removing the T3 features, whereas removing both
the T2 and T3 features considerably worsens the performance. It may occur because
T3 features have a lot of missing values, and basing the outcome prediction on T1
features is not sufficient.
Additionally, it seems that certain features are highly valuable only at certain
time steps. For example, Lactate levels seems to have the most predictive value at T2,
X Norepinephrine and Respiratory rate are particularly valuable at T1, Urine Output –
at T1 and T2 and Heart rate at T3. These conclusions are based on the performances
of the individual feature sets for the outcome prediction and their stability scores.
These hypotheses were further tested in the causal discovery experiments.
7.1.3 Causal Discovery Experiments
The causal discovery experiments are described in Chapter 6. The purpose of these
experiments was to identify the causal relationships of biomarkers and the outcome.
The Bayesian Network approach was used to construct two structures for each of
the six feature sets. The first one was built only with features without the outcome
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feature, and the second one used all of them. The experiments showed that the
structures were stable enough and adding the target feature did not change much
in the causal relationships. The causal Bayesian Networks structures revealed the
connections between the features and the outcome.
The assumption behind the evaluation of the most important biomarkers for the
outcome prediction was that such features are the closest to the outcome in a graph.
The direction of the edge from feature to the outcome is also a good indicator that the
feature is important. According to six structures that contain Result in ICU, SOFA at
the time-step 2 is the most important feature for the outcome prediction. In almost all
structure it has the direct connection to the outcome. The features that are connected
to SOFA at T2 are also valuable. The CBNs for the Full+ (9, UFS) and the Full+ (10,
UFS) feature sets indicate the importance of APACHE II at T2, SOFA at T3, Inferior
vena cava distensibility index at T3. The CBNs for the Full (24, UFS) feature set add
SOFA at T1, Lactate levels at T2, Tracheal Intubation at T2 to this list. In these CBNs
the outcome influences X Norepinephrine at T1 and FiO2 at T2, and they might be
also important indicators for the outcome prediction. The rest of the CBNs for the
last three feature sets confirm some of the candidates for mortality indicators. They
confirm the usage of SOFA at T1, T2 and T3, APACHE II at T2, Lactate Levels at T2 and
X Norepinephrine at T1. The CBNs for the Full (7, RF) and the T1+T2 (5, RF) feature
sets also justify the usefulness of APACHE II at T1.
These findings agree with other studies that support the use of certain biomark-
ers for mortality prediction. For instance, the SOFA score shows a significant prog-
nostic value for in-hospital mortality prediction [37] [36]. The APACHE II score is
often used for the outcome prediction too [39]–[41]. And in the study by Jansen et
al. [22], targeting a decrease of at least 20% in the blood lactate level over a 2-hour
period seemed to be associated with reduced in-hospital mortality in patients with
shock. However, some of the biomarkers that are also related to the mortality in pa-
tients with shock, like mean blood pressure [13], mean arterial pressure [92], or low
LVEF [14] did not show significant predictive value in this study.
7.2 Criticism and Future Work
The study at hand has several limitations. Firstly, the analyzed dataset has too few
observations and too many missing data. This means that the findings of this study
might not be general enough. And in order to increase the confidence in the as-
sumption that the better the performance of a certain feature set, the more important
individual features, more cases should be added to the study. Some of the patterns
might have been missed because there were too few cases that represent them, and
some patterns that were considered general enough might turn out to be very spe-
cific for the patients in the dataset. Additionally, some of the features, that may be
good indicators for mortality, might have a lot of missing values and lost valuable
information for prediction. In order to address these issues, the findings of this study
should be tested on a different and considerably larger dataset.
Secondly, the study attempted to identify mortality prediction indicators for cir-
culatory shock. Unfortunately, the dataset contained only septic and cardiogenic
shock patients with a control group. So naturally, the biomarkers that were found
in this study should be tested for hypovolaemic and obstructive shock, as well. Sep-
tic and cardiogenic shocks are the most common types, but the treatment and the
diagnosis of the shock type ideally should go in parallel. And if two other types of
shock can have completely different biomarkers for mortality prediction, then this
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makes it difficult to plan the treatment. This problem can be addressed by including
patients with other two types of shock and repeating the feature selection and causal
discovery experiments.
Third, although the study proposed the causal relationships for the promising
feature sets, there is still a lot of missing relationship information. Most of the edges
in the Bayesian Network structures are undirected and hence, it is impossible to
build a model that can be tested and evaluated. The uncertainties in the structures
are very likely related to a small number of observation. So in order to build the
Bayesian Network that could predict the outcome of a patient with shock, these
uncertainties should be eliminated. Once the structures are known, it is required to
measure the performance of the model. And the training and the testing should be
done using the dataset with enough observations
The work of this Master’s thesis was based on the ShockOmics project dataset.
Therefore, the criticism and the future work proposed in this section are closely re-
lated to improving the quality of data. Although the ShockOmics dataset proposes a
huge number of clinical features, more patient observations and more types of shock
are needed to corroborate the findings of the thesis and build an interpretable model.
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Appendix A
Chapter 4: Complementary Tables
and Figures
A.1 Dataset Overview
FIGURE A.1: The first 83 features of the ShockOmics data and their
missing values.
64 Appendix A. Chapter 4: Complementary Tables and Figures
FIGURE A.2: Features of the ShockOmics data from 84 to 166 and
their missing values.
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FIGURE A.3: Features of the ShockOmics data from 167 to 248 and
their missing values.
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FIGURE A.4: Features of the ShockOmics data from 249 to 333 and
their missing values.
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FIGURE A.5: Observations, features, their types and missing values
of the ShockOmics dataset.
68 Appendix A. Chapter 4: Complementary Tables and Figures
A.2 Bayesian Networks Configurations Performance
Struct. Discr. Accuracy MCC
1 2 0.7368 ± 0.0666 0.2955 ± 0.1622
1 3 0.8526 ± 0.0614 0.6023 ± 0.1441
1 4 0.8526 ± 0.1219 0.6381 ± 0.2973
1 5 0.7158 ± 0.0855 0.0966 ± 0.1358
2 2 0.7263 ± 0.0614 0.2653 ± 0.138
2 3 0.8421 ± 0.0471 0.5723 ± 0.1157
2 4 0.8 ± 0.0614 0.1063 ± 0.1399
2 5 0.8316 ± 0.0211 0.0913 ± 0.1826
3 2 0.7579 ± 0.0537 0.2845 ± 0.1569
3 3 0.7895 ± 0.0333 0.364 ± 0.1988
3 4 0.8421 ± 0.0881 0.2749 ± 0.3367
3 5 0.7579 ± 0.0976 0.0 ± 0.0
4 2 0.6316 ± 0.0333 0.0357 ± 0.0662
4 3 0.7053 ± 0.0537 0.0585 ± 0.1893
4 4 0.7368 ± 0.0881 0.1405 ± 0.2938
4 5 0.6632 ± 0.1272 -0.1148 ± 0.0992
5 2 0.6842 ± 0.0333 0.0199 ± 0.1455
5 3 0.6316 ± 0.0577 0.0337 ± 0.1509
5 4 0.7053 ± 0.0976 0.0009 ± 0.1749
5 5 0.7684 ± 0.0537 -0.027 ± 0.0662
6 2 0.6632 ± 0.0714 0.1298 ± 0.1066
6 3 0.7263 ± 0.0394 0.0094 ± 0.1194
6 4 0.7474 ± 0.0394 -0.0092 ± 0.1216
6 5 0.7474 ± 0.1021 0.0982 ± 0.2392
TABLE A.1: Bayesian Networks structures, different number of vari-
able discretization trained with the Maximum Likelihood Estimator:
their accuracy and MCC. The best results in each column are high-
lighted in bold.
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Struct. Discr. Sensitivity Specificity AUC
1 2 0.8336 ± 0.0989 0.4533 ± 0.2409 0.7368 ± 0.0666
1 3 0.9565 ± 0.0361 0.5776 ± 0.1227 0.8526 ± 0.0614
1 4 1.0 ± 0.0 0.5305 ± 0.3853 0.8526 ± 0.1219
1 5 0.9846 ± 0.0308 0.0667 ± 0.0816 0.7158 ± 0.0855
2 2 0.8167 ± 0.0834 0.4667 ± 0.1633 0.7263 ± 0.0614
2 3 0.959 ± 0.0538 0.5167 ± 0.1476 0.8421 ± 0.0471
2 4 0.9857 ± 0.0286 0.0733 ± 0.0904 0.8 ± 0.0614
2 5 1.0 ± 0.0 0.05 ± 0.1 0.8316 ± 0.0211
3 2 0.8758 ± 0.0514 0.3833 ± 0.1183 0.7579 ± 0.0537
3 3 1.0 ± 0.0 0.22 ± 0.1392 0.7895 ± 0.0333
3 4 1.0 ± 0.0 0.2 ± 0.2449 0.8421 ± 0.0881
3 5 1.0 ± 0.0 0.0 ± 0.0 0.7579 ± 0.0976
4 2 0.7971 ± 0.1142 0.25 ± 0.1667 0.6316 ± 0.0333
4 3 0.8215 ± 0.0814 0.2667 ± 0.2261 0.7053 ± 0.0537
4 4 0.9571 ± 0.0857 0.1167 ± 0.1453 0.7368 ± 0.0881
4 5 0.9261 ± 0.0607 0.0 ± 0.0 0.6632 ± 0.1272
5 2 0.9733 ± 0.0533 0.025 ± 0.05 0.6842 ± 0.0333
5 3 0.8328 ± 0.0519 0.2071 ± 0.117 0.6316 ± 0.0577
5 4 0.905 ± 0.0617 0.1067 ± 0.1373 0.7053 ± 0.0976
5 5 0.9464 ± 0.0527 0.04 ± 0.08 0.7684 ± 0.0537
6 2 0.8337 ± 0.1517 0.3405 ± 0.3442 0.6632 ± 0.0714
6 3 0.9082 ± 0.0873 0.09 ± 0.1114 0.7263 ± 0.0394
6 4 0.9317 ± 0.0631 0.0667 ± 0.1333 0.7474 ± 0.0394
6 5 0.9526 ± 0.0622 0.1071 ± 0.1317 0.7474 ± 0.1021
TABLE A.2: Bayesian Networks structures, different number of vari-
able discretization trained with the Maximum Likelihood Estimator:
their sensitivity, specificity and AUC. The best results in each column
are highlighted in bold.
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Struct. Discr. Accuracy MCC
1 2 0.7789 ± 0.0842 0.3945 ± 0.2034
1 3 0.8632 ± 0.0537 0.6181 ± 0.0854
1 4 0.8421 ± 0.0577 0.5863 ± 0.1127
1 5 0.8 ± 0.0394 0.3313 ± 0.1707
2 2 0.7474 ± 0.0906 0.3471 ± 0.1915
2 3 0.8 ± 0.0774 0.4197 ± 0.1773
2 4 0.8421 ± 0.0744 0.368 ± 0.2782
2 5 0.7684 ± 0.0421 0.1607 ± 0.1998
3 2 0.8105 ± 0.0421 0.393 ± 0.1537
3 3 0.8526 ± 0.0211 0.1882 ± 0.2306
3 4 0.7158 ± 0.0855 0.153 ± 0.1931
3 5 0.7684 ± 0.0788 0.0 ± 0.0
4 2 0.6947 ± 0.0906 -0.0101 ± 0.1705
4 3 0.7053 ± 0.0632 0.0924 ± 0.168
4 4 0.7368 ± 0.0577 0.0502 ± 0.2463
4 5 0.7368 ± 0.1331 0.1104 ± 0.2311
5 2 0.7158 ± 0.1228 -0.1181 ± 0.1039
5 3 0.7158 ± 0.0421 0.0056 ± 0.1152
5 4 0.7579 ± 0.0537 0.1688 ± 0.2054
5 5 0.7263 ± 0.0516 -0.011 ± 0.0777
6 2 0.6947 ± 0.0394 -0.0143 ± 0.1935
6 3 0.7263 ± 0.0774 0.11 ± 0.1692
6 4 0.7474 ± 0.0842 0.2249 ± 0.1893
6 5 0.6947 ± 0.0906 -0.0034 ± 0.1997
TABLE A.3: Bayesian Networks structures, different number of vari-
able discretization trained with the Bayesian Estimator: their accu-
racy and MCC. The best results in each column are highlighted in
bold.
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Struct. Discr. Sensitivity Specificity AUC
1 2 0.8897 ± 0.0658 0.4833 ± 0.2134 0.7789 ± 0.0842
1 3 0.9446 ± 0.0782 0.5833 ± 0.1229 0.8632 ± 0.0537
1 4 1.0 ± 0.0 0.4271 ± 0.1356 0.8421 ± 0.0577
1 5 0.9857 ± 0.0286 0.2133 ± 0.1306 0.8 ± 0.0394
2 2 0.8291 ± 0.0876 0.51 ± 0.1281 0.7474 ± 0.0906
2 3 0.9332 ± 0.0423 0.4319 ± 0.2023 0.8 ± 0.0774
2 4 0.9739 ± 0.0322 0.2733 ± 0.1665 0.8421 ± 0.0744
2 5 1.0 ± 0.0 0.0833 ± 0.1054 0.7684 ± 0.0421
3 2 0.8814 ± 0.0477 0.5033 ± 0.16 0.8105 ± 0.0421
3 3 0.9867 ± 0.0267 0.15 ± 0.2 0.8526 ± 0.0211
3 4 1.0 ± 0.0 0.0786 ± 0.102 0.7158 ± 0.0855
3 5 1.0 ± 0.0 0.0 ± 0.0 0.7684 ± 0.0788
4 2 0.9405 ± 0.0894 0.05 ± 0.1 0.6947 ± 0.0906
4 3 0.8213 ± 0.0824 0.24 ± 0.1679 0.7053 ± 0.0632
4 4 0.9198 ± 0.0658 0.115 ± 0.1513 0.7368 ± 0.0577
4 5 0.9509 ± 0.0406 0.1202 ± 0.1224 0.7368 ± 0.1331
5 2 0.9149 ± 0.0798 0.0 ± 0.0 0.7158 ± 0.1228
5 3 0.8692 ± 0.118 0.1667 ± 0.2108 0.7158 ± 0.0421
5 4 0.8814 ± 0.0654 0.2467 ± 0.1356 0.7579 ± 0.0537
5 5 0.9583 ± 0.0527 0.0286 ± 0.0571 0.7263 ± 0.0516
6 2 0.8687 ± 0.0549 0.1067 ± 0.1373 0.6947 ± 0.0394
6 3 0.8253 ± 0.0617 0.2833 ± 0.1633 0.7263 ± 0.0774
6 4 0.9414 ± 0.0541 0.2138 ± 0.1155 0.7474 ± 0.0842
6 5 0.9542 ± 0.0651 0.0333 ± 0.0667 0.6947 ± 0.0906
TABLE A.4: Bayesian Networks structures, different number of vari-
able discretization trained with the Bayesian Estimator: their sensi-
tivity, specificity and AUC. The best results in each column are high-
lighted in bold.
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B.1 Feature Selection Results
F Accuracy MCC Sensitivity Specificity AUC
2 0.812 ± 0.072 0.503 ± 0.2 0.578 ± 0.194 0.896 ± 0.071 0.812 ± 0.072
3 0.846 ± 0.072 0.617 ± 0.183 0.716 ± 0.179 0.893 ± 0.08 0.846 ± 0.072
4 0.803 ± 0.066 0.502 ± 0.172 0.624 ± 0.199 0.867 ± 0.08 0.803 ± 0.066
5 0.807 ± 0.076 0.509 ± 0.196 0.618 ± 0.196 0.875 ± 0.084 0.807 ± 0.076
6 0.819 ± 0.076 0.544 ± 0.195 0.648 ± 0.202 0.88 ± 0.087 0.819 ± 0.076
7 0.843 ± 0.077 0.617 ± 0.193 0.744 ± 0.198 0.878 ± 0.081 0.843 ± 0.077
8 0.857 ± 0.074 0.654 ± 0.181 0.768 ± 0.18 0.889 ± 0.085 0.857 ± 0.074
9 0.862 ± 0.069 0.667 ± 0.168 0.784 ± 0.178 0.89 ± 0.076 0.862 ± 0.069
10 0.863 ± 0.078 0.663 ± 0.194 0.752 ± 0.184 0.903 ± 0.082 0.863 ± 0.078
11 0.838 ± 0.084 0.607 ± 0.208 0.734 ± 0.186 0.876 ± 0.087 0.838 ± 0.084
12 0.839 ± 0.067 0.62 ± 0.157 0.768 ± 0.189 0.864 ± 0.089 0.839 ± 0.067
13 0.851 ± 0.061 0.627 ± 0.151 0.704 ± 0.168 0.903 ± 0.079 0.851 ± 0.061
14 0.848 ± 0.066 0.609 ± 0.176 0.68 ± 0.179 0.908 ± 0.066 0.848 ± 0.066
15 0.835 ± 0.071 0.594 ± 0.175 0.706 ± 0.164 0.881 ± 0.082 0.835 ± 0.071
16 0.833 ± 0.077 0.577 ± 0.207 0.666 ± 0.212 0.893 ± 0.084 0.833 ± 0.077
17 0.829 ± 0.071 0.563 ± 0.192 0.662 ± 0.195 0.889 ± 0.073 0.829 ± 0.071
18 0.835 ± 0.068 0.584 ± 0.182 0.69 ± 0.193 0.887 ± 0.072 0.835 ± 0.068
19 0.826 ± 0.076 0.558 ± 0.201 0.654 ± 0.208 0.887 ± 0.082 0.826 ± 0.076
20 0.833 ± 0.074 0.581 ± 0.193 0.688 ± 0.199 0.884 ± 0.081 0.833 ± 0.074
21 0.843 ± 0.072 0.597 ± 0.204 0.696 ± 0.22 0.895 ± 0.072 0.843 ± 0.072
22 0.851 ± 0.081 0.624 ± 0.207 0.716 ± 0.198 0.899 ± 0.078 0.851 ± 0.081
23 0.831 ± 0.088 0.594 ± 0.199 0.724 ± 0.183 0.869 ± 0.102 0.831 ± 0.088
24 0.835 ± 0.08 0.59 ± 0.201 0.706 ± 0.184 0.881 ± 0.089 0.835 ± 0.08
25 0.843 ± 0.07 0.618 ± 0.167 0.736 ± 0.167 0.881 ± 0.082 0.843 ± 0.07
26 0.843 ± 0.077 0.622 ± 0.176 0.748 ± 0.166 0.876 ± 0.092 0.843 ± 0.077
27 0.844 ± 0.073 0.625 ± 0.166 0.748 ± 0.171 0.878 ± 0.091 0.844 ± 0.073
28 0.832 ± 0.077 0.583 ± 0.188 0.688 ± 0.184 0.884 ± 0.088 0.832 ± 0.077
29 0.828 ± 0.08 0.588 ± 0.189 0.718 ± 0.196 0.868 ± 0.103 0.828 ± 0.08
30 0.831 ± 0.088 0.585 ± 0.211 0.704 ± 0.201 0.876 ± 0.096 0.831 ± 0.088
TABLE B.1: The UFS features performance measures for Full+
dataset.
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F Accuracy MCC Sensitivity Specificity AUC
2 0.711 ± 0.053 -0.003 ± 0.166 0.046 ± 0.084 0.948 ± 0.071 0.711 ± 0.053
3 0.681 ± 0.073 0.038 ± 0.193 0.156 ± 0.122 0.868 ± 0.093 0.681 ± 0.073
4 0.733 ± 0.083 0.234 ± 0.254 0.312 ± 0.201 0.883 ± 0.092 0.733 ± 0.083
5 0.729 ± 0.079 0.213 ± 0.241 0.28 ± 0.172 0.889 ± 0.088 0.729 ± 0.079
6 0.74 ± 0.081 0.275 ± 0.229 0.352 ± 0.188 0.879 ± 0.092 0.74 ± 0.081
7 0.738 ± 0.101 0.339 ± 0.252 0.502 ± 0.211 0.823 ± 0.11 0.738 ± 0.101
8 0.719 ± 0.08 0.26 ± 0.2 0.414 ± 0.17 0.828 ± 0.098 0.719 ± 0.08
9 0.723 ± 0.089 0.27 ± 0.24 0.43 ± 0.214 0.827 ± 0.09 0.723 ± 0.089
10 0.692 ± 0.081 0.215 ± 0.207 0.428 ± 0.2 0.786 ± 0.103 0.692 ± 0.081
11 0.679 ± 0.088 0.162 ± 0.214 0.364 ± 0.191 0.791 ± 0.109 0.679 ± 0.088
12 0.719 ± 0.08 0.264 ± 0.218 0.436 ± 0.205 0.821 ± 0.1 0.719 ± 0.08
13 0.738 ± 0.095 0.35 ± 0.242 0.54 ± 0.224 0.809 ± 0.111 0.738 ± 0.095
14 0.713 ± 0.085 0.285 ± 0.212 0.494 ± 0.209 0.791 ± 0.105 0.713 ± 0.085
15 0.729 ± 0.099 0.329 ± 0.233 0.518 ± 0.225 0.805 ± 0.125 0.729 ± 0.099
16 0.765 ± 0.083 0.359 ± 0.237 0.428 ± 0.208 0.886 ± 0.097 0.765 ± 0.083
17 0.751 ± 0.064 0.316 ± 0.2 0.41 ± 0.216 0.872 ± 0.093 0.751 ± 0.064
18 0.748 ± 0.078 0.288 ± 0.246 0.354 ± 0.194 0.889 ± 0.086 0.748 ± 0.078
19 0.739 ± 0.076 0.284 ± 0.214 0.388 ± 0.189 0.864 ± 0.085 0.739 ± 0.076
20 0.763 ± 0.076 0.354 ± 0.21 0.422 ± 0.206 0.884 ± 0.1 0.763 ± 0.076
21 0.739 ± 0.084 0.284 ± 0.235 0.396 ± 0.214 0.861 ± 0.1 0.739 ± 0.084
22 0.747 ± 0.079 0.313 ± 0.227 0.416 ± 0.199 0.865 ± 0.091 0.747 ± 0.079
23 0.739 ± 0.082 0.289 ± 0.232 0.398 ± 0.218 0.861 ± 0.095 0.739 ± 0.082
24 0.741 ± 0.082 0.287 ± 0.232 0.388 ± 0.215 0.866 ± 0.103 0.741 ± 0.082
25 0.735 ± 0.076 0.269 ± 0.22 0.376 ± 0.21 0.863 ± 0.095 0.735 ± 0.076
26 0.724 ± 0.071 0.244 ± 0.194 0.362 ± 0.185 0.854 ± 0.098 0.724 ± 0.071
27 0.725 ± 0.08 0.256 ± 0.222 0.392 ± 0.206 0.844 ± 0.098 0.725 ± 0.08
28 0.722 ± 0.09 0.244 ± 0.239 0.368 ± 0.191 0.849 ± 0.1 0.722 ± 0.09
29 0.748 ± 0.088 0.312 ± 0.256 0.414 ± 0.235 0.867 ± 0.103 0.748 ± 0.088
30 0.739 ± 0.085 0.284 ± 0.244 0.39 ± 0.222 0.864 ± 0.094 0.739 ± 0.085
TABLE B.2: The RFE features performance measures for the Full+
dataset.
F Accuracy MCC Sensitivity Specificity AUC
17 0.748 ± 0.081 0.31 ± 0.233 0.388 ± 0.196 0.877 ± 0.1 0.748 ± 0.081
19 0.719 ± 0.084 0.228 ± 0.235 0.354 ± 0.213 0.849 ± 0.107 0.719 ± 0.084
TABLE B.3: The RFECV features performance measures for the Full+
dataset. The first entry with 17 features used the average precision met-
ric. The second one used the accuracy.
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F Accuracy MCC Sensitivity Specificity AUC
2 0.802 ± 0.09 0.491 ± 0.198 0.576 ± 0.168 0.882 ± 0.112 0.802 ± 0.09
3 0.818 ± 0.111 0.54 ± 0.25 0.604 ± 0.21 0.894 ± 0.125 0.818 ± 0.111
4 0.842 ± 0.104 0.6 ± 0.235 0.664 ± 0.196 0.905 ± 0.11 0.842 ± 0.104
5 0.793 ± 0.114 0.51 ± 0.232 0.66 ± 0.175 0.841 ± 0.14 0.793 ± 0.114
6 0.8 ± 0.098 0.525 ± 0.209 0.696 ± 0.178 0.837 ± 0.118 0.8 ± 0.098
7 0.782 ± 0.109 0.496 ± 0.217 0.698 ± 0.187 0.812 ± 0.129 0.782 ± 0.109
8 0.794 ± 0.09 0.504 ± 0.216 0.674 ± 0.191 0.836 ± 0.101 0.794 ± 0.09
9 0.814 ± 0.079 0.537 ± 0.187 0.642 ± 0.184 0.876 ± 0.096 0.814 ± 0.079
10 0.769 ± 0.106 0.439 ± 0.219 0.602 ± 0.182 0.829 ± 0.131 0.769 ± 0.106
11 0.806 ± 0.083 0.517 ± 0.191 0.63 ± 0.182 0.869 ± 0.101 0.806 ± 0.083
12 0.787 ± 0.105 0.47 ± 0.233 0.584 ± 0.205 0.859 ± 0.128 0.787 ± 0.105
13 0.788 ± 0.109 0.482 ± 0.227 0.61 ± 0.188 0.851 ± 0.135 0.788 ± 0.109
14 0.813 ± 0.097 0.541 ± 0.208 0.654 ± 0.198 0.87 ± 0.121 0.813 ± 0.097
15 0.818 ± 0.095 0.558 ± 0.206 0.676 ± 0.167 0.869 ± 0.114 0.818 ± 0.095
16 0.78 ± 0.096 0.45 ± 0.234 0.592 ± 0.217 0.847 ± 0.117 0.78 ± 0.096
17 0.789 ± 0.112 0.48 ± 0.242 0.604 ± 0.214 0.855 ± 0.142 0.789 ± 0.112
18 0.809 ± 0.083 0.515 ± 0.196 0.618 ± 0.198 0.877 ± 0.1 0.809 ± 0.083
19 0.828 ± 0.075 0.559 ± 0.197 0.632 ± 0.203 0.898 ± 0.088 0.828 ± 0.075
20 0.825 ± 0.086 0.555 ± 0.216 0.62 ± 0.193 0.899 ± 0.096 0.825 ± 0.086
21 0.81 ± 0.093 0.53 ± 0.212 0.638 ± 0.189 0.871 ± 0.11 0.81 ± 0.093
22 0.808 ± 0.086 0.521 ± 0.213 0.64 ± 0.21 0.868 ± 0.103 0.808 ± 0.086
23 0.833 ± 0.083 0.583 ± 0.193 0.684 ± 0.165 0.886 ± 0.093 0.833 ± 0.083
24 0.816 ± 0.072 0.535 ± 0.171 0.626 ± 0.162 0.884 ± 0.088 0.816 ± 0.072
25 0.815 ± 0.087 0.539 ± 0.209 0.646 ± 0.194 0.876 ± 0.099 0.815 ± 0.087
26 0.827 ± 0.086 0.568 ± 0.216 0.676 ± 0.205 0.881 ± 0.093 0.827 ± 0.086
27 0.831 ± 0.081 0.583 ± 0.193 0.68 ± 0.192 0.885 ± 0.097 0.831 ± 0.081
28 0.821 ± 0.085 0.553 ± 0.218 0.674 ± 0.203 0.874 ± 0.09 0.821 ± 0.085
29 0.823 ± 0.086 0.558 ± 0.205 0.66 ± 0.189 0.881 ± 0.096 0.823 ± 0.086
30 0.841 ± 0.079 0.605 ± 0.189 0.688 ± 0.182 0.896 ± 0.094 0.841 ± 0.079
TABLE B.4: The UFS+RFE features performance measures for the
Full+ dataset.
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F Accuracy MCC Sensitivity Specificity AUC
2 0.839 ± 0.064 0.571 ± 0.18 0.55 ± 0.195 0.943 ± 0.071 0.839 ± 0.064
3 0.822 ± 0.08 0.532 ± 0.214 0.58 ± 0.189 0.908 ± 0.084 0.822 ± 0.08
4 0.844 ± 0.067 0.581 ± 0.194 0.6 ± 0.194 0.931 ± 0.06 0.844 ± 0.067
5 0.848 ± 0.067 0.615 ± 0.171 0.686 ± 0.175 0.906 ± 0.075 0.848 ± 0.067
6 0.807 ± 0.077 0.517 ± 0.199 0.64 ± 0.208 0.867 ± 0.087 0.807 ± 0.077
7 0.831 ± 0.07 0.57 ± 0.186 0.66 ± 0.184 0.891 ± 0.078 0.831 ± 0.07
8 0.839 ± 0.081 0.613 ± 0.201 0.754 ± 0.194 0.87 ± 0.088 0.839 ± 0.081
9 0.818 ± 0.073 0.556 ± 0.178 0.682 ± 0.192 0.867 ± 0.095 0.818 ± 0.073
10 0.808 ± 0.066 0.515 ± 0.172 0.632 ± 0.178 0.871 ± 0.076 0.808 ± 0.066
11 0.799 ± 0.072 0.48 ± 0.191 0.58 ± 0.184 0.877 ± 0.08 0.799 ± 0.072
12 0.785 ± 0.076 0.457 ± 0.203 0.584 ± 0.215 0.857 ± 0.093 0.785 ± 0.076
13 0.808 ± 0.081 0.506 ± 0.216 0.612 ± 0.219 0.878 ± 0.085 0.808 ± 0.081
14 0.821 ± 0.086 0.568 ± 0.213 0.722 ± 0.2 0.856 ± 0.092 0.821 ± 0.086
15 0.824 ± 0.077 0.549 ± 0.204 0.634 ± 0.212 0.892 ± 0.085 0.824 ± 0.077
16 0.844 ± 0.08 0.623 ± 0.184 0.716 ± 0.186 0.889 ± 0.104 0.844 ± 0.08
17 0.836 ± 0.08 0.597 ± 0.198 0.71 ± 0.201 0.881 ± 0.094 0.836 ± 0.08
18 0.83 ± 0.08 0.571 ± 0.207 0.672 ± 0.201 0.886 ± 0.085 0.83 ± 0.08
19 0.843 ± 0.079 0.608 ± 0.208 0.708 ± 0.212 0.891 ± 0.09 0.843 ± 0.079
20 0.838 ± 0.077 0.605 ± 0.183 0.722 ± 0.194 0.879 ± 0.092 0.838 ± 0.077
21 0.855 ± 0.068 0.638 ± 0.183 0.724 ± 0.193 0.901 ± 0.08 0.855 ± 0.068
22 0.845 ± 0.071 0.605 ± 0.188 0.684 ± 0.196 0.903 ± 0.074 0.845 ± 0.071
23 0.841 ± 0.076 0.606 ± 0.192 0.702 ± 0.197 0.89 ± 0.089 0.841 ± 0.076
24 0.849 ± 0.064 0.63 ± 0.166 0.74 ± 0.193 0.888 ± 0.082 0.849 ± 0.064
25 0.848 ± 0.062 0.622 ± 0.171 0.738 ± 0.191 0.887 ± 0.069 0.848 ± 0.062
26 0.859 ± 0.064 0.649 ± 0.172 0.744 ± 0.196 0.9 ± 0.07 0.859 ± 0.064
27 0.854 ± 0.062 0.63 ± 0.172 0.708 ± 0.205 0.906 ± 0.071 0.854 ± 0.062
28 0.861 ± 0.062 0.655 ± 0.161 0.748 ± 0.169 0.901 ± 0.069 0.861 ± 0.062
29 0.843 ± 0.074 0.615 ± 0.193 0.72 ± 0.212 0.886 ± 0.094 0.843 ± 0.074
30 0.852 ± 0.07 0.628 ± 0.193 0.706 ± 0.216 0.904 ± 0.084 0.852 ± 0.07
TABLE B.5: The RF performance measures for the Full+ dataset.
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B.2 Feature Sets Rankings
R Univariate feature selection Recursive feature elimination
1 Inferior vena cava distensibility in-
dex _T3
Hematocrit _T1
2 SOFA_T2 K Ur_T1
3 APACHE II_T1 Tricuspid regurgitation max vel _T2
4 APACHE II_T2 Platelet count_T1
5 APACHE II_T3 Creat Ur_T1
6 SOFA_T3 PT_T1
7 SOFA_T1 Tricuspid regurgitation max vel _T1
8 LA dilatation by eyeballing_T1=Yes Respiratory rate rpm _T1
9 LA dilatation by eyeballing_T1=No Tidal volume VT _T3
10 X Norepinephrine xb5g kg min _T2 Tidal volume VT _T1
11 Glasgow Coma Scale_T2 aPTT_T1
12 FiO2_T3 HCO3 mmol L _T1
13 E e _T3 E wave cm s _T1
14 pH_T2 Creat Ur_T3
15 Lactate levels mmol L _T2 Diastolic Blood Pressure mmHg _T3
16 PCT_Value mg mL _T2 Neutro abs count_T2
17 Sedation Scale SAS _T2 Value _T1
18 Na Ur_T3 Heart rate bpm _T2 1
19 FiO2_T2 K Ur_T3
20 Respiratory rate_T1 APACHE II_T2
21 Tricuspid regurgitation max vel _T1 Leukocytes total 1000 mm 3 _T2
22 Tracheal Intubation_T2=Yes PCT_Value mg mL _T2
23 Tracheal Intubation_T2=No CRP_Value mg L _T3
24 Sat O2 FiO2_T3 WBC abs count_T2
25 X Norepinephrine xb5g kg min _T1 SvO2 _T3
26 Creatinine mg dL _T3 Mean arterial pressure mmHg _T3
27 Sat O2 FiO2_T2 Leukocytes total 1000 mm 3 _T3
28 Hypotension,MAP or SBP decrease_-
T2=Yes
Inferior vena cava distensibility in-
dex _T1
29 Hypotension,MAP or SBP decrease_-
T2=No
APACHE II_T1
30 Number of affected organs PaCO2 mmHg _T1
TABLE B.6: The UFS and the RFE feature rankings for the Full+
dataset.
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AVERAGE PRECISION: Creat Ur_T1, Creat Ur_T3, Diastolic Blood Pressure
mmHg_T3, E wave cm s _T1, HCO3 mmol L _T1, Hematocrit _T1, K Ur_T1,
Neutro abs count_T2, PT_T1, Platelet count_T1, Respiratory rate
rpm _T1, Tidal volume VT _T1, Tidal volume VT _T3, Tricuspid
regurgitation maximal velocity by CW cm s _T1, Tricuspid
regurgitation maximal velocity by CW cm s _T2, Value _T1, aPTT_T1;
ACCURACY: Creat Ur_T1, Creat Ur_T3, Diastolic Blood Pressure mmHg _T3,
E wave cm s _T1, HCO3 mmol L _T1, Heart rate bpm _T2 1, Hematocrit
_T1, K Ur_T1, K Ur_T3, Neutro abs count_T2, PT_T1, Platelet
count_T1, Respiratory rate rpm _T1, Tidal volume VT _T1, Tidal
volume VT _T3, Tricuspid regurgitation maximal velocity by CW cm s
_T1, Tricuspid regurgitation maximal velocity by CW cm s _T2, Value
_T1, aPTT_T1;
List of features for the RFECV with the average precision and the accuracy metrics for
the Full+ dataset.
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R UFS+FSE Random Forest
1 Inferior vena cava distensibility in-
dex_T3
Inferior vena cava distensibility in-
dex_T3
2 Tracheal Intubation_T2=No Lactate levels mmol L _T2
3 X Dobutamine xb5g kg min_T3 SOFA_T2
4 LVOT average diameter mm _T1 SOFA_T3
5 Tracheal Intubation_T2=Yes Na Ur_T3
6 Glasgow Coma Scale_T3 APACHE II_T2
7 Glasgow Coma Scale_T1 FiO2_T3
8 PCT_Value mg mL _T3 APACHE II_T1
9 K Ur_T1 PCT_Value_T1
10 PCT_Value mg mL _T1 X Norepinephrine _T2
11 APACHE II_T3 K Ur_T2
12 Heart rate bpm _T3 1 APACHE II_T3
13 Lactate levels mmol L _T1 Urine Output_T1
14 Tricuspid regurgitation max vel_T1 Respiratory rate_T1
15 SOFA_T1 Sat O2 FiO2_T3
16 Respiratory rate_T1 Pplat_T3
17 PT_T2 X Dobutamine_T3
18 Platelet count_T1 Lateral_T3
19 Platelets _T3 Tricuspid regurgitation max vel_T3
20 LA dilatation by eyeballing_T1=No Tidal volume VT _T2
21 LA dilatation by eyeballing_T1=Yes Heart rate bpm _T3 1
22 Glasgow Coma Scale_T2 E e _T3
23 Number of affected organs E wave_T1
24 APACHE II_T2 X Norepinephrine_T1
25 APACHE II_T1 Tricuspid annular plane syst excur-
sion_T3
26 SOFA_T3 Na Ur_T2
27 CRP_Value mg L _T3 CRP_Value_T3
28 Na Ur_T3 Urine Output _T2
29 Platelet count_T2 Glasgow Coma Scale_T3
30 Tidal volume VT_T1 SOFA_T1
TABLE B.7: The UFS+RFE and the RF feature rankings for the Full+
dataset.
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Chapter 5: Full dataset
C.1 Feature Selection Results
F Accuracy MCC Sensitivity Specificity AUC
2 0.848 ± 0.071 0.615 ± 0.19 0.71 ± 0.205 0.897 ± 0.072 0.848 ± 0.071
3 0.802 ± 0.072 0.496 ± 0.196 0.62 ± 0.203 0.866 ± 0.082 0.802 ± 0.072
4 0.82 ± 0.082 0.572 ± 0.19 0.732 ± 0.173 0.851 ± 0.09 0.82 ± 0.082
5 0.832 ± 0.08 0.586 ± 0.201 0.712 ± 0.197 0.874 ± 0.088 0.832 ± 0.08
6 0.814 ± 0.074 0.546 ± 0.173 0.688 ± 0.18 0.859 ± 0.091 0.814 ± 0.074
7 0.803 ± 0.084 0.517 ± 0.215 0.68 ± 0.214 0.847 ± 0.086 0.803 ± 0.084
8 0.801 ± 0.081 0.494 ± 0.219 0.622 ± 0.208 0.865 ± 0.084 0.801 ± 0.081
9 0.795 ± 0.083 0.471 ± 0.22 0.578 ± 0.217 0.873 ± 0.092 0.795 ± 0.083
10 0.824 ± 0.088 0.553 ± 0.224 0.654 ± 0.217 0.884 ± 0.09 0.824 ± 0.088
11 0.823 ± 0.077 0.543 ± 0.212 0.636 ± 0.199 0.889 ± 0.081 0.823 ± 0.077
12 0.811 ± 0.097 0.539 ± 0.218 0.668 ± 0.198 0.862 ± 0.114 0.811 ± 0.097
13 0.802 ± 0.096 0.543 ± 0.187 0.726 ± 0.149 0.829 ± 0.119 0.802 ± 0.096
14 0.796 ± 0.11 0.534 ± 0.23 0.722 ± 0.187 0.823 ± 0.131 0.796 ± 0.11
15 0.832 ± 0.096 0.599 ± 0.213 0.734 ± 0.186 0.867 ± 0.11 0.832 ± 0.096
16 0.843 ± 0.097 0.64 ± 0.194 0.79 ± 0.158 0.862 ± 0.115 0.843 ± 0.097
17 0.825 ± 0.106 0.595 ± 0.232 0.76 ± 0.185 0.849 ± 0.116 0.825 ± 0.106
18 0.836 ± 0.097 0.616 ± 0.209 0.764 ± 0.163 0.861 ± 0.108 0.836 ± 0.097
19 0.829 ± 0.085 0.614 ± 0.181 0.798 ± 0.166 0.84 ± 0.103 0.829 ± 0.085
20 0.853 ± 0.085 0.653 ± 0.201 0.79 ± 0.184 0.876 ± 0.097 0.853 ± 0.085
21 0.845 ± 0.081 0.635 ± 0.186 0.776 ± 0.161 0.87 ± 0.09 0.845 ± 0.081
22 0.845 ± 0.095 0.635 ± 0.207 0.768 ± 0.159 0.872 ± 0.106 0.845 ± 0.095
23 0.85 ± 0.081 0.643 ± 0.18 0.764 ± 0.153 0.881 ± 0.096 0.85 ± 0.081
24 0.872 ± 0.073 0.687 ± 0.173 0.782 ± 0.147 0.904 ± 0.079 0.872 ± 0.073
25 0.841 ± 0.089 0.621 ± 0.207 0.752 ± 0.175 0.873 ± 0.097 0.841 ± 0.089
26 0.832 ± 0.083 0.597 ± 0.199 0.754 ± 0.189 0.859 ± 0.084 0.832 ± 0.083
27 0.832 ± 0.079 0.602 ± 0.189 0.746 ± 0.192 0.862 ± 0.096 0.832 ± 0.079
28 0.832 ± 0.062 0.59 ± 0.156 0.728 ± 0.176 0.869 ± 0.079 0.832 ± 0.062
29 0.827 ± 0.069 0.59 ± 0.161 0.75 ± 0.163 0.854 ± 0.086 0.827 ± 0.069
30 0.851 ± 0.068 0.636 ± 0.17 0.756 ± 0.191 0.884 ± 0.077 0.851 ± 0.068
TABLE C.1: The UFS features performance measures for the Full
dataset.
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F Accuracy MCC Sensitivity Specificity AUC
2 0.72 ± 0.077 0.223 ± 0.232 0.348 ± 0.213 0.853 ± 0.098 0.72 ± 0.077
3 0.755 ± 0.069 0.335 ± 0.208 0.436 ± 0.22 0.869 ± 0.087 0.755 ± 0.069
4 0.759 ± 0.083 0.437 ± 0.204 0.662 ± 0.217 0.794 ± 0.098 0.759 ± 0.083
5 0.767 ± 0.092 0.466 ± 0.224 0.7 ± 0.225 0.791 ± 0.104 0.767 ± 0.092
6 0.783 ± 0.081 0.508 ± 0.196 0.73 ± 0.218 0.802 ± 0.101 0.783 ± 0.081
7 0.76 ± 0.092 0.435 ± 0.214 0.638 ± 0.226 0.804 ± 0.121 0.76 ± 0.092
8 0.77 ± 0.096 0.456 ± 0.223 0.654 ± 0.222 0.811 ± 0.121 0.77 ± 0.096
9 0.78 ± 0.08 0.482 ± 0.181 0.66 ± 0.195 0.823 ± 0.112 0.78 ± 0.08
10 0.806 ± 0.085 0.524 ± 0.213 0.662 ± 0.226 0.857 ± 0.105 0.806 ± 0.085
11 0.822 ± 0.088 0.559 ± 0.222 0.682 ± 0.219 0.871 ± 0.096 0.822 ± 0.088
12 0.803 ± 0.075 0.51 ± 0.188 0.644 ± 0.199 0.86 ± 0.097 0.803 ± 0.075
13 0.828 ± 0.083 0.546 ± 0.229 0.592 ± 0.242 0.912 ± 0.084 0.828 ± 0.083
14 0.825 ± 0.087 0.547 ± 0.22 0.6 ± 0.204 0.905 ± 0.095 0.825 ± 0.087
15 0.806 ± 0.082 0.484 ± 0.233 0.548 ± 0.22 0.899 ± 0.082 0.806 ± 0.082
16 0.751 ± 0.066 0.221 ± 0.271 0.256 ± 0.252 0.927 ± 0.08 0.751 ± 0.066
17 0.759 ± 0.065 0.265 ± 0.26 0.292 ± 0.242 0.926 ± 0.072 0.759 ± 0.065
18 0.75 ± 0.075 0.227 ± 0.269 0.254 ± 0.228 0.927 ± 0.087 0.75 ± 0.075
19 0.759 ± 0.066 0.266 ± 0.255 0.296 ± 0.239 0.925 ± 0.074 0.759 ± 0.066
20 0.783 ± 0.071 0.373 ± 0.24 0.38 ± 0.227 0.926 ± 0.067 0.783 ± 0.071
21 0.774 ± 0.069 0.335 ± 0.247 0.334 ± 0.232 0.931 ± 0.076 0.774 ± 0.069
22 0.769 ± 0.067 0.308 ± 0.246 0.316 ± 0.225 0.931 ± 0.071 0.769 ± 0.067
23 0.77 ± 0.063 0.321 ± 0.238 0.332 ± 0.232 0.926 ± 0.072 0.77 ± 0.063
24 0.765 ± 0.075 0.299 ± 0.268 0.336 ± 0.241 0.918 ± 0.08 0.765 ± 0.075
25 0.757 ± 0.065 0.287 ± 0.235 0.336 ± 0.233 0.907 ± 0.077 0.757 ± 0.065
26 0.765 ± 0.073 0.317 ± 0.253 0.348 ± 0.243 0.914 ± 0.086 0.765 ± 0.073
27 0.777 ± 0.07 0.381 ± 0.223 0.424 ± 0.242 0.904 ± 0.092 0.777 ± 0.07
28 0.774 ± 0.065 0.36 ± 0.234 0.412 ± 0.25 0.903 ± 0.084 0.774 ± 0.065
29 0.778 ± 0.067 0.389 ± 0.204 0.442 ± 0.21 0.898 ± 0.086 0.778 ± 0.067
30 0.778 ± 0.072 0.397 ± 0.216 0.47 ± 0.23 0.888 ± 0.087 0.778 ± 0.072
TABLE C.2: The RFE features performance measures for the Full
dataset.
F Accuracy MCC Sensitivity Specificity AUC
12 0.788 ± 0.088 0.468 ± 0.223 0.602 ± 0.213 0.854 ± 0.107 0.788 ± 0.088
23 0.756 ± 0.071 0.292 ± 0.247 0.338 ± 0.233 0.906 ± 0.087 0.756 ± 0.071
TABLE C.3: The RFECV features performance measures for the Full
dataset. The first entry with 12 features used the precision metric. The
second one used the AUC.
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F Accuracy MCC Sensitivity Specificity AUC
2 0.767 ± 0.06 0.249 ± 0.208 0.144 ± 0.147 0.99 ± 0.099 0.767 ± 0.06
3 0.771 ± 0.027 0.248 ± 0.196 0.128 ± 0.104 1.0 ± 0.0 0.771 ± 0.027
4 0.776 ± 0.032 0.276 ± 0.205 0.15 ± 0.121 1.0 ± 0.0 0.776 ± 0.032
5 0.775 ± 0.031 0.28 ± 0.195 0.15 ± 0.111 0.999 ± 0.014 0.775 ± 0.031
6 0.773 ± 0.03 0.262 ± 0.201 0.142 ± 0.118 0.999 ± 0.014 0.773 ± 0.03
7 0.786 ± 0.067 0.329 ± 0.258 0.252 ± 0.262 0.976 ± 0.069 0.786 ± 0.067
8 0.769 ± 0.059 0.276 ± 0.24 0.236 ± 0.273 0.96 ± 0.099 0.769 ± 0.059
9 0.765 ± 0.052 0.271 ± 0.225 0.234 ± 0.232 0.954 ± 0.074 0.765 ± 0.052
10 0.764 ± 0.049 0.255 ± 0.223 0.206 ± 0.193 0.963 ± 0.069 0.764 ± 0.049
11 0.762 ± 0.049 0.257 ± 0.212 0.216 ± 0.195 0.957 ± 0.081 0.762 ± 0.049
12 0.768 ± 0.078 0.282 ± 0.275 0.274 ± 0.249 0.945 ± 0.081 0.768 ± 0.078
13 0.785 ± 0.058 0.356 ± 0.244 0.336 ± 0.27 0.945 ± 0.083 0.785 ± 0.058
14 0.791 ± 0.063 0.368 ± 0.258 0.33 ± 0.26 0.956 ± 0.065 0.791 ± 0.063
15 0.792 ± 0.06 0.38 ± 0.237 0.34 ± 0.266 0.953 ± 0.07 0.792 ± 0.06
16 0.778 ± 0.066 0.313 ± 0.261 0.276 ± 0.253 0.958 ± 0.08 0.778 ± 0.066
17 0.785 ± 0.068 0.348 ± 0.268 0.328 ± 0.309 0.949 ± 0.079 0.785 ± 0.068
18 0.779 ± 0.047 0.31 ± 0.226 0.212 ± 0.174 0.981 ± 0.036 0.779 ± 0.047
19 0.792 ± 0.06 0.351 ± 0.256 0.254 ± 0.228 0.984 ± 0.036 0.792 ± 0.06
20 0.792 ± 0.054 0.36 ± 0.241 0.286 ± 0.23 0.972 ± 0.04 0.792 ± 0.054
21 0.792 ± 0.045 0.363 ± 0.214 0.252 ± 0.197 0.984 ± 0.039 0.792 ± 0.045
22 0.785 ± 0.05 0.336 ± 0.231 0.244 ± 0.209 0.978 ± 0.046 0.785 ± 0.05
23 0.794 ± 0.055 0.372 ± 0.237 0.296 ± 0.237 0.972 ± 0.045 0.794 ± 0.055
24 0.788 ± 0.048 0.364 ± 0.212 0.282 ± 0.214 0.969 ± 0.053 0.788 ± 0.048
25 0.803 ± 0.071 0.395 ± 0.27 0.33 ± 0.263 0.971 ± 0.049 0.803 ± 0.071
26 0.779 ± 0.054 0.331 ± 0.228 0.288 ± 0.229 0.955 ± 0.056 0.779 ± 0.054
27 0.781 ± 0.064 0.341 ± 0.247 0.298 ± 0.224 0.953 ± 0.068 0.781 ± 0.064
28 0.78 ± 0.064 0.347 ± 0.233 0.312 ± 0.214 0.947 ± 0.062 0.78 ± 0.064
29 0.783 ± 0.058 0.347 ± 0.234 0.308 ± 0.22 0.953 ± 0.054 0.783 ± 0.058
30 0.799 ± 0.06 0.421 ± 0.221 0.368 ± 0.233 0.954 ± 0.063 0.799 ± 0.06
TABLE C.4: The UFS+RFE feature performance measures for the Full
dataset.
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F Accuracy MCC Sensitivity Specificity AUC
2 0.831 ± 0.071 0.569 ± 0.184 0.664 ± 0.204 0.89 ± 0.079 0.831 ± 0.071
3 0.797 ± 0.079 0.483 ± 0.212 0.594 ± 0.213 0.87 ± 0.091 0.797 ± 0.079
4 0.826 ± 0.076 0.565 ± 0.196 0.688 ± 0.201 0.875 ± 0.078 0.826 ± 0.076
5 0.829 ± 0.079 0.58 ± 0.196 0.704 ± 0.171 0.874 ± 0.086 0.829 ± 0.079
6 0.837 ± 0.081 0.596 ± 0.212 0.708 ± 0.211 0.884 ± 0.085 0.837 ± 0.081
7 0.866 ± 0.075 0.68 ± 0.179 0.796 ± 0.183 0.891 ± 0.087 0.866 ± 0.075
8 0.839 ± 0.078 0.603 ± 0.197 0.728 ± 0.205 0.879 ± 0.08 0.839 ± 0.078
9 0.846 ± 0.073 0.623 ± 0.183 0.744 ± 0.194 0.882 ± 0.079 0.846 ± 0.073
10 0.849 ± 0.075 0.62 ± 0.202 0.72 ± 0.192 0.896 ± 0.075 0.849 ± 0.075
11 0.834 ± 0.068 0.592 ± 0.16 0.708 ± 0.156 0.879 ± 0.087 0.834 ± 0.068
12 0.853 ± 0.067 0.635 ± 0.17 0.734 ± 0.181 0.895 ± 0.077 0.853 ± 0.067
13 0.855 ± 0.075 0.653 ± 0.193 0.762 ± 0.222 0.889 ± 0.101 0.855 ± 0.075
14 0.856 ± 0.069 0.644 ± 0.182 0.74 ± 0.203 0.898 ± 0.074 0.856 ± 0.069
15 0.866 ± 0.075 0.673 ± 0.18 0.752 ± 0.19 0.907 ± 0.09 0.866 ± 0.075
16 0.866 ± 0.07 0.663 ± 0.169 0.712 ± 0.186 0.921 ± 0.083 0.866 ± 0.07
17 0.836 ± 0.073 0.582 ± 0.192 0.674 ± 0.201 0.894 ± 0.082 0.836 ± 0.073
18 0.845 ± 0.074 0.613 ± 0.191 0.714 ± 0.188 0.891 ± 0.08 0.845 ± 0.074
19 0.853 ± 0.067 0.633 ± 0.178 0.724 ± 0.202 0.899 ± 0.076 0.853 ± 0.067
20 0.861 ± 0.081 0.671 ± 0.183 0.78 ± 0.173 0.89 ± 0.098 0.861 ± 0.081
21 0.851 ± 0.072 0.635 ± 0.174 0.738 ± 0.183 0.891 ± 0.084 0.851 ± 0.072
22 0.84 ± 0.078 0.6 ± 0.207 0.706 ± 0.213 0.888 ± 0.079 0.84 ± 0.078
23 0.837 ± 0.083 0.609 ± 0.201 0.748 ± 0.197 0.869 ± 0.092 0.837 ± 0.083
24 0.828 ± 0.077 0.587 ± 0.182 0.73 ± 0.186 0.863 ± 0.091 0.828 ± 0.077
25 0.838 ± 0.075 0.604 ± 0.194 0.724 ± 0.215 0.879 ± 0.088 0.838 ± 0.075
26 0.837 ± 0.07 0.592 ± 0.184 0.706 ± 0.189 0.884 ± 0.073 0.837 ± 0.07
27 0.841 ± 0.068 0.62 ± 0.16 0.758 ± 0.175 0.871 ± 0.084 0.841 ± 0.068
28 0.833 ± 0.078 0.603 ± 0.183 0.746 ± 0.183 0.864 ± 0.094 0.833 ± 0.078
29 0.838 ± 0.08 0.61 ± 0.182 0.724 ± 0.178 0.879 ± 0.101 0.838 ± 0.08
30 0.842 ± 0.07 0.614 ± 0.173 0.718 ± 0.192 0.886 ± 0.088 0.842 ± 0.07
TABLE C.5: The RF features performance measures for the Full
dataset.
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C.2 Feature Sets Rankings
R Univariate feature selection Recursive feature elimination
1 SOFA_T2 APACHE II_T1
2 APACHE II_T1 LVOT average velocity time integral
cm _T1
3 APACHE II_T2 HCO3 mmol L _T1
4 SOFA_T1 SOFA_T1
5 APACHE II_T3 Heart rate bpm _T3 1
6 Glasgow Coma Scale_T2 Weight kg
7 FiO2_T3 Na mmol L _T1
8 FiO2_T2 Leukocytes total 1000 mm 3 _T2
9 pH_T2 Mean arterial pressure mmHg _T3
10 Respiratory rate_T1 Sat O2 FiO2_T3
11 Sedation Scale SAS _T2 Diastolic Blood Pressure mmHg _T3
12 Tracheal Intubation_T2=Yes Hematocrit_T2
13 Tracheal Intubation_T2=No PaO2 mmHg _T2
14 SOFA_T3 E wave cm s _T1
15 Lactate levels mmol L _T2 Systolic blood pressure mmHg _T3
16 X Norepinephrine xb5g kg min _T1 Lympho abs count_T2
17 Sat O2 FiO2_T3 Tidal volume VT _T1
18 Sat O2 FiO2_T2 Heart rate bpm _T1 1
19 Number of affected organs SvcO2_T1
20 Heart rate bpm _T3 1 APACHE II_T3
21 Tidal volume VT _T1 Chloride_T1
22 LA dilatation by eyeballing_T1=No PT_T1
23 LA dilatation by eyeballing_T1=Yes Glasgow Coma Scale_T2
24 Glasgow Coma Scale_T3 Systolic blood pressure mmHg _T2
25 Creatinine mg dL _T2 Platelet count_T1
26 Glasgow Coma Scale_T1 Base Excess mmol L _T1
27 Fluid Balance ml _T1 APACHE II_T2
28 Platelet count_T1 Value _T1
29 Creatinine mg dL _T3 PaCO2 mmHg _T1
30 K mmol L _T2 Glasgow Coma Scale_T1
TABLE C.6: The UFS and RFE feature rankings for the Full dataset.
PRECISION: APACHE II_T1, Diastolic Blood Pressure mmHg _T3, HCO3 mmol
L_T1, Heart rate bpm _T3 1, Hematocrit _T2, LVOT average velocity
time integral cm _T1, Leukocytes total 1000 mm 3 _T2, Mean arterial
pressure mmHg _T3, Na mmol L _T1, SOFA_T1, Sat O2 FiO2_T3, Weight
kg;
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AUC: APACHE II_T1, APACHE II_T3, Chloride_T1, Diastolic Blood Pressure
mmHg _T3, E wave cm s _T1, Glasgow Coma Scale_T2, HCO3 mmol L _T1,
Heart rate bpm _T1 1, Heart rate bpm _T3 1, Hematocrit _T2, LVOT
average velocity time integral cm _T1, Leukocytes total 1000 mm 3
_T2, Lympho abs count_T2, Mean arterial pressure mmHg _T3, Na mmol
L _T1, PT_T1, PaO2 mmHg _T2, SOFA_T1, Sat O2 FiO2_T3, SvcO2 _T1,
Systolic blood pressure mmHg _T3, Tidal volume VT _T1, Weight kg;
List of features for the RFECV with the precision and the AUC metrics for the Full
dataset.
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R UFS+FSE Random Forest
1 LV Dilatation LVEDV _T1=Moderate SOFA_T2
2 Aortic Valve Stenosis_T1=Moderate APACHE II_T1
3 Is the patient under other drugs_-
T1=Yes
APACHE II_T3
4 Is the patient under other drugs_-
T1=No
Lactate levels mmol L _T2
5 Sedation Scale SAS _T2 Urine Output mL day _T1
6 SOFA_T1 Heart rate bpm _T3 1
7 Site of sampling=Urine Respiratory rate_T1
8 SOFA_T3 APACHE II_T2
9 Glasgow Coma Scale_T3 Urine Output mL day _T2
10 Acute Kidney Injury_T2=AKIN III X Norepinephrine_T1
11 APACHE II_T3 E wave_T1
12 Sedation Scale SAS _T1 FiO2_T3
13 HCO3 mmol L _T1 Sat O2 FiO2_T3
14 Respiratory rate_T1 SOFA_T1
15 Is the patient under other drugs_-
T3=No
SOFA_T3
16 Is the patient under other drugs_-
T3=Yes
pH_T2
17 Hematocrit_T3 Creatinine mg dL _T2
18 E A ratio_T1=1 39 Fluid Balance ml _T2
19 LA dilatation by eyeballing_T1=Yes CRP_Value mg L _T3
20 Number of affected organs K mmol L _T3
21 LA dilatation by eyeballing_T1=No Tidal volume VT _T1
22 Base Excess mmol L _T1 Glasgow Coma Scale_T3
23 K mmol L _T2 Fluid Balance ml _T1
24 LVOT average diameter mm _T1 E e _T1
25 Heart rate bpm _T3 1 Glasgow Coma Scale_T2
26 K mmol L _T3 Pplat_T2
27 Respiratory rate rpm _T1 Temperature C _T3
28 PT_T2 PT_T2
29 Pplat_T1 Platelet count_T2
30 PEEP_T1 Heart rate bpm _T1
TABLE C.7: The UFS+RFE and the RF feature rankings for the Full
dataset.
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Chapter 5: T1+T2 dataset
D.1 Feature Selection Results
F Accuracy MCC Sensitivity Specificity AUC
1 0.791 ± 0.066 0.416 ± 0.213 0.448 ± 0.21 0.914 ± 0.069 0.791 ± 0.066
2 0.836 ± 0.08 0.582 ± 0.212 0.666 ± 0.208 0.897 ± 0.083 0.836 ± 0.08
3 0.815 ± 0.067 0.536 ± 0.174 0.662 ± 0.176 0.869 ± 0.078 0.815 ± 0.067
4 0.832 ± 0.073 0.595 ± 0.171 0.734 ± 0.155 0.866 ± 0.088 0.832 ± 0.073
5 0.793 ± 0.078 0.511 ± 0.174 0.696 ± 0.166 0.827 ± 0.098 0.793 ± 0.078
6 0.801 ± 0.073 0.486 ± 0.206 0.606 ± 0.214 0.87 ± 0.08 0.801 ± 0.073
7 0.791 ± 0.081 0.476 ± 0.203 0.604 ± 0.185 0.858 ± 0.097 0.791 ± 0.081
8 0.825 ± 0.07 0.552 ± 0.192 0.63 ± 0.201 0.895 ± 0.08 0.825 ± 0.07
9 0.815 ± 0.076 0.536 ± 0.201 0.65 ± 0.237 0.874 ± 0.092 0.815 ± 0.076
10 0.797 ± 0.096 0.523 ± 0.205 0.68 ± 0.202 0.839 ± 0.119 0.797 ± 0.096
11 0.784 ± 0.11 0.534 ± 0.212 0.776 ± 0.17 0.787 ± 0.132 0.784 ± 0.11
12 0.803 ± 0.093 0.54 ± 0.201 0.728 ± 0.187 0.829 ± 0.108 0.803 ± 0.093
13 0.827 ± 0.084 0.593 ± 0.187 0.748 ± 0.176 0.856 ± 0.099 0.827 ± 0.084
14 0.839 ± 0.087 0.621 ± 0.191 0.756 ± 0.169 0.869 ± 0.105 0.839 ± 0.087
15 0.807 ± 0.094 0.557 ± 0.203 0.746 ± 0.181 0.829 ± 0.109 0.807 ± 0.094
16 0.815 ± 0.09 0.586 ± 0.188 0.796 ± 0.157 0.822 ± 0.101 0.815 ± 0.09
17 0.804 ± 0.096 0.551 ± 0.207 0.746 ± 0.165 0.824 ± 0.107 0.804 ± 0.096
18 0.837 ± 0.075 0.606 ± 0.175 0.742 ± 0.161 0.871 ± 0.084 0.837 ± 0.075
19 0.807 ± 0.086 0.549 ± 0.193 0.722 ± 0.19 0.838 ± 0.106 0.807 ± 0.086
20 0.817 ± 0.086 0.585 ± 0.186 0.778 ± 0.167 0.831 ± 0.099 0.817 ± 0.086
21 0.796 ± 0.076 0.523 ± 0.173 0.712 ± 0.18 0.826 ± 0.095 0.796 ± 0.076
22 0.815 ± 0.078 0.556 ± 0.194 0.718 ± 0.194 0.849 ± 0.087 0.815 ± 0.078
23 0.809 ± 0.077 0.545 ± 0.19 0.716 ± 0.198 0.842 ± 0.093 0.809 ± 0.077
24 0.812 ± 0.077 0.559 ± 0.186 0.738 ± 0.191 0.839 ± 0.091 0.812 ± 0.077
25 0.837 ± 0.08 0.615 ± 0.205 0.772 ± 0.215 0.861 ± 0.087 0.837 ± 0.08
26 0.849 ± 0.072 0.641 ± 0.169 0.764 ± 0.168 0.88 ± 0.09 0.849 ± 0.072
27 0.845 ± 0.076 0.609 ± 0.205 0.704 ± 0.207 0.895 ± 0.077 0.845 ± 0.076
28 0.855 ± 0.06 0.64 ± 0.155 0.736 ± 0.165 0.898 ± 0.07 0.855 ± 0.06
29 0.853 ± 0.069 0.64 ± 0.167 0.726 ± 0.176 0.899 ± 0.088 0.853 ± 0.069
30 0.839 ± 0.07 0.605 ± 0.181 0.716 ± 0.196 0.884 ± 0.084 0.839 ± 0.07
TABLE D.1: The UFS features performance measures for the T1+T2
dataset.
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F Accuracy MCC Sensitivity Specificity AUC
1 0.744 ± 0.052 0.186 ± 0.224 0.178 ± 0.141 0.946 ± 0.057 0.744 ± 0.052
2 0.772 ± 0.08 0.356 ± 0.245 0.392 ± 0.204 0.908 ± 0.083 0.772 ± 0.08
3 0.769 ± 0.078 0.398 ± 0.204 0.51 ± 0.201 0.862 ± 0.092 0.769 ± 0.078
4 0.681 ± 0.098 0.318 ± 0.19 0.65 ± 0.173 0.691 ± 0.125 0.681 ± 0.098
5 0.682 ± 0.096 0.311 ± 0.191 0.63 ± 0.209 0.701 ± 0.135 0.682 ± 0.096
6 0.694 ± 0.086 0.334 ± 0.179 0.646 ± 0.189 0.711 ± 0.117 0.694 ± 0.086
7 0.734 ± 0.081 0.379 ± 0.174 0.618 ± 0.17 0.775 ± 0.106 0.734 ± 0.081
8 0.725 ± 0.095 0.359 ± 0.221 0.604 ± 0.208 0.768 ± 0.118 0.725 ± 0.095
9 0.743 ± 0.084 0.383 ± 0.207 0.592 ± 0.213 0.797 ± 0.104 0.743 ± 0.084
10 0.727 ± 0.082 0.347 ± 0.218 0.578 ± 0.238 0.781 ± 0.103 0.727 ± 0.082
11 0.741 ± 0.097 0.392 ± 0.222 0.614 ± 0.214 0.786 ± 0.12 0.741 ± 0.097
12 0.732 ± 0.093 0.359 ± 0.225 0.58 ± 0.231 0.786 ± 0.114 0.732 ± 0.093
13 0.735 ± 0.085 0.384 ± 0.198 0.626 ± 0.201 0.774 ± 0.111 0.735 ± 0.085
14 0.726 ± 0.1 0.342 ± 0.229 0.562 ± 0.203 0.784 ± 0.121 0.726 ± 0.1
15 0.765 ± 0.076 0.403 ± 0.21 0.55 ± 0.239 0.841 ± 0.103 0.765 ± 0.076
16 0.769 ± 0.08 0.465 ± 0.179 0.678 ± 0.204 0.801 ± 0.111 0.769 ± 0.08
17 0.755 ± 0.077 0.385 ± 0.2 0.552 ± 0.21 0.828 ± 0.097 0.755 ± 0.077
18 0.764 ± 0.093 0.431 ± 0.223 0.626 ± 0.218 0.813 ± 0.103 0.764 ± 0.093
19 0.766 ± 0.072 0.436 ± 0.167 0.63 ± 0.18 0.814 ± 0.094 0.766 ± 0.072
20 0.782 ± 0.081 0.481 ± 0.197 0.674 ± 0.209 0.82 ± 0.098 0.782 ± 0.081
21 0.797 ± 0.08 0.521 ± 0.2 0.714 ± 0.204 0.826 ± 0.093 0.797 ± 0.08
22 0.785 ± 0.087 0.492 ± 0.214 0.686 ± 0.214 0.821 ± 0.105 0.785 ± 0.087
23 0.777 ± 0.081 0.479 ± 0.192 0.688 ± 0.205 0.809 ± 0.1 0.777 ± 0.081
24 0.791 ± 0.087 0.515 ± 0.203 0.72 ± 0.202 0.816 ± 0.102 0.791 ± 0.087
25 0.79 ± 0.089 0.487 ± 0.233 0.658 ± 0.23 0.837 ± 0.092 0.79 ± 0.089
26 0.813 ± 0.077 0.56 ± 0.196 0.74 ± 0.214 0.839 ± 0.09 0.813 ± 0.077
27 0.819 ± 0.085 0.561 ± 0.212 0.71 ± 0.205 0.858 ± 0.088 0.819 ± 0.085
28 0.813 ± 0.083 0.543 ± 0.214 0.69 ± 0.218 0.856 ± 0.093 0.813 ± 0.083
29 0.812 ± 0.077 0.551 ± 0.189 0.714 ± 0.206 0.847 ± 0.091 0.812 ± 0.077
30 0.806 ± 0.087 0.519 ± 0.233 0.664 ± 0.23 0.857 ± 0.089 0.806 ± 0.087
TABLE D.2: The RFE features performance measures for the T1+T2
dataset.
F Accuracy MCC Sensitivity Specificity AUC
2 0.762 ± 0.078 0.313 ± 0.256 0.356 ± 0.205 0.907 ± 0.076 0.762 ± 0.078
3 0.757 ± 0.083 0.363 ± 0.214 0.482 ± 0.202 0.856 ± 0.097 0.757 ± 0.083
41 0.812 ± 0.078 0.534 ± 0.201 0.662 ± 0.215 0.866 ± 0.093 0.812 ± 0.078
42 0.808 ± 0.075 0.526 ± 0.181 0.658 ± 0.19 0.861 ± 0.09 0.808 ± 0.075
55 0.77 ± 0.086 0.444 ± 0.226 0.64 ± 0.237 0.816 ± 0.103 0.77 ± 0.086
TABLE D.3: The RFECV features performance measures for the
T1+T2 dataset. The first entry uses the log loss, followed by the ac-
curacy, the precision, the average precision and the f1-macro metrics.
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F Accuracy MCC Sensitivity Specificity AUC
1 0.72 ± 0.137 0.158 ± 0.193 0.16 ± 0.265 0.92 ± 0.271 0.72 ± 0.137
2 0.779 ± 0.024 0.313 ± 0.169 0.162 ± 0.092 1.0 ± 0.0 0.779 ± 0.024
3 0.766 ± 0.036 0.239 ± 0.208 0.154 ± 0.129 0.985 ± 0.029 0.766 ± 0.036
4 0.762 ± 0.034 0.215 ± 0.2 0.146 ± 0.129 0.981 ± 0.031 0.762 ± 0.034
5 0.783 ± 0.038 0.327 ± 0.196 0.226 ± 0.149 0.981 ± 0.031 0.783 ± 0.038
6 0.786 ± 0.037 0.349 ± 0.182 0.214 ± 0.13 0.99 ± 0.025 0.786 ± 0.037
7 0.784 ± 0.033 0.332 ± 0.183 0.208 ± 0.135 0.989 ± 0.026 0.784 ± 0.033
8 0.779 ± 0.039 0.307 ± 0.203 0.202 ± 0.143 0.985 ± 0.029 0.779 ± 0.039
9 0.784 ± 0.037 0.341 ± 0.187 0.22 ± 0.131 0.986 ± 0.029 0.784 ± 0.037
10 0.78 ± 0.041 0.317 ± 0.201 0.218 ± 0.144 0.981 ± 0.032 0.78 ± 0.041
11 0.776 ± 0.037 0.295 ± 0.196 0.192 ± 0.135 0.984 ± 0.03 0.776 ± 0.037
12 0.775 ± 0.04 0.286 ± 0.21 0.198 ± 0.154 0.981 ± 0.032 0.775 ± 0.04
13 0.774 ± 0.037 0.29 ± 0.193 0.188 ± 0.132 0.983 ± 0.031 0.774 ± 0.037
14 0.784 ± 0.035 0.334 ± 0.184 0.222 ± 0.149 0.984 ± 0.03 0.784 ± 0.035
15 0.773 ± 0.036 0.279 ± 0.197 0.2 ± 0.15 0.977 ± 0.033 0.773 ± 0.036
16 0.777 ± 0.038 0.296 ± 0.205 0.196 ± 0.147 0.984 ± 0.03 0.777 ± 0.038
17 0.775 ± 0.038 0.294 ± 0.199 0.192 ± 0.132 0.984 ± 0.03 0.775 ± 0.038
18 0.773 ± 0.037 0.301 ± 0.18 0.236 ± 0.151 0.964 ± 0.041 0.773 ± 0.037
19 0.776 ± 0.04 0.313 ± 0.188 0.238 ± 0.154 0.968 ± 0.043 0.776 ± 0.04
20 0.78 ± 0.036 0.331 ± 0.171 0.254 ± 0.147 0.968 ± 0.038 0.78 ± 0.036
21 0.769 ± 0.041 0.292 ± 0.184 0.232 ± 0.143 0.961 ± 0.046 0.769 ± 0.041
22 0.776 ± 0.035 0.319 ± 0.174 0.244 ± 0.149 0.966 ± 0.043 0.776 ± 0.035
23 0.769 ± 0.042 0.276 ± 0.202 0.21 ± 0.148 0.969 ± 0.044 0.769 ± 0.042
24 0.77 ± 0.041 0.288 ± 0.196 0.232 ± 0.152 0.962 ± 0.045 0.77 ± 0.041
25 0.776 ± 0.046 0.311 ± 0.209 0.232 ± 0.141 0.97 ± 0.042 0.776 ± 0.046
26 0.768 ± 0.044 0.265 ± 0.22 0.2 ± 0.162 0.971 ± 0.04 0.768 ± 0.044
27 0.781 ± 0.038 0.34 ± 0.182 0.26 ± 0.175 0.967 ± 0.046 0.781 ± 0.038
28 0.791 ± 0.052 0.371 ± 0.216 0.296 ± 0.182 0.967 ± 0.045 0.791 ± 0.052
29 0.784 ± 0.051 0.332 ± 0.222 0.266 ± 0.188 0.969 ± 0.041 0.784 ± 0.051
30 0.781 ± 0.049 0.332 ± 0.216 0.272 ± 0.178 0.963 ± 0.043 0.781 ± 0.049
TABLE D.4: The UFS+RFE features performance measures for the
T1+T2 dataset.
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F Accuracy MCC Sensitivity Specificity AUC
1 0.758 ± 0.041 0.172 ± 0.225 0.166 ± 0.245 0.969 ± 0.059 0.758 ± 0.041
2 0.826 ± 0.068 0.515 ± 0.214 0.508 ± 0.214 0.939 ± 0.06 0.826 ± 0.068
3 0.806 ± 0.071 0.488 ± 0.197 0.532 ± 0.21 0.904 ± 0.086 0.806 ± 0.071
4 0.855 ± 0.081 0.652 ± 0.197 0.77 ± 0.188 0.885 ± 0.091 0.855 ± 0.081
5 0.874 ± 0.073 0.693 ± 0.181 0.784 ± 0.187 0.906 ± 0.079 0.874 ± 0.073
6 0.826 ± 0.081 0.596 ± 0.182 0.764 ± 0.177 0.848 ± 0.098 0.826 ± 0.081
7 0.84 ± 0.07 0.597 ± 0.182 0.688 ± 0.201 0.894 ± 0.079 0.84 ± 0.07
8 0.862 ± 0.059 0.651 ± 0.159 0.706 ± 0.191 0.917 ± 0.075 0.862 ± 0.059
9 0.834 ± 0.083 0.592 ± 0.205 0.694 ± 0.197 0.884 ± 0.096 0.834 ± 0.083
10 0.845 ± 0.075 0.615 ± 0.186 0.716 ± 0.188 0.891 ± 0.084 0.845 ± 0.075
11 0.852 ± 0.073 0.628 ± 0.185 0.7 ± 0.187 0.906 ± 0.082 0.852 ± 0.073
12 0.865 ± 0.061 0.664 ± 0.157 0.748 ± 0.173 0.906 ± 0.072 0.865 ± 0.061
13 0.841 ± 0.071 0.604 ± 0.197 0.726 ± 0.197 0.882 ± 0.074 0.841 ± 0.071
14 0.832 ± 0.074 0.6 ± 0.173 0.746 ± 0.181 0.862 ± 0.095 0.832 ± 0.074
15 0.828 ± 0.069 0.58 ± 0.168 0.706 ± 0.171 0.871 ± 0.086 0.828 ± 0.069
16 0.838 ± 0.068 0.607 ± 0.163 0.718 ± 0.19 0.881 ± 0.093 0.838 ± 0.068
17 0.828 ± 0.074 0.568 ± 0.182 0.666 ± 0.179 0.886 ± 0.086 0.828 ± 0.074
18 0.832 ± 0.071 0.592 ± 0.167 0.706 ± 0.191 0.876 ± 0.096 0.832 ± 0.071
19 0.828 ± 0.067 0.587 ± 0.162 0.732 ± 0.184 0.862 ± 0.085 0.828 ± 0.067
20 0.816 ± 0.074 0.551 ± 0.179 0.696 ± 0.175 0.859 ± 0.087 0.816 ± 0.074
21 0.813 ± 0.066 0.549 ± 0.162 0.704 ± 0.187 0.851 ± 0.09 0.813 ± 0.066
22 0.806 ± 0.076 0.538 ± 0.184 0.712 ± 0.184 0.839 ± 0.088 0.806 ± 0.076
23 0.825 ± 0.079 0.579 ± 0.182 0.72 ± 0.194 0.862 ± 0.098 0.825 ± 0.079
24 0.815 ± 0.08 0.568 ± 0.186 0.73 ± 0.186 0.846 ± 0.102 0.815 ± 0.08
25 0.817 ± 0.076 0.534 ± 0.197 0.62 ± 0.187 0.888 ± 0.092 0.817 ± 0.076
26 0.818 ± 0.073 0.543 ± 0.19 0.642 ± 0.199 0.881 ± 0.089 0.818 ± 0.073
27 0.809 ± 0.073 0.506 ± 0.2 0.594 ± 0.227 0.886 ± 0.091 0.809 ± 0.073
28 0.827 ± 0.068 0.558 ± 0.176 0.63 ± 0.203 0.897 ± 0.086 0.827 ± 0.068
29 0.81 ± 0.073 0.494 ± 0.211 0.556 ± 0.224 0.901 ± 0.081 0.81 ± 0.073
30 0.809 ± 0.066 0.511 ± 0.177 0.594 ± 0.216 0.886 ± 0.087 0.809 ± 0.066
TABLE D.5: The RF features performance measures for the T1+T2
dataset.
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D.2 Feature Sets Rankings
R Precision Area under the ROC curve
1 SOFA_T2 LVOT average diameter mm _T1
2 APACHE II_T1 SOFA_T1
3 APACHE II_T2 HCO3 mmol L _T1
4 SOFA_T1 Glasgow Coma Scale_T1
5 Glasgow Coma Scale_T2 PEEP_T2
6 FiO2_T2 PT_T1
7 pH_T2 PT_T2
8 Respiratory rate_T1 Respiratory rate rpm _T1
9 Sedation Scale SAS _T2 Na mmol L _T1
10 Tracheal Intubation_T2=Yes Hematocrit _T1
11 Tracheal Intubation_T2=No Value _T1
12 Lactate levels mmol L _T2 Heart rate bpm _T1 1
13 X Norepinephrine mg kg min _T1 Platelet count_T1
14 Sat O2 FiO2_T2 SvcO2 _T1
15 Number of affected organs Tidal volume VT _T1
16 Tidal volume VT _T1 APACHE II_T1
17 LA dilatation by eyeballing_T1=No aPTT_T2
18 LA dilatation by eyeballing_T1=Yes SOFA_T2
19 Creatinine mg dL _T2 Hematocrit _T2
20 Glasgow Coma Scale_T1 APACHE II_T2
21 Fluid Balance ml _T1 Sat O2 FiO2_T2
22 Platelet count_T1 Respiratory rate_T2
23 K mmol L _T2 PaO2 FiO2_T2
24 Platelet count_T2 Base Excess mmol L _T1
25 LV Dilatation LVEDV _T1=Moderate Platelet count_T2
26 E A ratio_T1=1 39 BMI
27 Aortic Valve Stenosis_T1=Moderate Weight kg
28 Base Excess mmol L _T1 WBC abs count_T1
29 RBC count_T2 Base Excess mmol L _T2
30 Urine Output mL day _T1 PaO2 mmHg _T1
TABLE D.6: The UFS and the RFE feature rankings for the T1+T2
dataset.
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NEG LOG LOSS: LVOT average diameter mm _T1, SOFA_T1;
ACCURACY: HCO3 mmol L _T1, LVOT average diameter mm _T1, SOFA_T1;
PRECISION: APACHE II_T1, APACHE II_T2, BMI, Base Excess mmol L _T1,
Base Excess mmol L _T2, CRP_Value mg L _T2, Diastolic Blood
Pressure mmHg _T2, E wave cm s_T1, Glasgow Coma Scale _T1, Glasgow
Coma Scale_T2, Glycemia mg dL _T1, HCO3 mmol L _T1, HCO3 mmol L _T2
, Heart rate bpm _T1 1, Heart rate bpm _T2 1, Hematocrit_T1,
Hematocrit _T2, LVOT average diameter mm _T1, Leukocytes total 1000
mm 3 _T2, Na mmol L _T1, PEEP_T1, PEEP_T2, PT_T1, PT_T2, PaCO2
mmHg _T1, PaO2 FiO2_T2, PaO2 mmHg _T1, Platelet count_T1, Platelet
count_T2, Respiratory rate rpm _T1, Respiratory rate_T2, SOFA_T1,
SOFA _T2, Sat O2 FiO2_T2, SvcO2 _T1, Tidal volume VT _T1, Value_T1,
WBC abs count_T1, WBC abs count_T2, Weight kg , aPTT_T2;
AVERAGE PRECISION: APACHE II_T1, APACHE II_T2, BMI, Base Excess mmol L
_T1, Base Excess mmol L _T2, CRP_Value mg L _T2, Diastolic Blood
Pressure mmHg _T2, E wave cm s _T1, Glasgow Coma Scale_T1, Glasgow
Coma Scale_T2, Glycemia mg dL _T1, HCO3 mmol L _T1, HCO3 mmol L _T2
, Heart rate bpm _T1 1, Heart rate bpm _T2 1, Hematocrit _T1,
Hematocrit _T2, LVOT average diameter mm _T1, Leukocytes total 1000
mm 3 _T2, Na mmol L _T1, PEEP_T1, PEEP_T2, PT_T1, PT_T2, PaCO2
mmHg _T1, PaO2 FiO2_T2, PaO2 mmHg _T1, Platelet count_T1, Platelet
count_T2, Respiratory rate rpm _T1, Respiratory rate_T2, SOFA_T1,
SOFA_T2, Sat O2 FiO2_T2, SvcO2 _T1, Systolic blood pressure mmHg
_T2, Tidal volume VT _T1, Value _T1, WBC abs count_T1, WBC abs
count_T2, Weight kg , aPTT_T2;
F1 MACRO: A wave cm s _T1, APACHE II_T1, APACHE II_T2, BMI, Base Excess
mmol L_T1, Base Excess mmol L _T2, CRP_Value mg L _T1, CRP_Value
mg L _T2, Diastolic Blood Pressure mmHg _T2, E wave cm s _T1,
Glasgow Coma Scale_T1, Glasgow Coma Scale_T2, Glycemia mg dL _T1,
HCO3 mmol L _T1, HCO3 mmol L _T2, Heart rate bpm _T1 1, Heart rate
bpm _T2 1, Height cm , Hematocrit _T1, Hematocrit _T2, LA
dilatation by eyeballing_T1=No, LA dilatation by eyeballing_T1=Yes,
LVOT average diameter mm_T1, LVOT average velocity time integral
cm _T1, Lactate levels mmol L _T1, Leukocytes total 1000 mm 3 _T1,
Leukocytes total 1000 mm 3 _T2, Midazolam mg kg min _T1, Na mmol L
_T1, Na mmol L _T2, PEEP_T1, PEEP_T2, PT_T1, PT_T2, PaCO2 mmHg_T1,
PaO2 FiO2_T2, PaO2 mmHg_T1, PaO2 mmHg _T2, Platelet count_T1,
Platelet count_T2, Pplat_T2, Respiratory rate rpm _T1, Respiratory
rate_T2, SOFA_T1, SOFA_T2, Sat O2 FiO2_T2, Sat O2 _T2, SvcO2 _T1,
Systolic blood pressure mmHg _T2, Tidal volume VT _T1, Value _T1,
WBC abs count_T1, WBC abs count_T2, Weight kg, aPTT_T2;
List of features for the RFECV with the precision and the average precision metrics for
the T1+T2 dataset.
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R UFS+FSE Random Forest
1 LV Dilatation LVEDV _T1=Moderate Lactate levels mmol L _T2
2 E A ratio_T1=1 39 SOFA_T2
3 E A ratio_T1=0 69 Respiratory rate_T1
4 E A ratio_T1=0 6 APACHE II_T1
5 Aortic Valve Stenosis_T1=Moderate E wave cm s _T1
6 Is the patient under other drugs_-
T1=Yes
APACHE II_T2
7 Sedation Scale SAS _T2 X Norepinephrine mg kg min _T1
8 Site of sampling=CSF Urine Output mL day _T2
9 Number of affected organs Urine Output mL day _T1
10 Is the patient under other drugs_-
T1=No
SOFA_T1
11 Site of sampling=Urine pH_T2
12 Aortic Valve Regurgitation_-
T2=Moderate
Tidal volume VT _T1
13 Aortic Valve Regurgitation_-
T1=Moderate
Glasgow Coma Scale_T2
14 Is the patient under sedation drugs_-
T2=No
Fluid Balance ml _T1
15 K mmol L _T2 Fluid Balance ml _T2
16 HCO3 mmol L _T1 Creatinine mg dL _T2
17 Segments affected by eyeballing_T2 Pplat_T2
18 E A ratio_T1=0 76 Lactate levels mmol L _T1
19 Glasgow Coma Scale_T1 Platelet count_T2
20 Temperature C _T1 E e _T1
21 Aortic Valve Regurgitation_-
T1=Severe
Sat O2 FiO2_T2
22 Is the patient under sedation drugs_-
T2=Yes
PT_T2
23 Acute Kidney Injury_T2=AKIN III Respiratory rate_T2
24 SOFA_T1 Heart rate bpm _T1
25 Tricuspid Valve Regurgitation_-
T2=Mild
Lympho abs count_T2
26 Base Excess mmol L _T1 PEEP_T2
27 Anuria and or RRT_T1=No PaO2 mmHg _T2
28 Anuria and or RRT_T1=Yes Pplat_T1
29 Respiratory rate_T1 LVOT average velocity time integral
cm _T1
30 pH_T2 FiO2_T2
TABLE D.7: The UFS+RFE and the RF feature rankings for the T1+T2
dataset.
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E.1 Feature Selection Results
F Accuracy MCC Sensitivity Specificity AUC
1 0.781 ± 0.065 0.392 ± 0.196 0.426 ± 0.183 0.907 ± 0.072 0.781 ± 0.065
2 0.774 ± 0.089 0.502 ± 0.185 0.746 ± 0.176 0.784 ± 0.115 0.774 ± 0.089
3 0.815 ± 0.07 0.566 ± 0.166 0.742 ± 0.18 0.841 ± 0.086 0.815 ± 0.07
4 0.794 ± 0.077 0.462 ± 0.213 0.56 ± 0.223 0.877 ± 0.088 0.794 ± 0.077
5 0.804 ± 0.081 0.514 ± 0.218 0.644 ± 0.233 0.861 ± 0.097 0.804 ± 0.081
6 0.793 ± 0.081 0.485 ± 0.22 0.636 ± 0.227 0.849 ± 0.094 0.793 ± 0.081
7 0.819 ± 0.072 0.545 ± 0.187 0.654 ± 0.192 0.879 ± 0.087 0.819 ± 0.072
8 0.807 ± 0.081 0.515 ± 0.195 0.618 ± 0.181 0.874 ± 0.1 0.807 ± 0.081
9 0.771 ± 0.087 0.46 ± 0.195 0.66 ± 0.184 0.81 ± 0.107 0.771 ± 0.087
10 0.779 ± 0.074 0.463 ± 0.172 0.626 ± 0.167 0.834 ± 0.095 0.779 ± 0.074
11 0.81 ± 0.077 0.54 ± 0.186 0.688 ± 0.18 0.854 ± 0.093 0.81 ± 0.077
12 0.823 ± 0.07 0.551 ± 0.178 0.638 ± 0.193 0.889 ± 0.091 0.823 ± 0.07
13 0.85 ± 0.056 0.595 ± 0.176 0.574 ± 0.201 0.949 ± 0.055 0.85 ± 0.056
14 0.833 ± 0.06 0.53 ± 0.202 0.468 ± 0.23 0.964 ± 0.052 0.833 ± 0.06
15 0.833 ± 0.06 0.526 ± 0.203 0.446 ± 0.196 0.971 ± 0.046 0.833 ± 0.06
16 0.847 ± 0.062 0.584 ± 0.193 0.538 ± 0.199 0.958 ± 0.061 0.847 ± 0.062
17 0.809 ± 0.063 0.46 ± 0.216 0.44 ± 0.214 0.941 ± 0.058 0.809 ± 0.063
18 0.805 ± 0.062 0.427 ± 0.234 0.386 ± 0.21 0.954 ± 0.047 0.805 ± 0.062
19 0.831 ± 0.063 0.524 ± 0.201 0.46 ± 0.201 0.963 ± 0.056 0.831 ± 0.063
20 0.828 ± 0.066 0.515 ± 0.22 0.478 ± 0.224 0.954 ± 0.054 0.828 ± 0.066
21 0.827 ± 0.063 0.511 ± 0.216 0.47 ± 0.225 0.954 ± 0.052 0.827 ± 0.063
22 0.829 ± 0.066 0.522 ± 0.218 0.494 ± 0.214 0.949 ± 0.055 0.829 ± 0.066
23 0.846 ± 0.066 0.575 ± 0.207 0.542 ± 0.216 0.955 ± 0.048 0.846 ± 0.066
24 0.852 ± 0.072 0.595 ± 0.225 0.598 ± 0.231 0.942 ± 0.06 0.852 ± 0.072
25 0.859 ± 0.071 0.627 ± 0.205 0.642 ± 0.216 0.937 ± 0.064 0.859 ± 0.071
26 0.858 ± 0.063 0.638 ± 0.17 0.706 ± 0.184 0.912 ± 0.068 0.858 ± 0.063
27 0.846 ± 0.071 0.612 ± 0.177 0.686 ± 0.196 0.904 ± 0.082 0.846 ± 0.071
28 0.86 ± 0.065 0.641 ± 0.184 0.718 ± 0.19 0.911 ± 0.066 0.86 ± 0.065
29 0.838 ± 0.061 0.594 ± 0.16 0.694 ± 0.193 0.889 ± 0.075 0.838 ± 0.061
30 0.867 ± 0.063 0.668 ± 0.158 0.736 ± 0.181 0.914 ± 0.074 0.867 ± 0.063
TABLE E.1: The UFS features performance measures for the T1
dataset.
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F Accuracy MCC Sensitivity Specificity AUC
1 0.609 ± 0.21 0.0 ± 0.0 0.27 ± 0.444 0.73 ± 0.444 0.609 ± 0.21
2 0.614 ± 0.208 0.0 ± 0.0 0.26 ± 0.439 0.74 ± 0.439 0.614 ± 0.208
3 0.737 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 0.0 0.737 ± 0.0
4 0.732 ± 0.026 0.016 ± 0.086 0.028 ± 0.075 0.983 ± 0.048 0.732 ± 0.026
5 0.748 ± 0.036 0.105 ± 0.199 0.114 ± 0.214 0.974 ± 0.064 0.748 ± 0.036
6 0.741 ± 0.05 0.09 ± 0.19 0.108 ± 0.199 0.967 ± 0.079 0.741 ± 0.05
7 0.754 ± 0.057 0.145 ± 0.238 0.15 ± 0.234 0.97 ± 0.073 0.754 ± 0.057
8 0.727 ± 0.047 0.07 ± 0.151 0.116 ± 0.196 0.946 ± 0.103 0.727 ± 0.047
9 0.734 ± 0.066 0.1 ± 0.225 0.16 ± 0.27 0.939 ± 0.106 0.734 ± 0.066
10 0.735 ± 0.067 0.098 ± 0.224 0.15 ± 0.249 0.944 ± 0.106 0.735 ± 0.067
11 0.738 ± 0.053 0.085 ± 0.219 0.134 ± 0.259 0.954 ± 0.087 0.738 ± 0.053
12 0.738 ± 0.071 0.088 ± 0.237 0.124 ± 0.228 0.957 ± 0.094 0.738 ± 0.071
13 0.758 ± 0.059 0.179 ± 0.271 0.222 ± 0.306 0.95 ± 0.075 0.758 ± 0.059
14 0.74 ± 0.049 0.103 ± 0.224 0.154 ± 0.278 0.949 ± 0.091 0.74 ± 0.049
15 0.738 ± 0.079 0.121 ± 0.259 0.182 ± 0.297 0.937 ± 0.117 0.738 ± 0.079
16 0.746 ± 0.062 0.13 ± 0.253 0.178 ± 0.294 0.949 ± 0.093 0.746 ± 0.062
17 0.747 ± 0.048 0.134 ± 0.226 0.174 ± 0.266 0.951 ± 0.084 0.747 ± 0.048
18 0.735 ± 0.059 0.112 ± 0.225 0.166 ± 0.283 0.938 ± 0.112 0.735 ± 0.059
19 0.746 ± 0.06 0.128 ± 0.261 0.17 ± 0.283 0.952 ± 0.077 0.746 ± 0.06
20 0.764 ± 0.067 0.197 ± 0.296 0.222 ± 0.316 0.957 ± 0.069 0.764 ± 0.067
21 0.752 ± 0.078 0.158 ± 0.278 0.17 ± 0.275 0.96 ± 0.095 0.752 ± 0.078
22 0.747 ± 0.048 0.116 ± 0.221 0.126 ± 0.233 0.969 ± 0.071 0.747 ± 0.048
23 0.741 ± 0.075 0.142 ± 0.25 0.188 ± 0.274 0.938 ± 0.107 0.741 ± 0.075
24 0.748 ± 0.077 0.179 ± 0.273 0.232 ± 0.308 0.932 ± 0.108 0.748 ± 0.077
25 0.749 ± 0.074 0.157 ± 0.271 0.188 ± 0.291 0.95 ± 0.097 0.749 ± 0.074
26 0.751 ± 0.07 0.177 ± 0.272 0.214 ± 0.314 0.943 ± 0.104 0.751 ± 0.07
27 0.747 ± 0.055 0.159 ± 0.247 0.196 ± 0.281 0.944 ± 0.083 0.747 ± 0.055
28 0.738 ± 0.075 0.136 ± 0.247 0.19 ± 0.283 0.934 ± 0.119 0.738 ± 0.075
29 0.755 ± 0.058 0.207 ± 0.253 0.24 ± 0.294 0.939 ± 0.093 0.755 ± 0.058
30 0.738 ± 0.071 0.134 ± 0.251 0.17 ± 0.254 0.941 ± 0.103 0.738 ± 0.071
TABLE E.2: The RFE features performance measures for the T1
dataset.
F Accuracy MCC Sensitivity Specificity AUC
1 0.599 ± 0.215 0.0 ± 0.0 0.29 ± 0.454 0.71 ± 0.454 0.599 ± 0.215
2 0.614 ± 0.208 0.0 ± 0.0 0.26 ± 0.439 0.74 ± 0.439 0.614 ± 0.208
8 0.739 ± 0.041 0.093 ± 0.176 0.12 ± 0.202 0.961 ± 0.08 0.739 ± 0.041
31 0.75 ± 0.069 0.203 ± 0.252 0.24 ± 0.284 0.932 ± 0.106 0.75 ± 0.069
33 0.744 ± 0.072 0.183 ± 0.276 0.222 ± 0.276 0.93 ± 0.094 0.744 ± 0.072
154 0.681 ± 0.083 0.169 ± 0.222 0.374 ± 0.197 0.791 ± 0.101 0.681 ± 0.083
TABLE E.3: The RFECV features performance measures for the T1
dataset. The first entry uses the recall metric, followed by the average
precision, the weighted f1 and the AUC.
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F Accuracy MCC Sensitivity Specificity AUC
1 0.741 ± 0.113 0.209 ± 0.197 0.156 ± 0.216 0.95 ± 0.218 0.741 ± 0.113
2 0.757 ± 0.026 0.154 ± 0.192 0.078 ± 0.098 1.0 ± 0.0 0.757 ± 0.026
3 0.749 ± 0.033 0.132 ± 0.197 0.102 ± 0.131 0.98 ± 0.032 0.749 ± 0.033
4 0.767 ± 0.037 0.241 ± 0.21 0.16 ± 0.136 0.984 ± 0.03 0.767 ± 0.037
5 0.769 ± 0.032 0.252 ± 0.198 0.162 ± 0.132 0.986 ± 0.029 0.769 ± 0.032
6 0.769 ± 0.031 0.27 ± 0.184 0.162 ± 0.105 0.986 ± 0.028 0.769 ± 0.031
7 0.775 ± 0.035 0.289 ± 0.196 0.178 ± 0.126 0.988 ± 0.027 0.775 ± 0.035
8 0.772 ± 0.033 0.264 ± 0.204 0.164 ± 0.137 0.989 ± 0.027 0.772 ± 0.033
9 0.767 ± 0.035 0.24 ± 0.207 0.158 ± 0.139 0.985 ± 0.029 0.767 ± 0.035
10 0.773 ± 0.036 0.261 ± 0.208 0.178 ± 0.152 0.985 ± 0.029 0.773 ± 0.036
11 0.763 ± 0.068 0.255 ± 0.228 0.194 ± 0.175 0.966 ± 0.106 0.763 ± 0.068
12 0.778 ± 0.044 0.318 ± 0.196 0.216 ± 0.159 0.979 ± 0.055 0.778 ± 0.044
13 0.771 ± 0.057 0.29 ± 0.221 0.204 ± 0.15 0.974 ± 0.067 0.771 ± 0.057
14 0.759 ± 0.059 0.269 ± 0.218 0.238 ± 0.164 0.946 ± 0.071 0.759 ± 0.059
15 0.772 ± 0.061 0.313 ± 0.215 0.254 ± 0.16 0.957 ± 0.074 0.772 ± 0.061
16 0.768 ± 0.071 0.299 ± 0.245 0.246 ± 0.192 0.955 ± 0.091 0.768 ± 0.071
17 0.769 ± 0.056 0.297 ± 0.212 0.216 ± 0.149 0.967 ± 0.074 0.769 ± 0.056
18 0.778 ± 0.057 0.346 ± 0.2 0.26 ± 0.169 0.964 ± 0.075 0.778 ± 0.057
19 0.765 ± 0.064 0.292 ± 0.234 0.242 ± 0.199 0.952 ± 0.096 0.765 ± 0.064
20 0.777 ± 0.057 0.333 ± 0.197 0.252 ± 0.164 0.964 ± 0.077 0.777 ± 0.057
21 0.791 ± 0.043 0.357 ± 0.206 0.236 ± 0.156 0.989 ± 0.028 0.791 ± 0.043
22 0.782 ± 0.049 0.321 ± 0.226 0.22 ± 0.159 0.983 ± 0.041 0.782 ± 0.049
23 0.782 ± 0.045 0.319 ± 0.216 0.22 ± 0.161 0.982 ± 0.034 0.782 ± 0.045
24 0.787 ± 0.042 0.345 ± 0.201 0.222 ± 0.152 0.989 ± 0.031 0.787 ± 0.042
25 0.777 ± 0.046 0.301 ± 0.21 0.208 ± 0.17 0.981 ± 0.057 0.777 ± 0.046
26 0.784 ± 0.043 0.345 ± 0.192 0.238 ± 0.152 0.979 ± 0.043 0.784 ± 0.043
27 0.783 ± 0.059 0.345 ± 0.225 0.274 ± 0.193 0.964 ± 0.076 0.783 ± 0.059
28 0.766 ± 0.084 0.374 ± 0.223 0.404 ± 0.274 0.896 ± 0.147 0.766 ± 0.084
29 0.776 ± 0.072 0.393 ± 0.198 0.396 ± 0.235 0.912 ± 0.123 0.776 ± 0.072
30 0.776 ± 0.078 0.39 ± 0.238 0.42 ± 0.271 0.903 ± 0.128 0.776 ± 0.078
TABLE E.4: The UFS+RFE features performance measures for the T1
dataset.
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F Accuracy MCC Sensitivity Specificity AUC
1 0.788 ± 0.069 0.409 ± 0.212 0.436 ± 0.203 0.914 ± 0.08 0.788 ± 0.069
2 0.826 ± 0.081 0.562 ± 0.198 0.654 ± 0.165 0.888 ± 0.087 0.826 ± 0.081
3 0.822 ± 0.068 0.539 ± 0.185 0.614 ± 0.188 0.896 ± 0.078 0.822 ± 0.068
4 0.848 ± 0.078 0.621 ± 0.206 0.72 ± 0.198 0.894 ± 0.076 0.848 ± 0.078
5 0.821 ± 0.071 0.545 ± 0.188 0.638 ± 0.191 0.886 ± 0.083 0.821 ± 0.071
6 0.809 ± 0.078 0.516 ± 0.199 0.624 ± 0.197 0.875 ± 0.088 0.809 ± 0.078
7 0.829 ± 0.067 0.594 ± 0.167 0.752 ± 0.188 0.857 ± 0.083 0.829 ± 0.067
8 0.834 ± 0.082 0.603 ± 0.194 0.728 ± 0.213 0.872 ± 0.101 0.834 ± 0.082
9 0.813 ± 0.075 0.545 ± 0.193 0.688 ± 0.216 0.858 ± 0.094 0.813 ± 0.075
10 0.821 ± 0.061 0.532 ± 0.174 0.606 ± 0.189 0.897 ± 0.073 0.821 ± 0.061
11 0.807 ± 0.065 0.497 ± 0.184 0.592 ± 0.198 0.884 ± 0.074 0.807 ± 0.065
12 0.834 ± 0.077 0.577 ± 0.203 0.66 ± 0.201 0.896 ± 0.084 0.834 ± 0.077
13 0.834 ± 0.077 0.573 ± 0.205 0.652 ± 0.207 0.899 ± 0.078 0.834 ± 0.077
14 0.805 ± 0.076 0.51 ± 0.195 0.622 ± 0.208 0.871 ± 0.091 0.805 ± 0.076
15 0.821 ± 0.073 0.531 ± 0.223 0.62 ± 0.236 0.892 ± 0.071 0.821 ± 0.073
16 0.812 ± 0.069 0.534 ± 0.178 0.646 ± 0.202 0.871 ± 0.095 0.812 ± 0.069
17 0.811 ± 0.071 0.518 ± 0.204 0.63 ± 0.225 0.876 ± 0.084 0.811 ± 0.071
18 0.823 ± 0.075 0.542 ± 0.215 0.638 ± 0.226 0.889 ± 0.078 0.823 ± 0.075
19 0.806 ± 0.071 0.504 ± 0.198 0.616 ± 0.234 0.874 ± 0.09 0.806 ± 0.071
20 0.818 ± 0.08 0.532 ± 0.208 0.622 ± 0.19 0.889 ± 0.081 0.818 ± 0.08
21 0.813 ± 0.078 0.526 ± 0.215 0.63 ± 0.218 0.878 ± 0.09 0.813 ± 0.078
22 0.794 ± 0.07 0.471 ± 0.184 0.59 ± 0.199 0.866 ± 0.082 0.794 ± 0.07
23 0.805 ± 0.076 0.481 ± 0.227 0.564 ± 0.239 0.891 ± 0.083 0.805 ± 0.076
24 0.786 ± 0.075 0.469 ± 0.195 0.612 ± 0.226 0.849 ± 0.101 0.786 ± 0.075
25 0.773 ± 0.084 0.376 ± 0.255 0.474 ± 0.239 0.88 ± 0.084 0.773 ± 0.084
26 0.777 ± 0.071 0.407 ± 0.205 0.516 ± 0.212 0.87 ± 0.081 0.777 ± 0.071
27 0.791 ± 0.073 0.444 ± 0.209 0.526 ± 0.218 0.886 ± 0.083 0.791 ± 0.073
28 0.792 ± 0.071 0.453 ± 0.192 0.532 ± 0.194 0.884 ± 0.084 0.792 ± 0.071
29 0.78 ± 0.083 0.427 ± 0.225 0.548 ± 0.226 0.863 ± 0.093 0.78 ± 0.083
30 0.782 ± 0.069 0.407 ± 0.216 0.474 ± 0.229 0.892 ± 0.081 0.782 ± 0.069
TABLE E.5: The RF features performance measures for the T1 dataset.
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R Precision Area under the ROC curve
1 APACHE II_T1 E A ratio_T1=0 6
2 SOFA_T1 Aortic Valve Regurgitation_-
T1=Moderate
3 Respiratory rate_T1 Is the patient under other drugs_-
T1=Yes
4 X Norepinephrine mg kg min _T1 Sedation Scale SAS _T1
5 Number of affected organs LA dilatation by eyeballing_T1=Yes
6 Tidal volume VT _T1 Is the patient under other drugs_-
T1=No
7 LA dilatation by eyeballing_T1=No Aortic Valve Regurgitation_T1=No
valv dysfunc
8 LA dilatation by eyeballing_T1=Yes Glasgow Coma Scale_T1
9 Glasgow Coma Scale_T1 LV Hypertrophy LV mass _-
T1=Moderate
10 Fluid Balance ml _T1 HCO3 mmol L _T1
11 Platelet count_T1 Respiratory rate_T1
12 LV Dilatation LVEDV _T1=Moderate LVOT average velocity time integral
cm _T1
13 E A ratio_T1=1 39 SOFA_T1
14 Aortic Valve Stenosis_T1=Moderate LA dilatation by eyeballing_T1=No
15 Base Excess mmol L _T1 LV Hypertrophy LV mass _T1=No
16 Urine Output mL day _T1 Sat O2 _T1
17 Anuria and or RRT_T1=Yes Fibrinogen_T1 g L
18 Anuria and or RRT_T1=No Pplat_T1
19 LVOT average diameter mm _T1 Base Excess mmol L _T1
20 Mode_T1=Volume controlled PT_T1
21 Lactate levels mmol L _T1 Lateral e cm s _T1
22 Is the patient under other drugs_-
T1=Yes
Shock diagnosed within 48 from ad-
mission=No
23 Is the patient under other drugs_-
T1=No
Neutro abs count_T1
24 Hypotension,MAP or SBP decrease
_T1=Yes
Number of affected organs
25 Site of sampling=Urine Respiratory rate rpm _T1
26 Hypotension,MAP or SBP decrease
_T1=No
Hematocrit _T1
27 Mode_T1=Pressure controlled Heart rate bpm _T1 1
28 Sedation Scale SAS _T1 Midazolam mg kg min _T1
29 Temperature C _T1 Weight kg
30 HCO3 mmol L _T1 aPTT_T1
TABLE E.6: The UFS and the RFE feature rankings for the T1 dataset.
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RECALL: E A ratio_T1=0 6;
AVERAGE PRECISION: Aortic Valve Regurgitation_T1=Moderate, E A ratio_T1
=0 6;
PRECISION: Aortic Valve Regurgitation_T1=Moderate, Aortic Valve
Regurgitation _T1=No valvular dysfunction, E A ratio_T1=0 6,
Glasgow Coma Scale_T1, Is the patient under other drugs_T1=No, Is
the patient under other drugs_T1=Yes, LA dilatation by
eyeballing_T1=Yes, Sedation Scale SAS _T1;
F1 WEIGHTED: Aortic Valve Regurgitation_T1=Moderate, Aortic Valve
Regurgitation _T1=No valvular dysfunction, Base Excess mmol L _T1,
E A ratio_T1=0 6, Fibrinogen_T1 g L , Glasgow Coma Scale_T1, HCO3
mmol L _T1, Heart rate bpm _T1 1, Hematocrit _T1, Is the patient
under other drugs_T1=No, Is the patient under other drugs_T1=Yes,
LA dilatation by eyeballing_T1=No, LA dilatation by eyeballing _T1=
Yes, LV Hypertrophy LV mass _T1=Moderate, LV Hypertrophy LV mass
_T1=No, LVOT average velocity time integral cm _T1, Lateral e cm s
_T1, Midazolam mg kg min _T1, Neutro abs count_T1, Number of
affected organs, PT_T1, Pplat_T1, Respiratory rate rpm _T1,
Respiratory rate_T1, SOFA_T1, Sat O2 _T1, Sedation Scale SAS _T1,
Value _T1, Was shock diagnosed within 48 from hospital admission=No
, Weight kg, aPTT_T1;
AUC: Aortic Valve Regurgitation_T1=Moderate, Aortic Valve
Regurgitation_T1=No valvular dysfunction, Base Excess mmol L _T1, E
A ratio_T1=0 6, Fibrinogen_T1 g L, Glasgow Coma Scale_T1, HCO3
mmol L _T1, Heart rate bpm _T1 1, Hematocrit _T1, Is the patient
under other drugs_T1=No, Is the patient under other drugs_T1=Yes,
LA dilatation by eyeballing_T1=No, LA dilatation by eyeballing_T1=
Yes, LV Dilatation LVEDV _T1=No, LV Hypertrophy LV mass _T1=
Moderate, LV Hypertrophy LV mass _T1=No, LVOT average velocity time
integral cm _T1, Lateral e cm s _T1, Midazolam mg kg min _T1,
Neutro abs count_T1, Number of affected organs, PT_T1, Pplat_T1,
Respiratory rate rpm _T1, Respiratory rate_T1, SOFA_T1, Sat O2 _T1,
Sedation Scale SAS _T1, SvcO2 _T1, Value _T1, Was shock diagnosed
within 48 from hospital admission=No, Weight kg , aPTT_T1;
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NEG LOG LOSS: A wave cm s _T1, AHF_T1=No, AHF_T1=no, AHF_T1=yes, APACHE
II_T1, Acute Kidney Injury_T1=AKIN I, Acute Kidney Injury_T1=AKIN
II, Acute Kidney Injury_T1=No, Anuria and or RRT_T1=No, Anuria and
or RRT_T1=Yes, Aortic Valve Regurgitation_T1=Mild, Aortic Valve
Regurgitation_T1=Moderate, Aortic Valve Regurgitation_T1=No
valvular assessment available, Aortic Valve Regurgitation_T1=No
valvular dysfunction, Aortic Valve Regurgitation_T1=Severe, Aortic
Valve Stenosis_T1=Moderate, Aortic Valve Stenosis_T1=No valvular
assessment available, BMI, Base Excess mmol L _T1, Bilirubin mg dL
_T1, CRP_Value mg L _T1, Chloride_T1, Creatinine mg dL _T1,
Diastolic Blood Pressure mmHg _T1, E A ratio_T1=0 6, E A ratio_T1=0
62, E A ratio_T1=0 69, E A ratio_T1=0 72, E A ratio_T1=0 73, E A
ratio_T1=0 78, E A ratio_T1=0 81, E A ratio_T1=0 84, E A ratio_T1=0
85, E A ratio_T1=0 89, E A ratio_T1=0 97, E A ratio_T1=1, E A
ratio_T1=1 01, E A ratio_T1=1 06, E A ratio_T1=1 18, E A ratio_T1=1
3, E A ratio_T1=1 39, E A ratio_T1=1 68, E A ratio_T1=9, E e _T1,
E wave cm s _T1, FiO2_T1, Fibrinogen_T1 g L , Gender=Female, Gender
=Male, Glasgow Coma Scale_T1, Glycemia mg dL _T1, HCO3 mmol L _T1,
Heart rate bpm _T1, Heart rate bpm _T1 1, Height cm , Hematocrit
_T1, Hypotension SBP 90 mmHg or MAP 70 mmHg or SBP decrease 40 mmHg
_T1=No, Hypotension SBP 90 mmHg or MAP 70 mmHg or SBP decrease 40
mmHg _T1=Yes, Is the patient affected by Acute Myocardial
Infarction AMI _T1=No, Is the patient affected by Acute Myocardial
Infarction AMI _T1=Yes, Is the patient affected by Prolonged
Arrhythmias PA _T1=No, Is the patient affected by Prolonged
Arrhythmias PA _T1=Yes, Is the patient under inotropic drugs_T1=No,
Is the patient under inotropic drugs_T1=Yes, Is the patient under
other drugs_T1=No, Is the patient under other drugs_T1=Yes, Is the
patient under sedation drugs_T1=No, Is the patient under sedation
drugs_T1=Yes, LA dilatation by eyeballing_T1=No, LA dilatation by
eyeballing_T1=Yes, LV Dilatation LVEDV _T1=Mild, LV Dilatation
LVEDV _T1=Moderate, LV Dilatation LVEDV _T1=No, LV Dilatation LVEDV
_T1=Severe, LV Hypertrophy LV mass _T1=Mild, LV Hypertrophy LV
mass _T1=Moderate, LV Hypertrophy LV mass _T1=No, LVOT average
diameter mm _T1, LVOT average velocity time integral cm _T1,
Lactate levels mmol L _T1, Lateral e cm s _T1, Leukocytes total
1000 mm 3 _T1, Lympho abs count_T1, Mean arterial pressure mmHg _T1
, Midazolam mg kg min _T1, Mitral Valve Regurgitation_T1=Mild,
Mitral Valve Regurgitation_T1=Moderate, Mitral Valve
Regurgitation_T1=No valvular assessment available, Mitral Valve
Regurgitation_T1=No valvular dysfunction, Mode_T1=Full pressure
support, ...
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... Mode_T1=Pressure controlled, Mode_T1=Volume controlled, Na mmol L
_T1, Neutro abs count_T1, Number of affected organs, PEEP_T1, PT_T1
, PaO2 FiO2_T1, PaO2 mmHg _T1, Paradoxical interventricular septum
movements_T1=Moderate, Paradoxical interventricular septum
movements_T1=No, Paradoxical interventricular septum movements_T1=
Severe, Platelet count_T1, Platelets 10 3 mm 3 _T1, Pplat_T1, RBC
count_T1, RV cross section D shape_T1=No, RV cross section D
shape_T1=Yes, Renal Replacement Therapy_T1=No, Renal Replacement
Therapy_T1=Yes, Respiratory rate rpm _T1, Respiratory rate_T1,
Result=Negative, Result=Positive, Rhythm_T1=Atrial fibrillation,
Rhythm_T1=Sinus, SOFA_T1, Sample 1=Negative, Sample 1=Positive,
Sample 2=Negative, Sample 2=Positive, Sample 3=Negative, Sample 3=
Positive, Sat O2 FiO2_T1, Sat O2 _T1, Sedation Scale SAS _T1,
Segmental LV wall kinetics_T1=Normal, Segmental LV wall kinetics_T1
=Reduced, Segments affected by eyeballing_T1, Site of sampling 1=
Abdominal drain, Site of sampling 1=Other, Site of sampling 1=
Respiratory tract, Site of sampling 1=Wound cultures, Site of
sampling 2=Respiratory tract, Site of sampling 2=Urine, Site of
sampling=Abdominal drain, Site of sampling=CSF, Site of sampling=
Other, Site of sampling=Respiratory tract, Site of sampling=Urine,
Site of sampling=Wound cultures, SvcO2 _T1, Systolic blood pressure
mmHg _T1, Temperature C _T1, The patient was already receiving
antibiotic treatment and this coverage has been maintained until
the onset of sepsis=No, The patient was already receiving
antibiotic treatment and this coverage has been maintained until
the onset of sepsis=Yes, Tidal volume VT _T1, Tracheal
Intubation_T1=No, Tracheal Intubation_T1=Yes, Tricuspid Valve
Regurgitation_T1=Mild, Tricuspid Valve Regurgitation_T1=Moderate,
Tricuspid Valve Regurgitation_T1=No valvular assessment available,
Tricuspid Valve Regurgitation_T1=No valvular dysfunction, Tricuspid
annular plane systolic excursion TAPSE mm _T1, Urine Output mL day
_T1, Value _T1, WBC abs count_T1, Was shock diagnosed within 48
from hospital admission=No, Was shock diagnosed within 48 from
hospital admission=Yes, Was the patient transfused_T1=No, Was the
patient transfused_T1=Yes, Weight kg , Which type of shock=
Cardiogenic, Which type of shock=Septic, X Norepinephrine mg kg min
_T1, aPTT_T1, pH_T1;
List of features for the RFECV with the average precision and the accuracy metrics for
the T1 dataset.
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R UFS+FSE Random Forest
1 E A ratio_T1=1 39 APACHE II_T1
2 Site of sampling=CSF Urine Output mL day _T1
3 E A ratio_T1=0 69 Respiratory rate_T1
4 Aortic Valve Stenosis_T1=Moderate E wave cm s _T1
5 Mode_T1=Volume controlled Lactate levels mmol L _T1
6 LA dilatation by eyeballing_T1=Yes Tidal volume VT _T1
7 RBC count_T1 SOFA_T1
8 Is the patient under other drugs_-
T1=Yes
Fluid Balance ml _T1
9 Is the patient under sedation drugs_-
T1=No
E e _T1
10 Is the patient under other drugs_-
T1=No
X Norepinephrine mg kg min _T1
11 E A ratio_T1=0 81 Heart rate bpm _T1
12 Is the patient under sedation drugs_-
T1=Yes
Pplat_T1
13 Glasgow Coma Scale_T1 Temperature C _T1
14 LV Hypertrophy LV mass _-
T1=Moderate
pH_T1
15 SOFA_T1 Fibrinogen_T1 g L
16 Sedation Scale SAS _T1 Respiratory rate rpm _T1
17 Aortic Valve Regurgitation_T1=No
val dysfunc
Platelet count_T1
18 HCO3 mmol L _T1 PEEP_T1
19 pH_T1 Leukocytes total 1000 mm 3 _T1
20 FiO2_T1 LVOT av vel time integral cm _T1
21 LV Dilatation LVEDV _T1=Moderate PaO2 FiO2_T1
22 Aortic Valve Regurgitation_-
T1=Severe
Midazolam mg kg min _T1
23 Respiratory rate_T1 Base Excess mmol L _T1
24 Is the patient under inotropic
drugs_T1=No
Neutro abs count_T1
25 LA dilatation by eyeballing_T1=No A wave cm s _T1
26 LV Dilatation LVEDV _T1=No Glycemia mg dL _T1
27 Hypotension, MAP or SBP decrease
_T1=Yes
Platelets 10 3 mm 3 _T1
28 Hypotension, MAP or SBP decrease
_T1=No
RBC count_T1
29 Mean arterial pressure mmHg _T1 LVOT average diameter mm _T1
30 Is the patient under inotropic
drugs_T1=Yes
Lympho abs count_T1
TABLE E.7: The UFS+RFE and the RF feature rankings for the T1
dataset.
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Full+ Random Forest
Tricuspid.regurgitation.max.velT1 1 Inferior.vena.cava.dist.indx_T3 0.688
Platelet.count_T1 0.8 Lactate.levels..mmol.L._T2 0.584
K.Ur_T1 0.8 SOFA_T2 0.568
Tidal.volume.VT_T1 0.8 SOFA_T3 0.548
Diastolic.Blood.Pressure.T3 0.6 Na.Ur_T3 0.512
Neutro.abs.count_T2 0.6 APACHE.II_T2 0.508
APACHE.II_T1 0.6 FiO2_T3 0.492
APACHE.II_T2 0.6 APACHE.II_T1 0.456
Respiratory.rate.rpm_T1 0.6 PCT_Value..mg.mL._T1 0.454
E.wave.cms_T1 0.6 X.Norepinephrine_T2 0.436
Value_T1 0.6 K.Ur_T2 0.418
Hematocrit_T1 0.6 APACHE.II_T3 0.414
Tricuspid.regurgitation.max.velT2 0.6 Urine.Output..mL.day._T1 207
Creat.Ur_T1 0.6 Respiratory.rate_T1 0.404
PT_T1 0.6 Sat.O2.FiO2_T3 0.4
Creat.Ur_T3 0.6 Pplat_T3 0.398
aPTT_T1 0.6 X..Dobutamine_T3 0.396
HCO3.mmolL_T1 0.6 Lateral.e._T3 0.394
Tidal.volume.VT_T3 0.6 Tricuspid.regurgitation.max.velT3 0.394
Inferior.vena.cava.dist.indx_T3 0.4 Tidal.volume_T2 0.39
Number.of.affected.organs 0.4 Heart.rate..bpm._T3.1 0.386
APACHE.II_T3 0.4 E.e._T3 0.382
Respiratory.rate_T1 0.4 E.wave_T1 0.38
K.Ur_T3 0.4 X..Norepinephrine_T1 0.378
LAdilatation.by.eyeballing_-
T1=Yes
0.4 Tricuspid.annular.plane.syst.exc._-
T3
0.378
Tracheal.Intubation_T2=Yes 0.4 Na.Ur_T2 0.372
PCT_Value.mgmL_T2 0.4 CRP_Value_T3 0.372
Tracheal.Intubation_T2=No 0.4 Urine.Output._T2 0.366
CRP_Value.mgL_T3 0.4 Glasgow.Coma.Scale_T3 0.364
LAdilatation.by.eyeballing_-
T1=No
0.4 SOFA_T1 0.356
TABLE F.1: The first 30 features stability scores using the Full+
dataset: for the RF (Random Forest) feature selection and for the rest
of the feature selection techniques (Full+).
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Full Random Forest
Heart.rate.bpm_T3.1 1 SOFA_T2 0.686
SOFA_T1 1 APACHE.II_T1 0.678
APACHE.II_T1 0.8 APACHE.II_T3 0.624
APACHE.II_T3 0.8 Lactate.levels..mmol.L._T2 0.614
HCO3.mmol.L_T1 0.8 Urine.Output..mL.day._T1 0.614
SatO2.FiO2_T3 0.8 Heart.rate.bpm._T3.1 0.606
Diastolic.Blood.Pressure.mmHg_-
T3
0.6 Respiratory.rate_T1 0.598
Mean.arterial.pressure.mmHg_-
T3
0.6 APACHE.II_T2 0.596
Na.mmolL_T1 0.6 Urine.Output..mL.day._T2 0.554
Leukocytes.total.1000mm3_T2 0.6 X.Norepinephrine_T1 0.552
Hematocrit_T2 0.6 E.wave..cm.s._T1 0.542
Weight.kg 0.6 FiO2_T3 0.524
Glasgow.Coma.Scale_T2 0.6 Sat.O2.FiO2_T3 0.52
Tidal.volume.VT_T1 0.6 SOFA_T1 0.516
Platelet.count_T1 0.2 SOFA_T3 0.51
APACHE.II_T2 0.2 pH_T2 0.508
K.mmolL_T2 0.2 Creatinine..mg.dL._T2 0.5
Sv.cO2_T1 0.2 Fluid.Balance..ml._T2 0.496
E.wave.cms_T1 0.2 CRP_Value..mg.L._T3 0.49
Heart.rate.bpm_T11 0.2 K..mmol.L._T3 0.486
Respiratory.rate_T1 0.2 Tidal.volume..VT._T1 0.486
Number.of.affected.organs 0.2 Glasgow.Coma.Scale_T3 0.476
LAdilatation.by.eyeballing_-
T1=No
0.2 Fluid.Balance..ml._T1 0.474
PaO2mmHg_T2 0.2 E.e._T1 0.46
Chloride_T1 0.2 Glasgow.Coma.Scale_T2 0.452
Systolic.blood.pressure.mmHg_-
T3
0.2 Pplat_T2 0.45
PT_T1 0.2 Temperature...C._T3 0.444
Glasgow.Coma.Scale_T1 0.2 PT_T2 0.434
Glasgow.Coma.Scale_T3 0.2 Platelet.count_T2 0.43
Lympho.abs.count_T2 0.2 Heart.rate..bpm._T1 0.426
TABLE F.2: The first 30 features stability scores using the Full dataset:
for the RF (Random Forest) feature selection and for the rest of the
feature selection techniques (Full).
Appendix F. Chapter 5: Stability Scores 109
T1+T2 Random Forest
SOFA_T1 1.0 Lactate levels mmol L _T2 0.756
Base Excess mmol L _T1 0.75 SOFA_T2 0.748
HCO3 mmol L _T1 0.75 Respiratory rate_T1 0.734
LVOT average diameter mm _-
T1
0.75 APACHE II_T1 0.72
Glasgow Coma Scale_T1 0.75 E wave cm s _T1 0.706
APACHE II_T2 0.625 APACHE II_T2 0.68
APACHE II_T1 0.625 X Norepinephrine mg kg min
_T1
0.68
Platelet count_T1 0.625 Urine Output mL day _T2 0.668
Platelet count_T2 0.625 Urine Output mL day _T1 0.66
Sat O2 FiO2_T2 0.625 SOFA_T1 0.658
SOFA_T2 0.625 pH_T2 0.616
Tidal volume VT _T1 0.625 Tidal volume VT _T1 0.614
Weight kg 0.5 Glasgow Coma Scale_T2 0.612
PEEP_T2 0.5 Fluid Balance ml _T1 0.606
Na mmol L _T1 0.5 Fluid Balance ml _T2 0.604
SvcO2 _T1 0.5 Creatinine mg dL _T2 0.6
PaO2 mmHg _T1 0.5 Pplat_T2 0.58
aPTT_T2 0.5 Lactate levels mmol L _T1 0.564
Respiratory rate rpm _T1 0.5 Platelet count_T2 0.552
WBC abs count_T1 0.5 E e _T1 0.552
BMI 0.5 Sat O2 FiO2_T2 0.544
PT_T2 0.5 PT_T2 0.538
PT_T1 0.5 Respiratory rate_T2 0.538
Respiratory rate_T2 0.5 Heart rate bpm _T1 0.534
PaO2 FiO2_T2 0.5 Lympho abs count_T2 0.53
Heart rate bpm _T1 1 0.5 PEEP_T2 0.512
Base Excess mmol L _T2 0.5 PaO2 mmHg _T2 0.512
Hematocrit _T1 0.5 Pplat_T1 0.488
Hematocrit _T2 0.5 LVOT average velocity time in-
tegral cm _T1
0.484
Value _T1 0.5 FiO2_T2 0.476
TABLE F.3: The first 30 features stability scores using the T1+T2
dataset: for the RF (Random Forest) feature selection and for the rest
of the feature selection techniques (T1+T2).
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T1 Random Forest
LA dilatation by eyeballing_-
T1=Yes
0.778 APACHE II_T1 0.898
E A ratio_T1=0.6 0.778 Urine Output mL day _T1 0.882
Sedation Scale SAS _T1 0.778 Respiratory rate_T1 0.878
Is the patient under other
drugs_T1=No
0.778 E wave cm s _T1 0.844
Glasgow Coma Scale_T1 0.778 Lactate levels mmol L _T1 0.822
Is the patient under other
drugs_T1=Yes
0.778 Tidal volume VT _T1 0.808
SOFA_T1 0.667 SOFA_T1 0.804
Respiratory rate_T1 0.667 Fluid Balance ml _T1 0.794
Aortic Valve Regurgitation_-
T1=Moderate
0.667 E e _T1 0.786
Aortic Valve Regurg._T1=No
val.dysfunc.
0.667 X Norepinephrine mg kg min
_T1
0.782
HCO3 mmol L _T1 0.667 Heart rate bpm _T1 0.776
LA dilatation by eyeballing_-
T1=No
0.667 Pplat_T1 0.764
Number of affected organs 0.556 Temperature C _T1 0.72
Base Excess mmol L _T1 0.556 pH_T1 0.706
LV Hypertrophy LV mass _-
T1=Moderate
0.556 Fibrinogen_T1 g L 0.706
Weight kg 0.444 Respiratory rate rpm _T1 0.7
LV Hypertrophy LV mass _-
T1=No
0.444 Platelet count_T1 0.68
Sat O2 _T1 0.444 PEEP_T1 0.676
Lateral e cm s _T1 0.444 Leukocytes total 1000 mm 3 _-
T1
0.656
aPTT_T1 0.444 LVOT avg.vel.time integral_T1 0.656
Midazolam mg kg min _T1 0.444 PaO2 FiO2_T1 0.654
Fibrinogen_T1 g L 0.444 Midazolam mg kg min _T1 0.65
Respiratory rate rpm _T1 0.444 Base Excess mmol L _T1 0.64
LVOT avg. vel. time integral
cm _T1
0.444 Neutro abs count_T1 0.64
PT_T1 0.444 A wave cm s _T1 0.632
Heart rate bpm _T1 1 0.444 Glycemia mg dL _T1 0.628
Neutro abs count_T1 0.444 Platelets 10 3 mm 3 _T1 0.628
Diagnosed within 48 from ad-
mission=No
0.444 RBC count_T1 0.622
Hematocrit _T1 0.444 LVOT average diameter mm _-
T1
0.62
Pplat_T1 0.444 Lympho abs count_T1 0.616
TABLE F.4: The first 30 features stability scores using the T1 dataset:
for the RF (Random Forest) feature selection and for the rest of the
feature selection techniques (T1).
